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Abstract  
 
Glaucoma describes a group of optic neuropathies characterised by progressive 
irreversible loss of visual function. Within this thesis, a health economic model was 
constructed to map service provision from diagnosis considering two competing 
strategies: the current practice of annual visual field (VF) monitoring against the 
proposed guidelines of performing 6 VFs in the first two years. The constructed model 
found the proposed practice to be cost effective at a willingness to pay ceiling ratio of 
£30,000 per quality adjusted life year (QALY), identifying an incremental cost 
effectiveness ratio (ICER) of £21,679. The findings of the model however were potentially 
sensitive to the modelled infrastructure improvement costs required to undertake the 
proposed guidelines and a costing study to more accurately ascertain these costs was 
recommended. 
Following this study, statistical analysis of 473,252 VFs was undertaken to investigate 
trends in initial identification and progression rates whilst also narrowing their 
parameters within the health economic model. Consequently, the average level of 
glaucomatous vision loss at diagnosis was found to be improving by 0.11 dB per year on 
average whilst proportions of patients with ‘advanced’ loss at diagnosis fell significantly 
from 30% to 21%. Average progression rates were found to have fallen from -0.11 dB per 
year to -0.06 dB per year whilst average rates of loss in older eyes (>70 years) were found 
to progress faster than in younger eyes (<60 years). Furthermore, testing frequency was 
found not to vary by visual impairment risk factors. The constructed health economic 
model was subsequently updated to incorporate the more narrowly defined parameter 
distributions whilst also being re-specified to incorporate societal costs of visual 
impairment to count the true costs of the disease. This resulted in an improved ICER of 
£11,382.  
In conclusion, it is likely that implementing the proposed guidelines of 6 VFs in the first 
two years is more cost-effective than annual monitoring. This argument is further 
reinforced once societal costs are accounted for however a scoping study to examine the 
required costs of improving the glaucoma monitoring infrastructure is required. 
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Chapter 1: Introduction 
 
1.1 Healthcare Provision in the UK 
1.1.1 The NHS  
Healthcare in the UK is delivered by the National Health Service (NHS), a service 
established in 1948 in order to bring hospitals, doctors, nurses, pharmacists, opticians 
and dentists under one organisation(5). Prior to its creation, patients were required to 
pay for their healthcare or to rely on voluntary hospitals to provide them with free 
healthcare. Now, healthcare provision is funded by taxation with richer members of 
society effectively subsidising the access of poorer people to healthcare. Alternative 
sources of funding for the NHS also exist with the most notable being charges to patients 
for prescriptions and dental work(6). Private healthcare is also available to those who 
wish to bypass NHS waiting lists and instead seek potentially more personalised care. 
Specific treatments such as certain cosmetic surgeries are not available on the NHS and 
are therefore only available through private providers. There can potentially be long 
waiting lists to access NHS resources although patients wishing to access immediate care 
can do so by visiting a private healthcare provider. The constitution of the NHS formalises 
the rights of the patients and staff in addition to the public as a whole and establishes the 
principles that underpin the foundations of the NHS, allowing it to operate effectively and 
in equity. All bodies working under the NHS umbrella, whether public or private, have to 
abide by these principles by law and consider the constitution in all decisions and 
actions(7).  
 
1.1.2 National Institute for Health and Care Excellence 
One of the key principles within the constitution of the NHS legislates for the cost 
effective service provision of healthcare in the UK(7). The service should therefore seek 
to achieve the best value for money possible for UK taxpayers. A body within the 
Department for Health was therefore required to ensure that the pathways of treatment 
undertaken by patients represented the most efficient interventions available, resulting 
in the establishment of the National Institute for Health and Care Excellence (NICE) in 
17 
 
England and Wales. NICE was set up in its earliest form in 1999 and has grown in size and 
scope from simple health outcome measurement to undertaking health technology 
appraisals that legally oblige the NHS to provide interventions that have been validated 
by NICEs technology appraisal board(8).  
There have been considerable benefits associated with introduction of NICE within the 
NHS organisational structure. Greater transparency is associated with NICE as it is fully 
independent of governmental oversight in addition to the lobbying power of both the 
pharmaceutical industry and special interest groups. NICE base their appraisals solely on 
the clinical and cost effectiveness of the intervention although exceptions can be made 
where the intervention provides supply to previously unmet demand(8). NICE also seeks 
to ensure a minimum standard of care is provided within the NHS by establishing clinical 
guidelines representing the most appropriate treatment strategies for differing 
conditions. The Guideline Development Group within NICEs structure, consisting of 
clinicians and patient representatives, considers both the medical interests of the patient 
and the economic arguments with relevant stakeholders(9). The guidelines provide 
information to both the clinician and the patient as to how their care pathway may be 
traversed, therefore increasing transparency in service provision. Transparency has been 
of increasing importance in recent years given, for example, the growing concern 
surrounding so called “postcode lotteries” in the UK. These arise where interventions are 
provided by certain regional health authorities but not by others due to local budgetary 
concerns, resulting in a disparity in service provision by differing regional health 
services(10). By introducing clinical care guidelines however, patients are not solely 
dependent on the clinician who may be influenced by the regional health authority to 
reduce access to care due to their financial state. 
There is a growing argument however that the NICE guidelines have created some 
unintended inefficiencies in service delivery. By creating these clinical guidelines, there is 
potential for over referral as clinicians are less willing to use their intuition and personal 
judgements, contributing to a growing burden on resource consumption within the NHS. 
For example, in health service delivery for the eye disease glaucoma, the subject of this 
thesis, studies have found falling positive predictive values for glaucoma or glaucoma 
suspects following the introduction of the NICE guidelines(11-13). This has consequently 
resulted in growing calls to further refine existing NICE guidelines on glaucoma detection 
18 
 
and management in order to ensure those consuming finite NHS resources are those 
most likely to progress to a state of visual impairment within their lifetime(14, 15) . 
 
1.1.3 The Current Financial Status of the NHS 
The NHS has been under growing economic scrutiny in recent years given the financial 
status of the UK economy in general. At the time of writing, the UK economy is currently 
running an annual budget deficit, implying that it is spending more than it accrues in 
revenues, amounting to around £90bn (4.9% of GDP), one of the highest within the 
OECD(16). To rectify this, the current UK government is seeking to run budget surpluses 
and to use these to pay off a proportion of its national debt. In order to run at a budget 
surplus, certain non-protected governmental departments such as defence, local 
government and work and pensions departments have faced spending cuts. The NHS 
however is a protected department and while the public health budget is being cut, the 
NHS budget itself will not be negatively impacted. NHS funding in fact is predicted to 
expand by £8bn in real terms by 2020-21(16), a necessary expansion in expenditure given 
a projected increase in demand for services due, in part, to population growth and 
growing proportions of elderly members of society who tend to consume more 
healthcare(17, 18). Furthermore, this growth in funding comes with the caveat of a 
demand for the delivery of an effective “7 day service” to be provided by both NHS trusts 
and GPs(16). As such, a growing squeeze on NHS finances is being observed with demands 
for maximal efficiency gains being made in order to ensure the expansion in provision can 
occur without a reduction in the existing quality of care. 
Monitor, an executive non-departmental public body of the Department of Health which 
regulates health services in the UK, has stated that due to growing demand  for 
healthcare in the UK, the NHS faces a £30bn shortfall in funding by 2020/21(19). Year on 
year, the Office for Budget Responsibility have estimated efficiency gains within the NHS 
at 0.8% annually. Yet this rate of gain will not be sufficient to fulfil the current goals of 
expanded service provision given current spending constraints(20). As such, Monitor 
stated an ambition for a 2-3% annual net efficiency gain over the next 10 years. In order 
to achieve this, Monitor indicated that it requires investment in new care models in 
addition to poorer performing providers partnering with more efficient providers in order 
to help implement more effective and efficient care provision(19). The Kings Fund 
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Quarterly Monitoring report on the financial performance of NHS foundation trusts in 
2014/15 painted a bleaker picture of finances within individual NHS organisations also 
finding financial performance to be declining with an overall net deficit of £349m 
identified(21). As such, the Kings Fund projected a deepening crisis on the horizon for the 
NHS if a significant growth in funding was not to occur or if increasing efficiency gains 
were not achieved beyond those of the quality, innovation, productivity and prevention 
challenge (QIPP)(22). This has led the King’s Fund amongst others to argue in favour of 
increasing the momentum of movement to incorporate aspects of health economics 
within healthcare provision in the UK(23-25). 
 
1.2 Health Economics 
1.2.1 Health Economic Theory 
Given the finite nature of resources and the continuously expanding demands being 
placed on healthcare systems, it is unsurprising that concepts within the field of 
economics have been increasingly fused with the concepts of welfare provision. This has 
resulted in the development of the field of health economics: a framework that seeks to 
examine healthcare as if it was any other producible commodity. Decisions are required 
to be made about where resources should be used in order to efficiently produce this 
commodity as considerable opportunity costs exist. These opportunity costs are defined 
as the foregone opportunities that exist due to the selection of an alternative(26). For 
example, using NHS funding to invest in a nationwide screening program for prostate 
cancer in the UK may yield increased life expectancies of males over 50 years of age. This 
however means that resources may not be available for other cancer screening programs 
due to the finite nature of resources within the NHS. This zero-sum game represents the 
opportunity cost of undertaking the screening program for prostate cancer, the 
opportunity that has been foregone as a result of decision making. Given the considerable 
implications on the public of these choices, it is vital that a validated framework is utilised 
to inform appraisals of the cost-effectiveness associated with them. 
 
 
20 
 
Figure 1-1: Supply and Demand diagram for the ‘market’ for healthcare in the UK 
 
Given the NHS provides healthcare free at the point of delivery, there is unconstrained 
demand for its services. Priority in service provision therefore has to be established in 
order to ensure those in the most need are provided with health care interventions in 
the most expedient fashion. Figure 1-1 represents the market for healthcare in the UK 
and the derivation of waiting lists graphically illustrated within a supply and demand 
diagram. Here, the Y-axis represents the price for healthcare and the X-axis represents 
the quantity of healthcare supplied. As the price of healthcare falls, the resultant quantity 
of healthcare that consumers demand would increase, therefore the demand curve is 
downward sloping (D). Conversely, as the price of healthcare increases, producers are 
more willing to supply healthcare to the market, therefore the supply curve is upward 
sloping (S). An equilibrium price in a normal, competitive market is found where the two 
curves intersect, where demand equals supply. This represents a hypothetical point of 
agreement between consumers and producers with a price that consumers are happy to 
pay (Pe) and a quantity that producers are happy to supply (Qe). This competitive market 
21 
 
equilibrium is achieved through market clearing, otherwise known as Adam Smith’s 
“invisible hand”(27). For example, if the price for the commodity is below the market 
equilibrium (P1), suppliers would be less willing to make the commodity available for 
purchase (Qs1) whilst more consumers would demand the commodity (Qd1). The 
resultant scarcity in the market (demand > supply) would therefore drive prices upwards 
and suppliers will be increasingly willing to produce the commodity. This increase in 
supply will continue until the point is reached where producers and consumers agree on 
an equilibrium price (Pe) and therefore an equilibrium quantity supplied (Qe) and the 
scarcity is cleared (demand = supply). The healthcare market in the UK however is 
different to that of a normal commodity due to the presence of the NHS. The market 
price for healthcare in the UK at the point of delivery is free (P0), and we therefore have 
scarcity in the market as demand exceeds supply (Qd2 > Qs2). Consequently, rationing 
occurs in order to ensure supply is provided to those in most desperate need, resulting 
in waiting lists (a). As populations age and expand however, demand for services expand 
(D>D2), scarcity increases and so does rationing and waiting lists (a+b). Therefore, in 
order to maintain the level of service year on year, supply needs to expand at the same 
proportion that demand expands and this can be achieved by increasing the amount of 
healthcare infrastructure and NHS staff that provide care or by increasing efficiency in 
service provision. 
Given trends in population growth, it should be unsurprising that efficiency is a key health 
economic concept. The allocation of resources towards the most effective production 
processes results in allocative efficiency, otherwise known as Pareto efficiency. This form 
of efficiency stems from the comparison of competing treatments or strategies in order 
to ascertain which would represent the best return given resources employed. In terms 
of economic efficiency, health economics attempts to examine the costs associated with 
resource use in the production of healthcare and seeks to incorporate these factors into 
the decision making process. The interested reader can find out more about the general 
principles of Health Economic theory elsewhere(28). 
 
1.2.2 Measurement of Quality of Life 
Since cost-effectiveness evaluation measures the benefits of interventions relative to 
their costs, the accurate quantification of the improvements in quality of life associated 
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with them are vitally important. Inexact measurement would lead to poor estimation of 
associated quality of life impacts leading to erroneous conclusions being drawn. Accurate 
quantification of quality of life however is difficult to achieve due to the varying nature 
of patient perception of wellbeing. For example, the same degree of pain may be 
quantified differently by two different people suffering from the same condition due to 
differing pain thresholds between them. Alternatively, people may differ in their general 
perception of quality of life due to their personality traits. Certain individuals may be 
classified as Type-D (distressed), consequently resulting in a gloomier perception of their 
quality of life(29), therefore potentially reporting lower quality of life. 
The development of the quality adjusted life year (QALY) in recent years has aided the 
process of economic evaluation in glaucoma. The QALY seeks to provide a numerical and 
comparable interpretation of the quality and quantity of life lived. Comparison of QALYs 
quantifies effectiveness of treatments in units of utility representing wellbeing whilst also 
taking into account adverse side effects. It is possible to establish the cost per QALY 
derived for a treatment by analysing the resources the treatment requires. This in turn 
allows cost-effectiveness of a treatment relative to its alternatives to be established. 
Simply put, the cost per QALY is calculated by dividing treatment costs associated with 
the intervention by the quantity of QALYs gained by it. 
There are certain requirements that need to be fulfilled by questionnaire respondents 
before utility calculation can be accurately ascertained. They are required to be utility 
independent and risk neutral as violations may lead to response bias. Respondents are 
also required to be consistent and to display rational trade-off behaviour. Violations of 
these requirements can lead to issues with QALY quantifications and these are potentially 
exacerbated by underlying flaws that can exist in the use of QALYs in relation to certain 
types of conditions. For example, a QALY gained by providing an intervention for erectile 
dysfunction is not equivalent to a QALY gained through dialysis to avoid renal failure as 
one improves quality of life whilst the other prolongs it. Cost-effectiveness analysis 
equates them on a unitary basis however, therefore the lack of attribution of societal 
value of the QALY could lead to misleading health policy decisions(30). Issues arise 
however when the population used to quantify QALYs associated with a condition suffer 
from it themselves. Volk and colleagues questioned 10 otherwise healthy male 
participants aged 56 years on average about how erectile dysfunction may impact their 
quality of life. A reduction of utility of 0.26 was identified however when their wives were 
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questioned their responses were different with a value of 0.02 identified despite the fact 
that they could equally be impacted by the erectile dysfunction(31). As such, it is 
important to understand the psychosocial interaction within QALY calculation as values 
may be over stated as a consequence. It has therefore been argued that those with the 
condition are best placed to comprehend the impact of the condition and, as such, people 
without experience of the condition should not be used to quantify QALYs. Issues arise 
out of this however as those with the condition may be bias towards exaggeration of 
quality of life impacts if they are aware that their feedback may have consequence upon 
their access to treatment. Furthermore, it could also be argued, given that society funds 
the NHS in the UK via taxation, societal value for the impact of the condition should be 
accounted for, thus arguing in favour of QALY estimation based on healthy non-patients. 
There are alternatives available to quantify quality of life beyond the QALYs and one such 
method is the quantification of disability-adjusted life years (DALYs), frequently used by 
the World Bank and the World Health Organisation(32). They are similar to QALYs in that 
they are both measures of health adjusted life years however, whilst QALYs measure 
health gains associated with interventions, DALYs measure the burden of disease. DALYs 
incorporate age-weighting and discounting of future values within their calculations and 
rather than applying measures of quality of life to different health states they apply these 
measures to discrete states of wellbeing(33). Age weighting has been argued to be 
controversial however as it argues that a young adults life is more valuable than an older 
adult or a child’s life whilst the use of instrumental value has been found to weight in 
favour of higher wage earners(34). There consequently remains debate over which 
quantification method is preferable, with understanding of the systematic differences 
between the two methods required when deciding which approach to choose(32, 35, 36). 
 
1.2.3 Tools for the Measurement of Quality of Life 
There are different methods available to the analyst seeking to quantify the amount of 
QALYs associated with different states of wellbeing. One such method is the 5 dimension 
EuroQol questionnaire (EQ-5D)(37). The intention of the questionnaire is for respondents 
to self-report their quality of life; it can be used in surveys and interviews alike and is 
easily implemented given its relatively short and simple nature. The EQ-5D has been 
chosen as the preferred method of QALY estimation in adult populations by the NICE 
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Methods Guidance on Methods in Technology Assessment(38). The key reasoning behind 
this is the generalisability of the instrument, the outcomes associated with them can be 
cross-compared irrespective of potential differences in medical arena. It has been noted 
however that the EQ-5D is not intended to measure all aspects of health related quality 
of life in complete detail and that disease specific instruments should be utilised in 
combination with the EQ-5D for truly representative QALYs(39). The EQ-5D however has 
been criticized for having low sensitivity to improvements related to conditions with low 
morbidity whilst also not being responsive enough to identify small changes in health(40-
42). An alternative to the EQ-5D is the SF-6D, an instrument derived from the SF-36 but 
with added ability to incorporate preferences into its scoring. This tool describes 1,800 
health states in total and does so by conversion of SF-36 measurements using preference 
weights identified from the UK general population. The SF-6D is not without its limitations 
too however as it has been found to overestimate the value of the worst health states in 
addition to not being responsive to changes in those conditions that experience high 
morbidity(40). 
Beyond questionnaires, health and behavioural economists have identified alternative 
methods of preference elicitation. The Standard gamble (SG) method, first presented by 
von Neumann and Morgenstern(43), measures preferences within the presence of 
uncertainties. With this method, participants are presented with two choices with the 
first being a certain state of health (for example frequent bouts of angina) and the second 
being a gamble between a better state of health (for example no angina) or worse (for 
example death). The participants are then requested to state the required probability of 
the improved outcome for them to be indifferent of the first or the second choice. 
Therefore, if a probability of 75% was stated as making them indifferent between the 
two, 0.75 would represent the utility. Given the way SGs are formulated they therefore 
are potentially impacted by the risk seeking nature of the respondent and therefore need 
to be undertaken by risk neutral individuals. The time trade off (TTO) method asks 
participants to consider the amount of time they would be willing to sacrifice in order to 
avoid a certain worse health state(44). If the respondent is provided with a 10-year time 
scale and they indicate that they would be willing to sacrifice 3 years that would leave 
them with 7 years remaining. As 70% of the original time scale, their utility score for the 
condition would be 0.7. TTO incorporates a certain outcome compared to the gamble 
associated with SGs, making the SG method likely to overestimate utility when risk averse 
respondents are utilised. A further preference elicitation method available is the use of 
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visual analogue scales (VAS). These are based on psychometric theory and consist of a 
single line incorporating anchors indicating the best and worst possible health. 
Participants are then required to place the different health states on this interval scale 
indicating perceived differences. These scales are often used to complement the SG and 
TTO methodologies although it has been argued that VASs have significant benefits over 
them(45). 
 
1.2.4 Economic Evaluation 
Economic evaluation creates a systematic framework for the comparison of quality of life 
measurements relative to the costs associated with implementing the associated 
interventions. Economic evaluations take a generally similar structure and require the 
measurement of costs and benefits associated with competing treatments or clinical 
strategies. They can be undertaken in conjunction with clinical trials but can also be 
implemented through existing medical literature. Clinical trial lengths are often 
prohibitive and costly(26) and are factors which have given rise to cost-effectiveness 
evaluation and modelling. There are four main types of economic evaluation, varying 
either in terms of how costs are quantified, how benefits are quantified and the 
assumptions that underpin their calculation: 
 
1. Cost-Effectiveness Analysis 
Cost-Effectiveness analysis (CEA) examines the outcomes associated with two different 
treatments relative of the costs derived to gain them. Costs are established in monetary 
terms with benefits measured in an alternative unit. An Incremental Cost Effectiveness 
Ratio (ICER) is then established to represent the cost of gaining an increased unit of 
benefit and is calculated by dividing the differences in costs between the interventions 
by the difference in effectiveness(26). For example, treatment A may cost an extra £100k 
compared to treatment B. If the outcome associated with treatment A yields an increased 
benefit of 5 QALYS over B, an incremental cost effectiveness ratio (ICER) of £20,000/unit 
is derived. If this ICER is below the willingness to pay threshold of the payer, then 
treatment A will be preferred to B and vice versa if the ICER is above the threshold. There 
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are various decision rules that exist within cost-effective analyses which can be illustrated 
using a cost effectiveness plane (CEP). 
 
Figure 1-2: The Cost-Effectiveness Plane 
 
 
The CEP (see Figure 1-2) is a plane split into four quadrants and plots the ICER according 
to whether the alternative is costlier and/or more effective than the current intervention. 
When the alternative is dominated due to being costlier and less effective (quadrant 1) it 
is represented by point such as A, with the alternative therefore being rejected. The 
alternative can dominate over the original treatment and therefore be preferred in the 
instance that the roles are reversed with costs being lower and effects being higher with 
the alternative (quadrant 4) such as point B.  Quadrant 2 and 3 illustrate more 
complicated outcomes than 1 and 4 however. These represent areas of the plane where 
the alternative is either less costly and less effective (quadrant 3) or costlier and more 
effective (quadrant 2), therefore a further decision rule must be employed. A willingness 
to pay decision rule is required as to what ratio of costs to increased benefit is acceptable 
with a willingness to accept ratio is also required to identify the acceptable ratio of 
Quadrant 1 Quadrant 2 
Quadrant 4 Quadrant 3 
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reduced benefit to reduced costs. An ICER represented by point C for example is likely to 
result in a rejection of the alternative despite the lower costs associated with it as it 
represents significantly lower effects for the patient. An ICER represented by point D 
however is likely to result in an acceptance of the alternative as the costs are only 
marginally higher and the effects are significantly larger than the comparator. Therefore, 
the ratio of costs to benefits is within the scope of the payer’s willingness to pay. The 
identified ratio can be indicated by a straight line running from the origin of the plot. 
Points above this line are likely to get rejected as they represent an area above the 
willingness to pay or accept ratio. Conversely, ICERs below this line will be accepted for 
being below this ratio. The line is observed to kink when traversing over the origin as 
payers are less willing to pay for a reduction in effects and costs than they are willing to 
pay for an increase in effects and an increase in costs, consequently requiring a higher 
cost benefit ratio(46). As such, a lower CER ceiling ratio exists in quadrant 2 compared to 
quadrant 3, indicted by the lower slope. Study of NICEs past decision making have found 
that this ceiling ratio is quantified at £20,000 to £30,000 for every extra QALY derived(47), 
indicated by the kinked ratio line in Figure 1-2.  
 
2. Cost-Utility Analysis 
Cost-Utility analysis (CUA) is similar to CEA analysis but instead examines the outcomes 
of interventions relative to a measurement of utility. This unit of measurement refers to 
the subjective level of wellbeing that people experience relative to differing levels of 
health states and is usually based upon the QALY(48). Costs are established in monetary 
units whilst benefits are expressed using the QALY. QALYs are argued to be a better 
indicator of improved outcomes compared to the units of measurement usually used in 
CEA as they relate directly to the wellbeing of the individual. Furthermore, the use of the 
QALY allows for the cross comparison of differing conditions with different improvements 
in patient outcomes given their analysis of uniform units(26). A drawback of this 
methodology however is that societal costs are often not taken into account when this 
method of evaluation is employed. For example, whilst the cost of visual impairment to 
the individual may be accounted for in a CUA, the costs to society of rehabilitation, 
environment adaptation and disability payments may not be accounted for. 
Consequently, benefits beyond the patient such as benefits to the patient’s family or to 
the productivity of society are not accounted for in CUAs. It is also argued that QALYs are 
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significantly more difficult to estimate than the monetary gains associated with 
treatment, with the resulting uncertainty clouding the findings of these studies.  
 
3. Cost-Benefit Analysis 
The cost benefit analysis (CBA) approach measures costs and benefits in monetary terms 
with both costs and benefits measured in the same units in order to be accurately 
assessed against one another(26). The measurement of benefit within a similar to 
framework to that of costs represents a significant issue however is it requires translating 
patient derived utility into monetary units. One measurement of treatment outcomes 
can be undertaken using either the human capital methodology or contingent  valuation 
methodology. The human capital method relies on the individual being seen as a 
productive form of capital and as such is measured in terms of productivity, usually 
represented by their salary. Consequently, the benefits of treatment can be measured as 
being related to the discounted future income that would potentially have been foregone 
as a result of non-treatment. Contingent valuation seeks to establish monetary value 
related to the benefits associated with the consumption of a commodity that is not 
currently available in the market. In order to do so, this form of valuation requires the 
construction of a hypothetical situations and questions in the form of questionnaires 
which allow respondents to convey preferences and their willingness to pay (WTP). There 
are various different methods within which these situations can constructed with simple 
open-ended questions generally avoided due to the subjective nature and reduced 
accuracy of response analysis. The take it or leave it (TIOLI) method utilises the 
presentation of an option paying a certain amount for a commodity, therefore giving the 
respondent a concrete decision making criteria that they can take or leave and is an 
efficient method but requires large sample sizes to achieve significance. Alternatively, 
bidding games can be utilised to extract valuation by using the TIOLI structure but going 
further by raising or lowering the TIOLI amount to establish a threshold value. Finally, the 
check box method offers the respondent a series of values which require them to check 
a box which represents their valuation although this method is subject to range bias 
where respondents tend towards middle values in the options provided(49). 
CBA and the decision rules that they generate are focused are ultimately focussed upon 
which intervention has the higher net benefit; the analyst then has the advantage of 
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being able to identify which treatments and strategies result in an aggregate gain to 
society, something that is not possible with the CEAs and CUAs. The CBA approach 
therefore allows the analyst to measure outcomes in terms of absolute costs rather than 
ratios of quality of life indices and therefore accounts for not only health related costs, 
but non-health related costs(50). Drawbacks of CBA are related to the method of 
establishing monetary benefit and costs. Converting health outcomes into monetary 
values places a monetary value on human life and this is potentially ethically 
objectionable. Furthermore, not all benefits may be possible to convert into monetary 
values.  
A net benefit analysis can often follow the analysis of cost benefit. The net benefit 
approach seeks to identify whether the net health benefit or net monetary benefit of one 
intervention compared against another is positive or not in order to ascertain which is 
preferable, essentially subtracting the costs of an intervention from its benefit to 
establish net benefit. This form of analysis is expressed in either monetary terms or in 
QALYs(26). Net health benefit is established by calculating the differences in quality of 
life while the net monetary benefit is established by calculating differences in costs.  
 
4. Cost-Minimisation Analysis 
Cost minimisation studies are generally undertaken when the benefits of health care have 
been found to be identical across the treatments being compared; for example, when a 
commercially available branded drug is compared to its identical generic version. Whilst 
a relatively simple form of economic evaluation, it is not common for health outcomes to 
be identical across treatment and strategy comparisons; there is consequently a burden 
of proof placed on the analyst to prove that this is indeed the case. 
 
1.2.5 Perspectives in Economic Evaluation 
The perspective taken in any health economic analysis is also of importance when 
considering the economic impact of the introduction of any new drug or therapeutic 
intervention. It has been argued that economic evaluation is pointless in the hospital 
setting as resources are simply moved elsewhere. However the increased productivity in 
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hospitals that occurs with the movement of resources derived after cost savings is reward 
in itself(51).  
It is also argued that the perspective taken by economic evaluations should be as wide as 
possible to account for all benefits of treatment. Health economic studies that focus 
simply on health service costs ignore the secondary benefits of treatments to 
patients(52). For example, laser or surgical interventions in optic neuropathies may have 
the primary effect of protecting the visual function of the patient, but the secondary 
benefit of reducing the reliance of adherence to a treatment regimen of daily eye drops 
cannot be underestimated for the patient too. The gold standard in the UK in terms of 
perspective of an economic evaluation is the societal perspective, therefore the 
perspective taken is from those who use and pay for the NHS. An evaluation that focuses 
primarily on the perspective of the NHS may produce outcomes that ensure the most 
efficient service mix is provided to patients however it will not necessarily maximise 
society welfare. This occurs when sectors outside of healthcare are impacted as a result 
of health care interventions. Furthermore, a societal perspective also allows the analyst 
to get a true picture of opportunity cost implications of decision making, therefore 
understanding in greater detail the value of resources employed outside of the 
healthcare system(53). 
 
1.2.6 Randomised Controlled Trials and Health Economic Modelling 
Newly introduced treatments are best evaluated through randomised controlled trials 
(RCTs). RCTs are undertaken to establish the efficacy of medical interventions and to gain 
information on the possible side effects associated with them. RCTs typically randomises 
participants to receive one of two or more possible interventions. Participants are treated 
the same in all other respects in order to examine solely the differences that the 
intervention has upon the participant. Whilst RCTs are recognised as the gold standard in 
effectiveness analysis there are notable limitations associated with them. They are 
sometimes non-generalizable and considerably expensive to undertake given the amount 
of people involved within them and their duration(54). Beyond costs, the RCT may 
potentially be less medically relevant once reporting is complete due to advances in 
medicine that may occur over the time the RCT has taken to run. Ethical questions also 
may arise when RCTs are utilised in the testing of conditions with considerable reductions 
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in quality of life. RCTs often require one of their arms to be a control with no treatment, 
and when these trials are blinded, the subjects thinking they are receiving potentially 
effective interventions are actually not receiving any. This is specifically problematic in 
the case of irreversible medical conditions as non-treatment potentially harms the 
subject physiologically by withholding treatment.  
Health Economic modelling can be used in conjunction or as an alternative to RCTs by 
providing information on the probability of cost effectiveness, potentially indicating the 
usefulness of the implementation of an RCT. Given their computerised nature, they 
provide a relatively inexpensive source of information for RCTs as they involve relatively 
few skilled professionals in their construction and processing. Whilst they are easier to 
undertake, like any modelling, they are restricted by the assumptions that underpin them 
however. They do still produce outcomes in a much more expedient fashion than with an 
RCT as the lead time from the initial planning stages to final data processing is usually 
around a year once full validation has been achieved(26). These models can also be 
adapted to address future research questions and used as a base for the economic 
evaluation of similar conditions that follow similar treatment pathways. Finally, and 
potentially most important, there are significantly fewer ethical concerns with health 
economic models compared to RCTs.  As such, health economic models have grown in 
terms of implementation within health technology appraisals. 
 
1.2.7 Types of Health Economic Modelling 
Beck and Pauker (1983) introduced the application of the Markov models to derive 
patient outcomes whilst accounting for life expectancy(55). Markov models stratify 
patients to one if its constituent states, a state that reflects the subjects existing level of 
well-being. Members of each state can then move into other health states as a 
consequence of an event, the likelihood of which being modelled as a transition 
probability. Each state is designated a utility and the individual accumulates utility 
according to how long they remain a member of each state until the time horizon, the 
length of time the model is accounting for, has been completed. Costs are accounted for 
by establishing the unit cost of membership per state per cycle. This is then multiplied by 
how many members in the state, with costs being accumulated across the time horizon.  
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Most Markov models allow for multi-directional transitional movement, but in the case 
of irreversible disease patients can only move one way. The absorbing state such as death 
means no further movement can occur with no additional utility accumulated. It is also 
possible to model conditions perceived to be worse than death, such as those related to 
dementia and coma, and this is possible by attributing negative utility values to these 
health states. The Markovian assumption is an important characteristic of the Markov 
model and stipulates that events that take place in time periods prior to the cycle being 
modelled have no effect upon them. As such, all patients in a specified state will have a 
similar prognosis irrespective of their personal history unless complex Markov chains are 
derived, arguably a limitation of this method of modelling(55).  
An alternative model structure to Markov models are the discrete event simulations 
(DES). A DES is relatively complex model that seeks to represent multiple interactions 
between individuals and clinical decisions. They are described as discrete event 
simulations as entities move forward from one event to another rather than in Markov 
cycles modelled within Markov models which move forward in time based phases. A DES 
is made up of patients that are provided with attributes, experience events and consume 
resources over time(56). The attributes can represent a multitude of patient 
characteristics that may influence the likelihood of an event whilst patient histories are 
also accounted for within the likelihood. Resource consumption can also be modelled on 
an individual basis within a DES. These type of models are especially relevant when the 
condition being mapped is event based and when there are multiple factors at play when 
decisions on treatment provision are made. There are limitations to the implementation 
of a DES however due to transparency issues around their reporting. They are often 
complex, limiting their interpretation and their adoption, especially within fields where 
the validation of outcome reporting is important. 
 
 
1.2.8 Limitations of Health Economic Modelling 
The difficulty associated with modelling treatment pathways linked to different 
conditions and the plurality of potential treatment modalities for them represents one 
particular limitation of health economic modelling. Furthermore, the definition of the 
parameters used in the model chosen also represents a significant challenge to the 
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analyst. Slight variation in parameters can lead to varying implications in terms of model 
interpretation, it is therefore important for the analyst to narrow the definition of 
parameters used as much as possible. These parameters are usually informed by existing 
medical research literature and there is often a lack in consensus when it comes to such 
research. This can often be due to slight variation in research methodology or sample 
populations. Therefore it is vital that medical research literature used to inform economic 
models are sourced from studies using the relevant research methodologies and relevant 
population demographics, a position supported by NICE(38).  
In order to understand the limitations placed on health economic model outputs, 
measures of uncertainty known as sensitivity analysis are performed. Univariate 
sensitivity analysis seeks to quantify how variation in singular parameters affects the 
model’s final output; it is a vital step in understanding uncertainty as it utilises the ranges 
around the parameters and re-simulates the model to produce alternative outputs(57). 
These outputs are then examined to see whether they surpass the chosen ceiling ratio 
against which cost-effectiveness is judged against. Deterministic univariate sensitivity 
analysis however seeks to identify the maximum limits of the parameter that can be 
tolerated before the health economic model moves into a non-cost-effective result. It 
therefore seeks to identity the cost-effective thresholds for the parameters utilised. 
Multivariate sensitivity analysis, otherwise known as probabilistic sensitivity analysis, 
establishes the distributions around which the models parameters can be explained and 
takes repeated samples from these distributions for each individual simulated patient. 
Once thousands of these patients have been simulated, CEPs can be plotted and the 
proportion of cost effective observations under specific ceiling ratios are calculated and 
plotted in cost-effectiveness acceptability curves(CEACs)(58). These CEACs provide a 
diagrammatic representation of the cumulative probability of acceptance according to 
varying willingness to pay. 
 
1.3 Glaucoma 
1.3.1 Epidemiology of Glaucoma 
Glaucoma is one of the most common causes of irreversible blindness in the world and 
has been projected to impact 79.6m people worldwide by 2020(59, 60). It is often termed 
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the “silent thief of sight” due to its long term and slow progressing nature and, as such, 
it is often not noticed until the person’s sight loss is advanced. Therefore, if left untreated, 
it can result in irreversible sight loss. The term “glaucoma” represents a group of 
irreversible progressive diseases thought to cause degeneration of the optic nerve due 
to damage of Retinal Ganglion Cells (RGCs)(61). Functional RGCs are essential to vision as 
they are responsible for collecting information from photoreceptors, transmitting it to 
the optic nerve which then transmits this information to the vision centres of the brain.  
 
Figure 1-3: Schematic of the eye illustrating impact of raised intraocular pressure 
 
 
There are subtypes of glaucoma each with their own specific characterisations. The most 
predominant form of glaucoma is primary open angle glaucoma (POAG) with around 2% 
of people over 40 years of age found to have POAG in the UK(62). One of the most 
significant risk factors for POAG is an elevated intraocular pressure (IOP) (see Figure 1-3). 
The pressure within the eye is usually regulated via management of aqueous fluid located 
within in the anterior chamber by its ‘drainage systems’. Reduction in aqueous outflow 
from the eye results in a build-up of pressure within the eye, resulting in optic nerve 
atrophy and, subsequently, damage of the subject’s visual field (VF). IOP is the only 
modifiable risk factor for glaucoma with detection usually centring upon elevated 
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pressures being observed, most commonly by opportunistic case detection, and 
managed through therapeutic intervention(63).  
A further less common subtype of glaucoma is acute angle closure glaucoma (AAG) which 
occurs when there is a rapid increase in IOP caused by a sudden blockage to one of the 
eyes drainage systems located at the angle between the peripheral cornea and the 
peripheral iris(64). The trabecular meshwork within the angle which acts as a filter for 
the drained aqueous fluid therefore cannot allow for aqueous outflow, subsequently 
resulting in raised IOP. Whilst POAG is asymptomatic until damage is advanced enough 
to be visually perceived, AAG can cause sudden pain to the subject making it easier to 
detect and treat. Whilst both of these glaucomas are characterised by a raised IOP, it 
does not always result in damage to the optic nerve. This leads to a diagnosis of ocular 
hypertension (OHT), a potential precursor for glaucoma and occurs when high pressures 
are observed within the eye but without VF loss.  
Optic nerve damage and VF deterioration can also occur in people with IOP values in the 
normal range, termed normal tension glaucoma (NTG). NTG has been suggested to have 
been attributed to fragile optics nerves susceptible to damage from normal IOPs or 
potentially by those who have previously had elevated pressure with optic nerve damage 
being halted once IOP has returned to normal levels(65).  It has also been suggested that 
the optic nerve damage associated with NTG runs a course independent of factors related 
to IOP(66).  
Optic nerve atrophy can also be caused by secondary glaucomas, so termed due to 
occurring as a side effect of other eye conditions with examples being exfoliative 
glaucoma, neovascular glaucoma and congenital glaucoma. Exfoliative glaucoma occurs 
due to blockage of the angle between the cornea and iris occurs caused by exfoliation of 
the lens(67), neovascular glaucoma occurs due to abnormal formation of blood vessels 
on the iris hindering the eye's drainage channels(68) whilst congenital glaucoma occurs 
in babies with inadequate drainage channel development(69). Secondary glaucomas are 
not common and represent the least prevalent form of glaucoma in the UK. 
Existing literature has identified specific subgroups who are most likely to be at high risk 
of suffering from glaucoma. One of the primary risk factors for glaucoma is older age. 
Around 2 in every 100 people over 40 years of age are affected by POAG in the UK whilst 
this rises to around 5 in every 100 people over 80 years of age(70). It has been argued 
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this is due to the increased mitochondrial dysfunction observed in older age accelerating 
the loss of RGCs(71). Ethnicity has also been found to play a role in the onset of glaucoma. 
People of African or Afro-Caribbean ethnicity have been found to be at an increased risk 
of POAG compared to Asians and Europeans(72) whilst people of Asian origin have been 
found to be at increased risk of developing AAG(73). It is not currently known why people 
of African or Afro-Caribbean origin are at greater risk of POAG but the higher rate of AAG 
in Asian is attributed to their shallower anterior chambers compared to those of 
European decent(74). Family history is a further risk factor for glaucoma whilst those 
suffering from myopia and diabetes may also be at an increased risk(75-78). 
 
1.3.2 Intraocular Pressure 
IOP measurement has been historically the predominant method of assessing disease 
progression(79, 80). It is measured in terms of millimetres of mercury with ‘normal’ 
pressures shown to exist between 12-21 mm Hg and elevated pressures above that 
range. It is normally measured using a tonometer,  an instrument that applies a small 
amount of pressure to the eye via a device or a short puff of air with the eyes IOP inferred 
from the force required to flatten an area of the cornea(81).  
The use of IOP as a proxy measurement for monitoring the patient with glaucoma is not 
ideal. Glaucoma itself is a complex collection pathophysiological processes that combine 
many different components, of which IOP is one. Other ‘structural’ components need to 
be assessed like the central corneal thickness (CCT) and cup disc ratios (CDR) as a 
surrogate of optic nerve head health. Measurement of the thickness of the cornea is 
important as corneal thickness can interact with IOP measurements, potentially causing 
under or over treatment. Subjects with thin corneas (less than 555µm) tend to produce 
IOP measurements that are artificially low, potentially resulting in under treatment and 
progression to glaucoma(64). Subjects with thick corneas may indicate higher IOPs than 
is the case, potentially resulting inefficient treatment for a condition that the subject is 
unlikely to develop.  
Assessment of the optic nerves, often clinically assessed as cup disc ratios, is important 
too. The optic disc represents the connected portion of the retina to the optic nerve and 
can either be flat or cupped in shape. Glaucoma detection depends on the measurement 
of the neuroretinal rim and the optic cup and their sizes relative to that of the optic 
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disc(82). As glaucoma progresses, the cup is observed to grow in size until it takes up the 
area of the optic disc. The cup disc ratio therefore compares the diameter of the cup of 
the optic disc to the diameter of the optic disc as a whole. A normal cup disc ratio is 
around 0.3-0.4 and ratios above this are potentially indicative of the presence of 
glaucoma. A high cup disc ratio is not necessarily an indication of glaucoma however; it 
is the change of ratio as the patient ages that provides evidence of its development. It is 
therefore difficult to diagnose glaucoma solely on the basis of optic nerve head 
analysis(83). 
Whilst the monitoring of all these components represent key aspects of glaucoma 
management, it is important to make the link between physiological health and patient 
outcomes themselves. As such, clinical measurements for glaucoma management can be 
divided into either structural or functional measures. The former encompasses 
aforementioned components of IOP, CCT and CDR whilst the functional side seeks to 
measure the subjects’ perceived vision. In the case of glaucoma, this is best estimated by 
the assessment of the VF. 
 
1.3.3 Visual Fields 
The visual field test can help detect defects in central and peripheral vision and is used in 
the diagnosis and management of glaucoma and its progression. The definition of the 
visual field is the area where light reaches the retina in the eye which in turn stimulates 
light perceiving cells located at the back of the eye. Ganglion cells process the information 
and transmit the data along their axons to the brain via electrical signals(84, 85).  
The visual field is normally assessed using perimetry whereby a person indicates when 
they detect the visual stimuli using one of their eyes whilst fixating, with the other eye 
being occluded. It can either be undertaken manually with the help of a clinical technician 
or automatically.  Computerised automatic perimetry, ubiquitous in glaucoma clinics, is 
significantly more efficient than manual perimetry and automatically modifies 
characteristics of the stimuli in order to identify minimum detection threshold(86).  
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Figure 1-4: A HFA output indicating a visual field produced by a left eye. Fixation losses, 
false positives and false negatives are indicated in the top left. 
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It is undertaken using a “white on white” test referred to as standard automated 
perimetry (SAP) which assesses the subjects’ light-difference sensitivity at different 
locations of the visual field (see Figure 1-4). The most common perimeters used are the 
Humphrey Field Analyzer (HFA) (Carl Zeiss Meditec Inc., USA) and the Octopus perimeter 
(Haag-Streit AG, Koeniz, Switzerland). This thesis will focus primarily on the outputs of 
the HFA as this instrument is the more commonly used in primary and secondary care 
eye clinics throughout the UK. 
 
Figure 1-5: The 24-2 HFA testing grid for the right eye. Spacing of the points is 6° 
starting 3° from the centre. The red points indicate the blind spot 
 
 
 
The HFA measures the visual field with different test patterns, the most commonly used 
clinically is the 24-2 grid; this tests the field to about 20 degrees (see Figure 1-5). Defects 
within the visual field are identified if light sensitivity at a specific location is below the 
average sensitivity that would be recorded by a visually healthy person of a similar age 
(age-matched control). These location based data can then be expressed in terms of a 
global aggregation such as the mean deviation (MD), a measure which represents how 
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much the test subjects’ visual field sensitivity deviates from age matched controls. Whilst 
the HFA provides a useful summation of the information on the subjects’ visual field, it 
can potentially be misleading in the presence of cataracts within the eye being tested as 
an opaque lens can lead to excessive light scatter(64). The pattern deviation plot is useful 
in this situation because it corrects for an overall depression in light sensitivity. The 
glaucoma hemifield test (GHT) also adds to the information available to the analyst by 
providing an assessment of how glaucomatous the visual field appears to be. The GHT 
assesses the probability maps of the HFA to detect localised VF loss whilst also examining 
for symmetrical loss across the horizontal meridian and provides a simple classification 
of the VF based upon common patterns of glaucomatous loss(87-89) and has been 
reported to have high sensitivity and specificity(90). The GHT however is not designed to 
provide definitive glaucoma diagnosis and is instead recommend to verify clinical 
interpretation of the VF(64). 
Perimetry is challenging for the patient and the VF results can be difficult to interpret. 
Perimetry is a psychophysical test and, simply put, relies on a person responding to a 
stimulus by pressing a button; the measurements are therefore not exact but are 
probabilities of reliably detecting a stimulus. One of the primary reasons for an unreliable 
visual field is the lack of perimetric experience in the subject undertaking the test and 
possible fatigue effects(91, 92). Learning effects occur when sensitivity increases during 
and between perimetric examinations whilst fatigue effects occur when sensitivity 
decreases during an examination(93, 94),  Consequently, VF test outputs at the earliest 
stages of testing may prove unreliable. Therefore, in the follow-up of a patient, the first 
recorded visual field is typically excluded from further analysis (95, 96). Visual fields can 
also be excluded on the basis of the reliability criteria that is reported as part of the HFA 
visual field test. The HFA tests for fixation losses, false negatives and false positive errors 
as part of its testing algorithm(97), although the usefulness of these indices have been 
called into question(98, 99). 
 
1.3.4 Quality of Life in glaucoma 
Clinical measures of visual function do not necessarily provide information on how the 
patients’ visual impairment may impact upon their quality of life. Visual field loss from 
glaucoma can impact upon the person’s ability to read, drive and navigate obstacles(100, 
101). The latter in particular can significantly impact upon the subjects as incidence of 
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falls have been found to be related to the degree of the patient’s functional vision(102, 
103). 
Clinical assessment of visual function in glaucoma relies on monocular visual fields yet, 
obviously people function binocularly. Whilst the better monocular VF provides a useful 
indication of the patient’s functional field of vision(104), a binocular VF provides a better 
representation of impairment faced by the glaucoma patient. The Esterman test is the 
one test for the binocular VF(105). The Esterman uses a set stimulus intensity of 10 dB 
over a 130o horizontal field with 120 test points. Another approach combines existing 
monocular fields into one aligned binocular visual field: binocular summation and 
integrated visual field (IVF). Binocular summation can be undertaken by taking equivalent 
locations in both of the eyes and calculating the square root of the sum of the squares of 
those sensitivities(106). The IVF is also conducted by comparing corresponding locations 
in both of the eyes and simply takes the better of the two sensitivities to represent the 
binocular representation of the visual field in that location(107). It is not a perimetric test 
in itself and rather it compares existing monocular visual field tests, therefore negating 
the need for the subject to undertake further visual field examination. It has also been 
shown to correlate with the Esterman test(105), making it a valid method to 
retrospectively establish binocular visual function and has also been shown to produce 
similar results to the better eye MD(104). 
The assessment of quality of life for glaucoma patients goes beyond the use of perimetric 
instrumentation and can be examined via the use of self-report questionnaires. Self-
report questionnaires and patient reported outcome measures (PROMs) such as the EQ-
5D in addition to patient interviews are becoming more frequently utilised as interest in 
patient orientated care expands. They are of growing interest as they give a direct 
representation as to how the patient themselves perceives the impact glaucoma has 
upon their quality of life(108). PROMs are sometimes used as end points in clinical trials 
but are not often used in the clinic but have been found to be popular for participants 
especially when the instrument is short, lending support to their utilisation within routine 
clinical practice(109). PROMs are, however, potentially limited when used within the 
context of visual impairment as individuals may feel they have an incentive to mask some 
of their responses in order to maximise their degree of care or to minimise the likelihood 
of having their driving license revoked(110). Furthermore, use of the EQ-5D in studies of 
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glaucoma and the impact of its treatment are limited as utility scores are argued to be 
related to MD in a nonlinear fashion(109). 
In comparison to other chronic conditions, the relationship between glaucoma and 
quality of life has not been explored in significant depth(111). The focus of research on 
quality of life in glaucoma patients however has centred upon its impact on fitness to 
drive and the ability to perform daily activities. Studies have found that those with 
advanced glaucoma are more likely to experience a motor vehicle collision than those 
with healthy vision(112). Legislation in the UK regarding fitness to drive specifies a 
minimum visual acuity of at least 6/12 (0.5 decimal) with both eyes open. Furthermore, 
significant binocular VF loss such as homonymous or bitemporal defects which come 
close to fixation, as measured by the Esterman test, indicates that the subject is no longer 
legally fit to drive(113). Studies have also found that glaucoma impacts upon the subjects 
ability to read with those with bilateral defects having a slower reading speed(114). 
Furthermore it has also been shown that glaucoma patients struggle with reaching and 
grasping objects(115), balance(116) and navigation(117, 118). 
 
1.3.5 NICE Guidelines on Glaucoma 
Guidelines were produced for the NHS in the UK by NICE for the treatment of those with 
or suspected of having glaucoma to establish clinical monitoring and treatment 
pathways(62). In order for the patient to make informed decisions, the guidelines state 
that patients should be supplied with relevant and accessible information pertaining to 
the pathophysiology of the condition, the patient’s existing health state and the possible 
lifelong implications of the disease. The guidelines also specify that the patient should be 
made aware that glaucoma is asymptomatic in its earliest stages and that all 
glaucomatous VF damage is irreversible, in addition to information on the role family 
history plays in the development of the disease.  
Guidelines on glaucoma further state that potential treatment pathways should be 
explained and detailed to the patient whilst describing the importance of patient 
compliance in the effective treatment of the disease(1). Information and support with 
registration and certification of visual impairment should also be provided, including 
details regarding contacting the Driver and Vehicle Licensing Agency (DVLA) about their 
condition. 
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Once the individual has been diagnosed with or is suspected of having glaucoma, baseline 
VF measurements for analysis are required. IOP measurement using Goldman 
applanation tonometry (GAT) should also be undertaken alongside the analysis of Central 
Corneal Thickness (CCT), gonioscopy to assess the depths of the anterior chamber and VF 
testing. Optic nerve head images should also be recorded in order to maximise the 
information available in the classification of disease status.  
 
Table 1-1: NICE Guidelines on COAG Monitoring Intervals 
  Patient Monitoring Intervals (Months) 
IOP at Target Progression IOP only IOP, Optic Nerve Head, 
VF 
Yes No n/a 6-12 
Yes Yes 1-4 2-6 
Yes Uncertain n/a 2-6 
No No 1-4 6-12 
No Yes 1-2 2-6 
No Uncertain 1-2 2-6 
Source: NICE Guidelines: CG85 (62) 
 
Following identification of disease, long term monitoring of IOP fluctuation, the optic 
nerve head and the VF is required (see Table 1-1). Progressing patients should have their 
IOP, optic nerve head and VF measured at 2-6 month intervals whilst those not 
progressing are recommended to undergo full testing every 6-12 months. Those with an 
uncertain definition regarding progression status should be monitored at 2-6 month 
intervals irrespective of whether IOP is at target or not.  
Guidelines on IOP monitoring alone vary according to IOP control, with those achieving 
target not recommended to undergo further testing unless progression is identified (1-4 
month intervals). Patients not achieving target IOP control are recommended to be 
monitored every 1-2 months if there is any suspicion of progression or 1-4 months if not. 
Treatments offered to the patient, as with monitoring, vary according to the risk of the 
individual progressing to a state of visual impairment. Those newly diagnosed with early 
to moderate COAG and at risk of visual impairment in their lifetime should be offered 
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pharmacological treatment depending on comorbidities and drug interactions. Those 
with severe COAG and at risk of further visual impairment in their lifetime should be 
offered surgical intervention in conjunction with pharmacological treatment. The 
information and benefits that are associated with surgery should also be provided to the 
patient in order to allow them to state their preference in terms of the treatment they 
receive. 
 
1.3.6 Treatment Modalities 
Treatment for glaucoma centres on the reduction in IOP because it is the only modifiable 
risk factor for disease progression. There are three main categories of interventions: 
pharmacological, laser and surgical. Pharmacological intervention often represents the 
first line of treatment for glaucoma and usually takes the form of self-administered eye 
drops; these seek to improve the drainage of the aqueous fluid in the eye or by the 
decreasing the production of the aqueous fluid, thereby reducing the amount of pressure 
in the eye. They are classed in terms of their active ingredient which can include 
prostaglandin analogues (PGAs), beta blockers, alpha agonists or carbonic anhydrase 
inhibitors (CAIs)(64). The different pharmacological agents are prescribed depending on 
how the side effect profile impacts upon the glaucoma patient. Prostaglandin analogues 
such as Latanoprost work by enhancing uveoscleral outflow whilst also being noted to 
have some effect upon the trabecular meshwork and has recently been shown to reduce 
IOP levels by 4 mm Hg in treatment naïve patients(119). Beta blockers such as Betaxolol 
work by decreasing the production of aqueous fluid in the eye whilst Alpha agonists such 
as Brimonidine work by both decreasing the production of aqueous fluid and by 
increasing its drainage. Carbonic anhydrase inhibitors also work by reducing the 
production of aqueous fluid and are available both in forms of eye drops (Dorzolamide) 
or pills (Acetazolamide).  
Pharmacological agents are limited due to patient non-adherence to treatment and this 
occurs for a variety of reasons. Patients have reported difficulty in directing the bottle 
over the eye appropriately resulting in missed drops, difficulty in squeezing the bottle 
and the inability to read bottle labels or to identify the bottle(120, 121). Patients have 
also reported issues remembering to administer the drops themselves whilst some have 
reported lack of belief in the eye drop regime impacting on their condition(122, 123). 
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Laser treatment (laser trabeculoplasties) tend to be one off procedures and suffers less 
from the issues relating to adherence. Laser is also occasionally used as the first line of 
treatment for glaucoma in those requiring more aggressive treatment for their glaucoma 
and those unable to adhere or tolerate the side effects of the pharmacological agents. 
Laser trabeculoplasty utilises high energy light beams in order to unblock the trabecular 
meshwork within the eye to increase aqueous outflow, therefore reducing IOP. They are 
usually relative quick to perform and, given the use of anaesthetic, painless. They are not 
a permanent solution however and the patient sometimes requires repeat procedures to 
prolong IOP management. There are two forms of laser trabeculoplasty: argon laser 
trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT). Of the two, ALT was the 
first to be developed with SLT developed in more recent years given issues associated 
with ALT regarding long term efficacy and attrition(124).   
The final line of treatment for glaucoma and therefore the most aggressive intervention 
is a surgical filtration intervention referred to as a trabeculectomy. With the patient 
placed under anaesthetic, part of the trabecular meshwork and adjacent structures are 
removed in order to improve the outflow of aqueous fluid in the eye. Fluid is 
subsequently drained into a “bleb” that is covered by the conjunctiva, consequently 
lowering eye pressure(64). Alternative forms of surgical intervention options are 
available such as a deep sclerectomy operations which implants a device inside of the eye 
to increase drainage whilst aqueous shunts implants tubing to drain aqueous fluid from 
the eye(125, 126). These forms of interventions tend to be the most invasive and 
expensive and, as such, are not prescribed to glaucoma patients unless an aggressive 
approach to treatment is required or if the other forms of interventions have failed(127). 
Treatment choices are complicated however due to the imperfect nature of the 
information available to the clinician. At the point of diagnosis, the clinician will have 
access to information regarding the patient’s IOP, CDR and existing level of VF damage 
amongst other factors, but there is a further level of information required in order to 
ensure allocatively efficient resource allocation: rate of glaucomatous VF progression. 
Those progressing at the fastest rates represent those who are most likely to have a 
negative impact upon their quality of life and as such represent the cohort that resources 
should be targeted at. Identifying these patients however requires considerable time and 
resources in itself, leading to growing discussion into whether we should be intensifying 
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monitoring at the earliest stage of glaucoma identification to reduce the long term 
economic burden of the condition by identifying these patients sooner(15, 128). 
 
1.3.7 The Role of visual fields in the Clinical Management of Glaucoma 
Whilst individual VFs are used to inform the clinician on the existing level of damage to 
the patient, VFs collected in series can provide information on the rate of deterioration 
of functional vision. Therapeutic decisions can therefore be based upon risk to patient 
quality of life in their residual lifetime given existing damage and progression rates. 
Accurate rate identification however requires a considerable length of VF series due to 
the variability associated with perimetry and risk factors alone cannot accurately indicate 
who will progress fast or slowly(129). Whilst a large proportion of patients progress 
slowly, a small but significant proportion of patients progress at rates that could quickly 
lead to visual disability. It is therefore important to understand each patient’s rate of 
progression in order to individualise treatment and to tailor it to their risk of progression 
to visual impairment(89).  
Frequency of monitoring of the VF usually depends on the severity of glaucoma and the 
age of the patient. Stable glaucoma patients are usually monitored every 6 to 12 months 
whilst progressive and advanced glaucoma being monitored every 2 to 4 months(64). The 
European Glaucoma Society (EGS) however has issued guidelines that recommend that 
the VF should be tested 6 times in the first two years in order to better identify those 
progressing rapidly(128), with the World Glaucoma Association echoing this 
sentiment(130). Such an intensified regime of follow up has been argued to be sufficient 
to detect fast progression with annual follow up being adequate following this intensified 
follow up period(15). Clinicians can therefore better target resources towards these fast 
progressors, increasing glaucoma service delivery efficiency by expediting access to more 
aggressive treatments to those most of risk of quality of life reductions, therefore 
reducing the economic burden of glaucoma. 
 
1.3.8 Economic Burden of Glaucoma 
Given its irreversible chronic nature, glaucoma consumes considerable clinical resources 
throughout the patient’s lifetime, therefore warranting further economic 
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evaluation(131). Studies have sought to quantify the burden of visual impairment and 
glaucoma has on healthcare systems worldwide. In the US, Lee and colleagues(132) 
examined the direct resource consumption associated with glaucoma at varying 
severities They found that ophthalmology-related resource use increases with glaucoma 
severity, with costs ranging from $623 to $2511 per year for glaucoma suspects and end 
stage glaucoma respectively. This finding has been supported by other studies(133, 134). 
These studies also suggested delay of disease progression to visual impairment would 
reduce the economic burden and should be of interest to policy makers. 
Beyond direct costs of visual impairment, significant indirect costs have been observed. 
In a study of age related macular degeneration, Meads et al. sought to examine and 
quantify the costs averted by treatment for the prevention of progression to visual 
impairment in the UK(135). A detailed top down study of the main cost factors relating 
to age related macular degeneration (AMD) was performed. Costs of blindness from the 
perspective of the NHS and other local and national government agencies in the first and 
following years were estimated. Resources relating to low vision clinics, low vision 
rehabilitation, acute hospital admissions resulting from injuries caused by low vision in 
addition to residential and community resource consumption. Cost ranges for the first 
year of blindness were estimated between £1375 and £17100 with the following years of 
blindness estimated at between £1325 and £16800 per year. 
Further expanding on the work of Meads et al., Lafuma and colleagues undertook an 
estimation of the total non-medical costs associated with visual impairment in France, 
Italy, Germany and the UK(136). Local prevalence rates of visual impairment were 
established along with estimates for the rates of non-registered visually impaired 
persons. Unit costs were sourced from national databases and from the manufacturers 
directly whilst healthcare professionals were interviewed to establish treatment 
durations. Total annual costs (per individual) were estimated at €10.749bn (£8.4bn) for 
France, €9.214bn (£12.7bn) for Germany, €12.069bn (£11.7bn) for Italy and €15.18bn 
(£13.7bn) for the UK. The main cost components of visual impairment in the community 
were loss of income (23-43%), burden on carer (24-39%) and paid assistance (13-29%). A 
significant proportion of economic consequences of visual impairment were concluded 
to lie beyond direct health costs, especially once effect on productivity has been 
accounted for. Payers must therefore take into account non-medical social costs in order 
to truly understand the economic consequences of visual impairment. Beyond the costs 
48 
 
faced by the payers, significant non-medical costs of glaucoma to the patient have been 
found. In a study of costs faced by glaucoma patients attending hospital based clinics, 
Sharma et al found the maximum mean cost per visit of £16.20 and a minimum mean 
cost of £12.90 with travel found to represent one-fifth of the total patient costs(137). 
There has also been study of the strategic management of glaucoma in order to increase 
the cost-effectiveness of glaucoma management, therefore reducing the economic 
burden of the disease. Following the release of NICEs guidance on glaucoma, there has 
been growing calls for referral refinement schemes to be put in place in local 
communities to reduce the amount of false positives associated with glaucoma 
detection(138-140). Sharma et al. studied the costs of running a community based care 
model whereby community optometrists were provided with training and accreditation 
in glaucoma. These optometrists were then able to run half day clinics in their own 
practices whilst also being available to assist in their local hospitals. The study found that 
the cost per attendance in the community clinic to be more than double that of hospital 
clinic attendance although the costs to the patients were marginally cheaper with the 
community clinic. These higher costs were explained by extra overheads tied to localised 
service provision, illustrating the complex nature of resource consumption associated 
with glaucoma and the NHS. 
Given the increasing direct and indirect resource burden, important decisions regarding 
the amount of resources that should be invested into optimal progression detection are 
required. Decisions need to be made as to whether the investment in progression 
reduction yields acceptable improvements in quality of life relative to non-investment. A 
key tool available to health care payers that helps inform the investment decision process 
is cost-effectiveness evaluation. 
 
1.4 Objectives of the Thesis 
1.4.1 Chapter 2 
Several HE studies have been carried out on competing treatments for glaucoma(141-
144), but the health economics of monitoring the condition in secondary care has 
received little attention. Monitoring and management of glaucoma patients in the UK 
cause considerable direct costs and, in England and Wales alone, it has been estimated 
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that there are more than one million glaucoma related outpatient visits in the hospital 
eye service annually(62). In addition to these direct costs, considerable indirect costs, to 
both the patient and caregivers, are also incurred (135, 145). Significant trends between 
the costs of glaucoma and the severity of disease have also been observed in the UK, 
Europe and the USA(133, 134). As such, there is a potential economic argument for earlier 
detection and better monitoring of glaucoma in order to reduce both the number of 
patients progressing to sight loss and the long-term economic burden of disease(15).  
The measurements from VF testing are notoriously variable which necessitates frequent 
monitoring and/or a long period of time to precisely detect true disease progression.  
There is sound evidence, from retrospective studies and statistical modelling that 
increasing the frequency of VF testing (more examinations per year) leads to earlier 
detection of progression(15, 146-149). An adequate number of VF tests must therefore 
be performed over a given period in order to separate true disease progression from the 
measurement variability inherent in VF data. This idea of more frequent monitoring 
however presents a dilemma for service delivery for patients with COAG: if VF changes 
are not detected early enough, because of infrequent testing, there may be long term 
costs associated with disease progression following inadequate treatment; conversely if 
patients are examined too often there is increased pressure on clinical resources. 
Whilst research recommendations by Chauhan et al (2008), adopted by the European 
Glaucoma Society, suggest that three VFs in each of the first two years of follow-up are 
necessary to detect ‘fast’ VF progression in newly-diagnosed glaucoma patients(15, 128), 
the economic consequences relative to the utility however has not been evaluated, and 
as such requires exposition. The best way to examine any new proposed monitoring 
scheme would be with a randomised clinical trial. No such study has been performed and 
it would have to be substantial and thus costly. A health economic model was therefore 
constructed using different monitoring intervals to detect VF progression rates in all 
newly-diagnosed COAG patients to examine the cost effectiveness of increased VF 
testing. Two different VF monitoring schemes were defined as current practice (annual 
VF testing) and proposed practice (three VF tests per year in the first two years after 
diagnosis) and examined. It is hypothesised that proposed practice applied to some 
groups of patients will yield improved clinical information and therefore increase the 
cost-effectiveness of clinical care. The outcome of this economic evaluation could 
potentially provide information to assist decision-makers allocating of scarce resources 
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so that benefits can be maximised, or inform the design of an appropriate prospective 
study. 
 
1.4.2 Chapter 3 
The work reported in Chapter 3 seeks to examine the parameters used in the health 
economic model. This chapter aimed to investigate how the severity of glaucoma at the 
point of detection is changing over time, specifically represented in the health economic 
model as the existing health state parameter. The identified methods can then be used 
to update the HE model whilst the finding will also be of interest to those stakeholders 
interested in case detection of glaucoma. Late presentation with an advanced stage of 
disease is a significant risk factor for long term adverse outcomes and better knowledge 
of the number of patients that fall into this category could be useful for clinicians (150, 
151). Population screening for glaucoma has been proven to not be cost effective given 
existing levels of prevalence and there is currently no existing glaucoma detection 
strategy in the UK with identification currently reliant upon opportunistic case 
finding(63).  
More detailed interrogation of the large-scale electronic records from routine clinical 
practice that were used to initially formulate the existing health state parameter in the 
health economic model was consequently undertaken. The long-term trends were then 
identified to test the hypothesis that the degree of vision loss at diagnosis had improved 
over time. 
 
1.4.3 Chapter 4 
The work reported in Chapter 4 also seeks to examine the parameters implemented 
within the health economic model, investigating how rates of glaucoma progression are 
changing over time. The identified methods can then be used to update the HE model 
whilst it is also of research interest to stakeholders to examine the trends associated with 
rates of glaucomatous VF loss over time. New topical treatments for glaucoma and OHT 
have been introduced since the turn of the millennium and it is still not clear whether the 
introduction of these interventions have resulted in a reduction in disease 
progression(152).  
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The study of large scale records routinely collected in clinics across England provides an 
opportunity to assess the real world outcome of treatment whilst also monitoring trends 
in health service delivery of glaucoma. This chapter therefore sought to test the 
hypothesis that rates of glaucomatous VF loss are improving over time whilst also seeking 
to more accurately describe the distribution of VF rates being observed in England by 
patient age and disease severity. Importantly, the work described in this chapter also 
considers the frequency of visual field testing that is currently carried out in glaucoma 
secondary care. 
 
1.4.4 Chapter 5 
The work in Chapter 5 updates the health economic model by incorporating the findings 
reported in Chapters 3 and 4. These re-simulations were undertaken to increase the 
confidence around the ICER that was derived. Also, costs of visual impairment were also 
added to the model in order to incorporate the societal costs of visual impairment into 
the analysis. It is relevant to consider the impact that such costs have upon the cost 
effectiveness of increased early stage glaucoma monitoring as, by reducing the 
proportion of those who progress to a state of visual impairment, such costs can be 
averted. Deterministic and probabilistic sensitivity analysis of the new ICERS were also 
undertaken to examine the degree of confidence surrounding the re-simulated models 
outputs. 
 
1.4.5 Chapter 6:  
Chapter 6 presents future work in the pipeline following the conclusion of the studies 
described in the previous chapters of the thesis. In order to fully comprehend priority in 
health service delivery, it is important to measure how patients perceive their condition. 
It has been argued that the quantification of patient utility represents an area that 
requires further research as it focuses specifically on the impact disease has upon patient 
wellbeing(111). This is especially the case in glaucoma as a significant proportion of those 
with the condition do not progress to a state of visual impairment(153).  
As an extension of the work being undertaken in this thesis, a study of patient perception 
of glaucoma is currently being set-up to study the impact of glaucoma diagnosis. It has 
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been suggested that the diagnosis of a disease can have greater impact on the patient’s 
quality of life than the disease has itself(154, 155). To examine the impact of patient 
diagnosis, a bespoke questionnaire comprising of the Brief Illness Perception 
Questionnaire (Brief IPQ), EuroQol 5D (EQ-5D) and the Type D Personality Scale (DS-14) 
was constructed to test the null hypothesis that there is no difference between mean 
Brief IPQ score for the cases and the controls.  
The questionnaire has been presented to patients at Bedford Hospital NHS Trust and 
Hinchingbrooke Hospital with cases identified as those newly diagnosed with glaucoma 
or OHT and controls representing matched existing patients. These matches are 
performed in terms of patient age and existing disease severity measured by visual acuity 
and HFA outputs. Personality variation is also being controlled for using the DS-14 in 
order to make sure the respondents general outlook on life doesn’t impact upon the 
study findings. This chapter also discusses other potential future work resulting from the 
findings in this thesis. 
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Chapter 2: Health economic modelling and 
evaluation of different monitoring intervals in 
glaucoma patients 
 
The work reported in this chapter formed Chapter 5 of a National Institute for Health 
Research (NIHR) report called, “Frequency of visual field testing when monitoring 
patients newly diagnosed with glaucoma: mixed methods and modelling”(1); see List of 
Supporting Publications.  For that chapter, Trishal Boodhna authored the entire health 
economic model, performed the data analysis and also led the write up of the chapter. 
The other significant contributors to this piece of work were Richard Russell (who helped 
with the writing and some of the analysis) and David Crabb who conceived the idea of 
the study and supervised it. Rodolfo Hernández (University of Aberdeen) assisted with 
some of the ideas underpinning the health economic model and commented on a draft 
of the work. Ananth Viswanathan and Rizwan Malik provided clinical advice on the health 
economic model. 
 
 
2.1 Introduction 
As discussed in the introduction to this thesis, glaucoma, as a chronic condition, requires 
care and management for life. Careful clinical follow-up is required in order to assess 
stability of the disease and to provide the appropriate level of treatment and, as such, 
the monitoring and management of the disease represents a significant economic burden 
to the NHS. Statistical modelling has highlighted the potential benefits of performing 3 
VF tests in each of the first two years of glaucoma follow-up in order to detect ‘fast’ 
progression of VF loss in newly diagnosed glaucoma patients(128). However, the 
economic consequences relative to the utility that would derive from such a strategy 
have not been evaluated.  
This chapter describes a study that examined the cost-effectiveness of existing practice 
(annual testing) compared with the recommended practice of 6 VF tests in the first two 
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years in the newly diagnosed patient. The benefit of moving to such a strategy is that 
clinicians would have earlier access to the subject’s rate of VF loss instead of relying on 
risk factors for progression; something that is currently not possible with any 
certainty(156, 157). By accounting for the rate of progression, clinicians can ultimately 
better target services for those individuals most likely to move into a state of visual 
impairment in their lifetime(15, 158, 159), improving the productivity of services 
rendered by the NHS. 
In order to examine the cost-effectiveness of extra VF testing at glaucoma identification, 
a health economic model was constructed to examine the ratio of extra costs relative to 
improvements in quality of life. These were then compared against the NICEs willingness 
to pay ceiling ratio for every extra QALY derived in order to ascertain whether the 
proposed practice was cost-effective for the NHS. In order to specify the health economic 
model, a detailed exploration of the literature pertaining to the costs, effects and 
management of glaucoma was undertaken to inform the parameters that represent the 
foundation of the model. Examination of existing health economic models used in 
glaucoma were also studied in order to help identify the structure of health economic 
model that best applied to the condition.  
 
2.2 Literature Review  
2.2.1 Costs of Glaucoma  
In terms of the direct costs of glaucoma, Traverso and colleagues examined resource 
utilisation in glaucoma and consequently established its economic impact in a 
multicentre study across Europe(134). When direct costs for the examined patients were 
identified across 6 universally accepted states of glaucoma, a statistically significant 
upward linear trend was observed with disease worsening (P=0.018). With each 
increment, costs increased by €86, starting from €455 at stage 0 to €969 at stage 4, with 
medication costs totalling 42% to 56% of total costs across all stages. This lead the authors 
to conclude that the effective delay of VF progression would significantly constrain the 
economic burden of glaucoma, a finding supported by further costing studies undertaken 
within ophthalmology(135, 136). 
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Beyond the direct costs of visual impairment, significant indirect costs have also been 
observed. Meads et al. sought to examine and quantify the costs averted by treatment 
for the prevention of progression to visual impairment in the UK(135). A detailed top 
down study of the main cost factors relating to AMD was performed. Costs of blindness 
from the perspective of the NHS and other local and national government agencies in the 
first and following years were estimated. Resources relating to low vision clinics, low 
vision rehabilitation, acute hospital admissions resulting from injuries caused by low 
vision in addition to residential and community resource consumption. Cost ranges for 
the first year of blindness was estimated between £1375 and £17100 with the following 
years of blindness estimated at between £1325 and £16800 per year with the highest 
costs being observed to be related to residential care. 
 
2.2.2 Utility Quantification in Glaucoma 
Kobelt et al.(160) undertook a study of the relationship between glaucomatous VF loss 
and patient quality of life using 199 patients responding to a bespoke questionnaire. The 
authors observed that progression from mild glaucoma to severe glaucoma resulted in a 
decrease in utility from 0.84 to 0.72 respectively. These differences were not statistically 
significant however until progression to the most severe stages of disease. When better 
eyes was examined against worst eyes, it was found that the better eye had improved 
correlation with quality of life whilst worst eye MD only had mild correlation. These 
results led the authors to conclude that there was a link between visual function and 
quality of life that was especially notable in those with the most severe forms of VF loss. 
In another study of glaucoma and quality of life, Burr et al.(161) measured utility by 
developing the Glaucoma Utility Index. Using focus group studies a new multi-
dimensional tool was developed incorporating central and near vision, lighting and glare, 
mobility, daily activities and eye discomfort amongst other factors. A scale of difficulty 
was then assigned to each dimension and a discrete choice experiment was used to 
develop a preference based utility measure. The greatest impact on respondents was 
found when moving from a state of perfect health to severe disability in central and near 
vision, resulting in in the most significant loss of utility in respondents with daily living 
and mobility the next biggest factors. Subsequently, utility scores of 0.8015, 0.7471, 
0.7133 and 0.5350 were derived to represent mild, moderate and severe glaucoma and 
visual impairment, defined using the Bascom Palmer staging system(162).  
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2.2.3 Treatment and Visual Function 
In the Canadian Glaucoma Study, Chauhan et al.(75) evaluated the impact of IOP 
reduction on rates of VF loss. 216 patients were followed at 4-month intervals; patients 
underwent VF testing at each visit and progression was analysed. Gender and mean 
follow up were not linked with MD rates but increasing age was associated with a worse 
MD rate. In terms of IOP and field change at the first endpoint in the analysis, an IOP 
reduction of 3.1mm Hg/year was associated with a change in MD rate equal to 
0.25dB/year whilst an IOP reduction of 3.0mm Hg/year corresponded to a change in MD 
rate equal to 0.24dB/year at the second endpoint. Consequently, the authors concluded 
that a relatively small reduction in IOP resulted in significant improvements to the rate of 
VF progression.  
In a similar study of IOP and the VF, Folgar et al(163) sought to establish the efficacy of 
surgery in reducing VF progression by conducting a retrospective analysis of patients with 
repeatable VF loss. Those enrolled underwent successful glaucoma surgery in either eye 
with at least 2 years of follow-up before and after the surgery. 28 eyes of 28 patients 
were enrolled with the mean number of VFs per patient equal to 13.4 spanning 7.1 years 
on average. Mean IOP was found to decrease from 19.0mm Hg to 11.3mm Hg following 
surgery, while mean global progression rates fell from -1.48 dB/year to -0.43 dB/year. 
Thus, a 1mm Hg reduction in IOP resulted in approximately a 0.1 dB/year increase 
(improvement) in global rates of progression. For a typical patient, surgical intervention 
would therefore impede progression to blindness by 19 years. The authors concluded 
that reduction in IOP levels caused by successful surgical intervention has a significant 
impact upon the glaucomatous VF progression. 
 
2.2.4 Health Economic Modelling of Glaucoma 
Burr et al. built a health economic model to compare opportunistic case finding to two 
proposed screening strategies to assess whether screening met the UK National 
Screening Committee (NSC) criteria(63). Opportunistic identification by community 
based optometrists was considered current practice, against which, a technician-based 
screening strategy, and a glaucoma specialist optometrist screening strategy, were 
compared. Markov modelling was then utilised to simulate how these different strategies 
would impact upon patients and resource use. The authors found that general population 
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screening was not cost-effective at the given prevalence rate and that screening would 
need to be targeted at specific subgroups aligned with the established risk factors in order 
for it to be considered cost-effective. However, the estimated low prevalence rate 
suggests that, even with targeted screening, cost-effectiveness may still not be achieved 
based upon a usual threshold value of around £30,000 per QALY gained(47). Prevalence 
was found to be a principal factor of cost-effectiveness; with a screening interval of 10 
years, a rate of around 3% to 4% in a 40-year-old cohort would be required for the 
strategies to be cost-effective. Perspective was also found to be an important element of 
analysis as when societal impact was accounted for, a prevalence of just 1% was deemed 
cost-effective. Less important parameters affecting cost-effectiveness were progression 
rates and utility values associated with each health state. Thus, it was concluded that 
COAG screening in the UK met with the NSC criteria for treatment but not for screening.  
More recently, van Gestel et al reported on the construction and validation of a Discrete 
Event Simulation (DES) health economic model, with sufficient transparency, using an 
existing model of ocular hypertension and glaucoma extended to account for decisions 
on treatment and effects(164). Utility was linked to the patient’s stage of glaucoma and 
costs were associated to the level of treatment undertaken. The model underwent 
stringent tests of internal and external validity, face validity was also achieved through 
interdisciplinary meetings analysing the input parameters. Credible health economic 
outputs could be derived after 30 minutes of computation per cohort. There were 
significant advantages identified with DES models, especially in the case of complex and 
diverse treatment modalities such as glaucoma; however, the authors noted that further 
work is required to increase the transparency of such models in terms of structure and 
outcomes as these are likely to cause difficulties in outcome reporting. 
 
2.3 Methods 
2.3.1 The Model 
A Markov model was constructed to model the proposed practice of increased VF 
monitoring frequency against existing practice. The Markov model was chosen because 
of its relative simplicity and relative transparency in comparison with other models (i.e. 
discrete event simulations). All the programming for the model was implemented in Excel 
(Microsoft Excel 2010; Microsoft Corporation, Redmond, WA, USA). Markov models 
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‘stratify’ patients to be always a member of one of its constituent Markov states, a state 
that reflects the subject’s existing level of well-being. The members of each state can 
then move into other health states dependent on the transition probability. Each Markov 
state is designated a utility weight and the individual accumulates utility according to how 
long he or she remains a member of each state. The model is run for a length of time (e.g. 
25 years) known as the ‘model time horizon’. This time horizon is broken down into equal 
parts, denoted as Markov cycles (e.g. 1-year intervals). In addition, all Markov models 
have at least one absorbing state in which all individuals will eventually enter if the model 
is given a sufficiently long time horizon. 
 
Figure 2-1: The structure of the Markov Model for glaucoma. Patients can only 
transition to the next state in sequential order, remain in the same state or be classified 
as deceased at each Markov cycle. 
 
 
Figure 2-1 presents a schematic representation of the Markov model constructed in this 
study. This Markov model seeks to represent how glaucomatous visual field progression 
manifests within the patient and how it is treated in real world clinical settings. It should 
be noted that this model focuses solely on those with a diagnosis of COAG, it therefore is 
not representative of the treatment pathways that OHT patients may experience. 
Furthermore, measurable damage to the patient's VF is used to represent the progression 
the disease and its severity over time. The disease in this model therefore progresses 
over time according to the rate of MD deterioration with this progression being 
controlled by treatment which lowers the patient IOP. By lowering the patient's IOP, we 
in turn lower the rate of progression and the probability of the patient progressing to 
worse disease severities. As such, the model seeks to evaluate the cost-effectiveness of 
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gaining expedited access to information on patient progression rate in the proposed 
practice so as to increase the amount and level of treatment the faster progressors 
receive. Model parameters were sourced from Medisoft VF databases (Medisoft Ltd., 
Leeds, UK) containing 473 252 VFs from 88 954 patients were downloaded in 2012 from 
glaucoma clinics at Moorfields Eye Hospital in London, Cheltenham General Hospital 
Gloucestershire Eye Unit, Queen Alexandra Hospital in Portsmouth and the Calderdale 
and Huddersfield NHS Foundation Trust. These databases were interrogated and 
analysed to provide data on patient initial health states and progression rates in addition 
to patient demographic distributions and how these initial damage and progression rates 
varied by these demographics. 
The Markov states in Figure 2-1 represent, from left to right, increasing disease severity. 
Individuals can start in any of these states according to the state of their disease at 
diagnosis. In a particular model cycle, patients can remain within their existing state of 
health, or progress towards increased disease severity. Most Markov models would allow 
for multidirectional transitional movement, but in the case of an irreversible disease, 
such as glaucoma, a unidirectional movement (towards a worse disease severity) is the 
only transition possible. In addition, it is assumed that patients move sequentially and 
cannot skip states because of the relatively slow evolution of the disease and the yearly 
defined cycle lengths defined in the model. Patients may also leave the model and move 
into the absorbing state (death). 
Chauhan et al. supported the idea that performing three VF tests in each of the first two 
years of follow-up is helpful in detecting ‘fast’ progression of VF loss in newly diagnosed 
glaucoma patients(15). Identification of these patients is hampered by the large 
variability of VF test results over time, and thus it was suggested that at least six VF tests 
are required in the first two years to identify those progressing rapidly (at a power of 
80%). Two different strategies, defined as current practice (annual VF testing) and 
proposed practice (three VF tests per year in the first two years after diagnosis), were 
consequently modelled. The specific hypothesis was constrained to investigating if the 
proposed practice was more cost-effective than current practice. In short, this study 
seeks the benefit of getting more precise information of progression earlier by using 
proposed practice. This gain in information, especially in identifying rapidly progressing 
patients sooner, is hypothesised to yield improved cost-effectiveness of clinical care. 
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Table 2-1: Intervention years by strategy 
Strategy Rate of 
progression 
VFs Required Improved information 
intervention year 
Current practice Stable 13 14 
Slow 13 14 
Medium 6 7 
Fast 5 6 
Proposed practice Stable 15 12 
Slow 15 12 
Medium 8 5 
Fast 7 4 
 
Table 2-1 shows how intervention points varied by strategy in this model. Current 
practice was specified such that fast progressors (defined as those patients in whom VF 
MD worsens by –1.5 dB/year) would be identified after five VF tests, medium progressors 
(defined as –1 dB/year) identified after six VF tests, and slow progressors (defined as –
0.25 dB/year) or patients defined as stable identified after 13 VF tests, that is a significant 
(p < 0.05) slope would be identified by linear regression of MD after these time periods. 
These intervention points are based on research by Chauhan et al.(15) however their 
model was further developed to account for duration of follow-up, as described by 
Alm(165). Like the Chauhan et al. research, simulations were based on a rate of 
progression of MD with statistical power equal to at least 80% and moderate variability 
(SD of MD measurements equal to 1). The results of the simulations indicated that 
proposed practice (six VF tests in the first two years, followed by one VF test per year) 
identifies fast progressors by the fourth year of monitoring, medium progressors by the 
fifth year, and slow and stable progressors by the 12th year, with at least 80% power. 
 
2.3.2 Treatment Pathways 
To model the decision-making process behind treatment allocation and its impact on the 
probability of transition to worse states of disease, ophthalmologists with a specialist 
interest in glaucoma on the project management group (hereafter referred to as ‘the 
clinical review panel’) were consulted to construct simplified treatment pathways that 
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patients would face in a UK NHS tertiary setting. It was concluded that, at the initial stages 
of treatment, decisions on treatment allocation are largely informed by the patient’s risk 
of progression (informed by IOP, central corneal thickness, optic nerve head and other 
clinical assessment), their existing level of damage and their age. Thus, treatment 
pathways were specified to depend on a variable that denoted to be progression risk, 
existing VF damage and the patient’s age. In short, those classified as a high priority were 
more likely to undergo surgical-based treatment strategy, whereas those categorised as 
a low priority were more likely to undergo a pharmacologically based treatment strategy. 
In order to model the effects of treatment on the probability of transition to a more 
severe state, the proportional relationship between IOP reduction and rate of MD 
progression identified by Folgar et al.(163) was used; consequently, a 1 mmHg reduction 
in IOP translated to a 0.1 dB/year improvement in MD rate. In terms of the treatments, 
three lines of therapy were defined: first-line therapy was stated as a pharmacological-
based regimen; second line as the patient undergoing argon laser trabeculoplasty (ALT) 
treatment alongside topical medication; and third line as surgery (i.e. trabeculectomy). 
Based on the recommendations of the clinical review panel, it was assumed that patients 
would be provided with pharmacotherapy from the point of identification as a glaucoma 
suspect; therefore, this level of treatment wasn’t modelled to have any further reduction 
on progression rate and probability of transition.  
 
Table 2-2: Decision Nodes for Treatment Lines given Imperfect Information 
 
High Risk Low Risk 
Health State 50 y/o 70 y/o 50 y/o 70 y/o 
1 2 1 1 1 
2 2 1 1 1 
3 3 2 2 1 
4 3 3 3 2 
Source: Clinical review panel 
 
To map how patients filter through the model into different treatment modalities, 
treatment pathways were identified and constructed based on NICE guidelines and 
expertise from the clinical review panel. Hypothetical subjects were assigned and 
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categorised according to characteristics based on age, risk of COAG progression, existing 
level of damage and rate of progression, resulting in 48 distinct patient groupings and 
pathways in the economic model. Within a time period described as ‘imperfect 
information’, where the managing clinician is ‘unaware’ of the patient’s rate of 
progression of glaucomatous VF damage, the clinical review panel was asked to grade the 
level of treatment that would be provided to the patient given his or her age, existing 
level of damage and risk of COAG conversion (see Table 2-2). A high and low risk 
stratification is used to represent probability of the patient progressing to a state of visual 
disability within their residual lifetime based upon structural measurement of the eye. 
This factor therefore seeks to represent those at high risk of progression based upon 
structural measurements such as cup disc ratios and central corneal thickness. It was 
deemed important by the clinical review panel to account for structural measurements 
in the assessment of treatment modality decision making, therefore a high risk low risk 
dichotomy reflecting the clinical review panels assumptions on structural distribution was 
incorporated into the model. After a defined number of VF tests, the patient’s 
progression rate is identified and then the model moves into a time period defined as 
‘perfect information’ (see Table 2-3). The clinician now had the opportunity to continue 
to provide the patient with the existing degree of treatment, or to increase it. 
Tables 2-3a and 2-3b detail the interaction between decision nodes utilised in the 
economic model given ‘perfect information’. For example, a 50-year-old patient entering 
into glaucoma care at health state 1 (mild damage) and defined as being low risk of 
progression would receive the first line of treatment. If the patient was subsequently 
defined as a ‘fast progressor’, he or she would be moved on to third-line treatment as a 
result of the increased risk of moving into a state of visual impairment in his or her 
lifetime. This functionality was built into the model to reflect the resource reallocation 
that occurs once the clinician identifies those patients who are potentially undertreated. 
This temporal improvement in patient management is what underpins this study, as the 
more expedient allocation of efficient treatment modalities differentiates the proposed 
practice of increased VF monitoring from what is presently carried out in clinical practice. 
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Table 2-3: Decision Nodes for Treatment Lines given Perfect Information and a) high 
patient risk of progression b) low patient risk of progression 
 
 
Stable Slow Medium Fast 
 Health state 50 
y/o 
70 y/o 50 y/o 70 y/o 50 y/o 70 y/o 50 y/o 70 y/o 
 1 2 1 2 1 3 2 3 3 
a) 2 2 1 2 1 3 2 3 3 
 3 3 2 3 2 3 3 3 3 
 4 3 3 3 3 3 3 3 3 
 Source: Clinical review panel 
 
  Stable Slow Medium Fast 
 Health state 50 y/o 70 y/o 50 y/o 70 y/o 50 y/o 70 y/o 50 y/o 70 y/o 
 1 1 1 1 1 3 2 3 3 
b) 2 1 1 1 1 3 2 3 3 
 3 2 1 2 1 3 2 3 3 
 4 3 2 3 2 3 3 3 3 
 Source: clinical review panel 
 
2.3.3 State Transition Probabilities 
The probability of transition from one state to another was defined as a function of the 
patient’s rate of progression and his or her existing level of damage. Following the 
methodology suggested by Hernández et al., the transition probability was calculated by 
first establishing the cohort mean level of damage then establishing the level of further 
damage required in order for a member of the cohort to move into the next health state. 
The years to threshold was established by dividing the change required to reach the 
threshold of the next state by the progression rate of the cohort. Finally, the transition 
probability was identified following the methods of Briggs et al.(26), dividing 1 by the 
amount of years to the threshold. 
Intrinsic to the model is how patients move across health states and progress from a mild 
disease severity to visual impairment. The key driver for this model is the individual’s 
progression rate; patients within the Medisoft databases are stratified by age group and 
whether they are stable, slow, medium or fast progressors. For patients in the younger 
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cohort, it was observed that 49.2%, 36.4%, 12.2% and 2.3% were characterised as stable, 
slow, medium and fast progressors respectively with 33.8%, 41.0%, 21.0% and 4.2% 
observed in the older cohort (see Table 2-6). These results are supported by the Canadian 
Glaucoma Study, which showed that increasing age was associated with a faster MD 
worsening rate(75). 
Once the patient has received a specified number of VF tests, and depending on the 
patient’s underlying rate of progression, a period defined as ‘perfect information’ starts. 
The patient’s rate of progression is now measured with sufficient accuracy to inform and 
adjust treatment allocation. At this stage, the patient is allocated resources efficiently, 
depending on the risk of reaching visual impairment within their lifetime. 
 
2.3.3 The Effectiveness of Treatment 
 
Table 2-4: Review of studies examining the effectiveness of laser (second line) and 
surgical (third line) intervention 
Modality Source Start IOP End IOP 
IOP 
Reduction 
MD 
Reduction 
Laser/ 
2nd Line 
Melamed (2003) 25.5 18.5 7.0 -0.70 
Heijl (2002) 20.6 15.5 5.1 -0.51 
McIlraith (2005) 26.0 17.7 8.3 -0.83 
GLT (1995) 27.2 17.7 9.5 -0.95 
Juzych (2004) 24.3 17.0 7.3 -0.73 
    Average -0.74 
Surgery/ 
3rd Line 
El-Sayyad (2000) 28.2 14.1 14.1 -1.41 
Kobayashi (2003) 24.8 12.6 12.2 -1.22 
Wilson (2003) 26.9 13.2 13.7 -1.37 
Beckers (2003) 22.3 12.6 9.7 -0.97 
Folgar (2010) 19.0 11.3 7.7 -1.05 
Gedde (2007) 25.6 12.7 12.9 -1.29 
     Average -1.22 
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To quantify the effectiveness of the treatment, a review of literature detailing the 
improvements in IOP associated with the treatments was performed. For studies where 
IOP change rather than MD progression rate changes were reported, the proportional 
relationship between IOP reduction and rate of MD progression identified by Folgar et 
al.(163) was used with a 1 mmHg reduction in IOP being translated to a 0.1 dB/year 
improvement in MD rate. Mean improvement in MD rate following ALT (second-line 
treatment) was equal to 0.74 dB/year whilst literature on surgical intervention 
(trabeculectomy) suggests it offers a mean improvement in MD rate of 1.22 dB/year (see 
Table 2-4). Transition probabilities were therefore adjusted for cases where second and 
third line levels of treatment were prescribed in accordance with the decision nodes 
specified by the clinical review panel. 
 
2.3.4 Patient Demographics 
Table 2-5: The modified Bascom Palmer glaucoma staging system 
Severity Range 
Mild 0 dB to -6 dB 
Moderate -6 dB to -12 dB 
Severe -12 dB to -20 dB 
Visually Impaired Worse than -20 dB 
Source: Bascom Palmer glaucoma staging system(162)  
 
Health states were defined according to a modified Bascom Palmer glaucoma staging 
system(162) because of its use of MD and to facilitate data synthesis from studies also 
using this staging system (see Table 2-5). This staging system identifies mild 
glaucomatous VF defects as those with a MD between 0 dB and –6 dB, moderate VF 
defects as those with a MD between –6 dB and –12 dB and severe VF defects as those 
with a MD between –12 dB and –20 dB; patients with worse MDs are classified as visually 
impaired. These levels of damage were required to exist in the patient’s better eye (the 
eye with the larger/healthier MD) rather than their worse eye, since research suggests 
that the level of VF damage in a patient’s better eye has a closer relationship with 
functional vision and utility estimates relative to that of the worse eye(166-169). Patients 
were, therefore, allocated to health states based on baseline disease severity. 
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Table 2-6: Population parameters for the health economic model 
Parameter Subgroup Stratification Input 
Population 
demographics 
Gender Male 52.90% 
Female 47.10% 
Age 50 years 28.15% 
70 years 71.85% 
COAG risk High 20.00% 
Low 80.00% 
Progression rate 
distributions 
50 years Stable 49.15% 
Slow 36.36% 
Medium 12.16% 
Fast 2.33% 
70 years Stable 33.82% 
Slow 41.00% 
Medium 20.97% 
Fast 4.22% 
Health state 
distributions 
50 years Mild 65.00% 
Moderate 21.40% 
Severe 9.96% 
Visually Impaired 3.65% 
70 years Mild 66.20% 
Moderate 20.90% 
Severe 9.25% 
Visually Impaired 3.72% 
Initial mean 
damage 
50 years Mild -3.08dB 
Moderate -8.32dB 
Severe -15.50dB 
Visually Impaired -23.98dB 
70 years Mild -3.11dB 
Moderate -8.42dB 
Severe -15.38dB 
Visually Impaired -23.64dB 
Source: Crabb et al. (1) 
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A retrospective multicentre study of VF databases (Medisoft) in the UK was performed 
to provide baseline population parameters for the Markov model (1). Findings suggested 
that the distributions observed could be represented as two clusters with mean ages of 
51.2 years (28%) and 70.2 years (72%); therefore, for simplicity, patients within the model 
were set to enter the analysis at either the age of 50 or 70 years in the proportions given 
(see Table 2-6).  
The ages at which patients are specified to enter are important, as returns on investments 
are dependent on the residual life expectancy of those being invested in; the longer the 
residual life expectancy, the greater the return of investment in terms of QALYs derived 
and years of visual impairment avoided. The ages chosen were also required to 
dichotomise younger patients and older patients with sufficient differential as decision 
nodes within the model also vary by age group. As a result of the clustering analysis, four 
separate cohorts were identified for individual cohort analysis within the model, in 
addition to an analysis of all cohorts (termed full simulation).  
Patients within the model were dichotomised by gender and by age characterisation 
analysing separate cohorts of males aged 50 and 70 years (M50 and M70 cohorts, 
respectively) and females aged 50 and 70 years (F50 and F70 cohorts respectively). The 
results of the full simulation and the M70 cohort were of most interest, as the full 
simulation represents all patients within the UK glaucoma service, while the M70 cohort 
represents the group of patients least likely to provide cost-effective results, given they 
have the lowest residual life expectancies of all cohorts modelled. 
In modelling existing damage at first presentation for the younger cohort, 65.0% of 
patients were specified as having mild glaucoma, 21.4% were defined as having moderate 
glaucoma, 10.0% were specified as having severe glaucoma and 3.7% of patients defined 
as visually impaired. In the older cohort, these figures were very similar, 66.2%, 20.9%, 
9.3% and 3.7% respectively. The mean level of existing VF damage for the younger cohort 
was –3.08 dB, –8.32 dB, –15.50 dB and –23.98 dB for the mild, moderate, severe and 
visually impaired subgroups, respectively, while these figures were –3.11, –8.42, –15.38 
and –23.64, respectively, for the older cohort. 
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2.3.5 Costs and Utilities within the Model 
The costs of treatment were derived from Traverso et al.(134) as the treatment patterns 
modelled by the authors were similar to those in the current study and the glaucoma 
staging system was identical; thus, facilitating the resource costs calculation associated 
with each health state. In seeking to study how glaucomatous disease severity interacted 
with resources consumed, the authors established costs for various stratified disease 
stages. As the analysis models only three possible lines of treatment, resource 
consumption was analysed within the findings of Traverso et al. Thus, the treatment 
pathway identified by the authors for ‘mild glaucoma’ was specified as the first line of 
treatment, the pathway identified for ‘moderate glaucoma’ was specified as the second 
line of treatment and the pathway identified for ‘severe glaucoma’ was specified as the 
third line of treatment. These pathways were chosen as they bore the closest semblance 
to the three pathways specified in this economic model. Consequently, patients in the 
second line of treatment were costed to undergo a trabeculoplasty every 12.3 years (an 
average of two times over the 25-year time horizon utilised in this model), while those in 
the third line of treatment were costed to undergo a trabeculectomy every 11.2 years. 
Table 2-7 indicates that additional consumption of medications and alternative 
treatments within lines of treatment were possible. For example, those in the second line 
of treatment are costed to undergo a trabeculectomy every 37.0 years; however, given 
the starting ages of the cohorts and the 25-year time horizon used, trabeculectomy is a 
relatively small cost in this treatment line. 
 
Table 2-7: Resource consumption by the three lines of treatment employed 
 Treatment Line 
Resource First  Second  Third  
Cost £777.47 £875.47 £1083.23 
Office visits (per year) 3.0 3.1 3.7 
Visual fields (per year) 1.4 1.5 1.6 
Medications (per year) 14.4 20.4 21.6 
Trabeculoplasties (per 100 years) 3.5 8.1 5.3 
Trabeculectomies (per 100 years) 2.5 2.7 8.9 
Sources: Traverso (2005) 
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A key driver of the cost-effectiveness of proposed practice is the cost of supplemental VF 
tests. In the main, these represent a short-term investment which may help clinicians to 
provide the appropriate level of service provision in the long term. For the health 
economic model, these extra VF tests were specified to be performed by technicians and 
costs, sourced from the National Schedule of Reference Costs (2010–11) were found to 
be £56.54 per additional test undertaken(170). 
 
2.3.5 Utilities within the Model 
Table 2-8: Utilities associated with the different health states used in the model 
Disease severity Utility Score 
Mild 0.8015 
Moderate 0.7471 
Severe 0.7133 
Visually Impaired 0.5350 
Source: Burr (2007) 
 
The utility weights associated with each health state were derived from Burr et al.(161). 
This glaucoma study was selected as it was based in the UK and, therefore, of direct 
relevance to the model presented here, a requirement of NICE(38). Participants were 
asked to select one choice out of 32 discrete choice sets to indicate preferences in 
addition to completing EQ-5D questionnaires and visual analogue scales (VASs). They 
were then objectively graded according to their binocular VFs using the integrated VF 
(IVF) method described by Crabb et al.(171). Analysis then followed using regression 
techniques to establish utility weights for each disease dimension, resulting in health 
state utility scores (see Table 2-8). As such, mild, moderate, severe and visual impairment 
stages were represented by scores of 0.8015, 0.7471, 0.7133 and 0.5350 respectively.  
 
2.3.7 Discounting 
The cost and QALYs associated with future treatment were discounted as costs and 
benefits accrued in the future are valued less than they are today due to the short-term 
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inter-temporal time preference of rational economic agents. Thus, costs and utilities 
were discounted at a rate of 3.5% per year, as specified by NICE(38). 
 
2.3.8 Model Validation 
To ensure that the model reflected clinical management in a rational manner, internal 
and external model validation was undertaken. Internal validation was performed by 
varying the parameters used in the model and analysing whether or not expected and 
rational outputs were derived. The model was then adapted or corrected based on the 
outcomes of these variations relative to assumptions. External validation was achieved 
by supplying the clinical review panel with access to the model in order to establish 
whether or not modelled pathways were representative of that observed within clinical 
contexts. Feedback was also provided as to whether or not the model generated rational 
outputs when parameters were altered within rational limits. 
 
2.3.9 Base case Analysis 
The economic evaluation was modelled in full (including all cohorts of glaucoma patients; 
‘full simulation’) and then stratified by each cohort to analyse how subgroups individually 
impacted model findings. Primarily, this analysis focuses on the findings of the full 
simulation and that of the M70 cohort, as this specific cohort represents the least cost-
effective cohort within the analysis (given the lower residual life expectancies based on 
their gender and starting age). The main outcome of interest was the incremental cost-
effectiveness ratio (ICER), representing the costs per QALY derived by proposed practice. 
ICERs were established by identifying the ratio of the changes in costs incurred to the 
QALYs achieved between current practice and the proposed strategy. The analysis was 
conducted from the perspective of the UK NHS, while costs were expressed in pound 
sterling. The cost and derived QALYs associated with future treatment were discounted 
at a rate of 3.5% per year, as specified by NICE(38) as costs and benefits accrued in the 
future are valued less than costs and benefits accrued today. 
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2.3.10 Sensitivity Analysis  
Table 2-9: Baseline parameters ranges used in tornado diagram modelling 
Description Parameter Baseline Low High 
Cost First Line £777.47 £388.74 £1,166.21 
Second Line £875.47 £437.74 £1,313.21 
Third Line £1,083.23 £541.62 £1,624.85 
Health State Health state 1 0.8015 0.7471 0.9720 
Health state 2 0.7471 0.7133 0.8015 
Health state 3 0.7133 0.5350 0.7471 
Health state 4 0.535 0.2700 0.7133 
50-year-old 
progression rate 
distribution 
Stable 49.15% 24.58% 73.73% 
Slow 36.36% 18.18% 54.54% 
Medium 12.16% 6.08% 18.24% 
Fast 2.33% 1.17% 3.50% 
70-year-old 
progression rate 
distribution 
Stable 33.82% 16.91% 50.73% 
Slow 41.00% 20.50% 61.50% 
Medium 20.97% 10.49% 31.46% 
Fast 4.22% 2.11% 6.33% 
50-year-old 
disease severity 
distribution 
Mild 65.00% 32.50% 97.50% 
Moderate 21.40% 10.70% 32.10% 
Severe 9.96% 4.98% 14.94% 
Visually Impaired 3.65% 1.83% 5.48% 
70-year-old 
disease severity 
distribution 
Mild 66.20% 33.10% 99.30% 
Moderate 20.90% 10.45% 31.35% 
Severe 9.25% 4.63% 13.88% 
Visually Impaired 3.72% 1.86% 5.58% 
Treatment 
effect 
First Line 0.00 0.00 0.00 
Second Line -0.74 -0.51 -0.95 
Third Line -1.22 -0.97 -1.41 
Risk of COAG High 20.00% 10.0% 30.0% 
Low 80.00% 70.0% 90.0% 
Discount rate 3.50% 1.75% 5.25% 
Implementation Cost £0.00 -£1,000.00 £1,000.00 
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One-way sensitivity analysis was undertaken in order to identify which parameters are 
most important on outcomes from the economic model using maximum and minimum 
model assumptions with results being displayed as tornado diagrams. Tornado diagrams 
utilise the maximal and minimal assumptions of each parameter to create a maximum 
and minimum derived ICER, the ratio between changes in costs and changes in effects, 
with differentials charted in order of magnitude (largest differentials are located at the 
top and the lowest at the bottom), creating the shape of a tornado. 
Table 2-9 indicates the limits for the health economic model’s parameters examined in 
the tornado analysis. Discount rate, costs and progression rates were all varied by 50% in 
order to set maximum and minimum limits. Utility was limited such that maximum and 
minimum limits were set to baseline assumptions of the parameters above and below 
the specific health state. Treatment effects were limited to the maximum and minimum 
observations for MD change associated with the modality identified in the review of 
literature, while risk distributions were varied by 10% in either direction. Further DSA, 
investigating the impact of marginal variations in parameters, was then performed 
focusing on the most important parameters that had been identified in the tornado 
diagrams. One-way analysis was then undertaken to investigate the impact caused by 
variation in individual parameters on ICERs identified. 
 
Table 2-10: Parameter distributions for probabilistic sensitivity analysis 
Description Parameter Mean Distribution Alpha Beta 
Utility Health state 1 0.8015 Beta 37.94 9.4 
Health state 2 0.7471 Beta 278.07 94.13 
Health state 3 0.7133 Beta 49.11 19.74 
Health state 4 0.535 Beta 9.87 8.58 
Costs First line £777.47 Gamma 15.37 50.6 
Second line £875.47 Gamma 15.37 56.98 
Third line £1,083.23 Gamma 15.37 70.5 
Implementation £410,000 Gamma 9.09 45,093.55 
Treatment 
effects 
First line  0.00 dB n/a n/a n/a 
Second line –0.74 dB Gamma 19.56 0.04 
Third line –1.22 dB Gamma 46.14 0.03 
n/a, not applicable. 
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The model’s parameters were also examined using PSA (Table 2-10). Simulations were 
performed 10,000 times in this study, with incremental QALY gains, incremental costs 
and the resultant costs per QALY associated with each simulation recorded. Once 
simulated, ICERs were calculated and plotted on the incremental cost-effectiveness plane 
(CEP). From these, cost-effectiveness acceptability curves (CEACs) were formulated 
indicating the probability of proposed practice being accepted at given levels of 
willingness to pay. 
A combination of the PSA and the DSA was performed in order to further examine the 
relationships between important parameters in the model and the probability of 
acceptance of proposed practice at a given willingness to pay. VF test costs, discount 
rates, risk distributions and costs of visual impairment were all selected to be analysed in 
combination with the PSA. The cost of performing individual VF tests was varied to gauge 
its impact on probabilistic cost-effectiveness; cost was varied from £38.76 (lowest 
estimation) to £70.45 (highest estimation) following the maximum and minimum 
assumptions of the National Schedule of Reference Costs (2010–11)(170).  
Discount rates were also varied to see how time preferences may impact on the health 
economic model’s findings. Time preference was varied between a low discount factor of 
0% (future costs and patient utility valued the same as they would be in the present) and 
a high discount factor of 5% (future costs and utility valued less than they would be in the 
present). The proportion of patients defined within the model as presenting with a high 
and low risk of progression was also varied in order to analyse how this parameter 
impacted on probabilistic cost-effectiveness. An initial division of 80% and 20% in low- 
and high-risk categories, respectively, was analysed within the model following 
consultations with the clinical review panel. In the PSA, these risk specifications were 
varied to 90% and 10% and to 70% and 30%, for the low- and high-risk patient groups 
respectively.  
Finally, as the economic model was performed from the perspective of the UK NHS, thus 
not accounting for the costs to society of patients progressing to visual impairment, 
analysis of the impact that a change in perspective may have on outcomes was 
introduced, with costs of patients being defined as visually impaired incorporated. Per 
annum costs to society of £250, £500, £750, £1000 and £1758.50 (the threshold where 
costs of visual impairment cause proposed practice to derive a lower total cost than 
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current practice, therefore dominating it) for each patient defined as visually impaired 
were, therefore, introduced. 
 
2.4 Results  
2.4.1 Base case analysis 
 
Table 2-11: Summary of results for all cohorts studied and the full simulation 
  Current Practice Proposed Practice Incremental   
Cohort Age Average 
Costs 
Average 
QALYs 
Average 
Costs 
Average 
QALYs 
Costs QALYs ICER 
M 50 £12,903 10.97 £13,204 10.98 £301 0.02 £17,655 
 70 £5,339 4.25 £5,627 4.26 £288 0.01 £26,531 
F 50 £13,289 11.33 £13,590 11.35 £301 0.02 £17,013 
 70 £6,065 4.91 £6,358 4.92 £293 0.01 £21,924 
Full Sim £7,765 6.41 £8,059 6.43 294 0.01 £21,679 
 
In total, 10,000 patients entered into the model under the full simulation while 3801 
patients entered into the model under the M70 cohort. Under the full simulation, a 
positive cost differential of £294 per patient was identified between proposed practice 
and current practice (see Table 2-11), unsurprisingly implying that higher costs were 
associated with proposed practice. A positive utility differential of 0.01 QALYs per patient 
was also identified, implying greater utility associated with proposed practice. Thus, an 
ICER of £21,679 was derived for proposed practice, a figure within the hypothetical NICE 
ceiling ratio of £30,000. For the M70 cohort, incremental costs per patient and 
incremental utility per patient were £288 and 0.011 respectively. 
The resulting ICER was thus equal to £26,531 per QALY, a ratio higher than that derived 
from the full simulation owing to the lower residual life expectancies of patients in the 
cohort. Findings were reflected in the F70 cohort with per patient cost and utility 
differentials of £293 and 0.013 QALYs, respectively, and an ICER equal to £21,923. 
Outcomes for the M50 and F50 cohorts were lower than that of the full simulation, as 
the residual life expectancies analysed for these cohorts were lower. Incremental costs 
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per patient were equal to £301, incremental utility per patient equalled 0.017 QALYs and 
0.018 QALYs and ICERs equalled £17,655 per QALY and £17,013 per QALY, for the M50 
and F50 cohorts respectively. Of the 10,000 patients who entered into the model under 
the full simulation, a total of 834.65 visual impairment-years were saved with proposed 
practice (see Table 2-12), equating to £3,517 per year of visual impairment saved. In the 
M70 cohort, this number was 229.18 years saved for proposed practice, while, in the 
M50, F50 and F70 cohorts, 173.97, 162.91 and 268.58 years were saved respectively. 
 
Table 2-12: Years of visual impairment saved with the proposed practice relative to 
current practice 
Cohort Subgroup Visual Impairment Years saved 
M 50 173.97 
 70 229.18 
F 50 162.91 
 70 268.58 
Total 834.65 
 
2.4.2 Deterministic Sensitivity Analysis: One way analyses 
One-way analyses verified that the M70 cohort was the least cost-effective subgroup for 
all parameters examined, while the F50 cohort the most cost-effective cohort; this result 
is expected given the differences in each cohort’s residual life expectancies and, 
therefore, the ability to recoup investment. In addition, the results for the M50 and F50 
cohorts were closer than those observed between other combinations of cohorts owing 
to the similarities between these cohorts’ residual life expectancies. 
The utilities associated with health state membership were varied in 0.01 QALY 
increments from baselines of 0.8015, 0.7471, 0.7133 and 0.5350 for utility health states 
1, 2, 3 and 4, respectively, with ICER impacts assessed (Figure 2-2). A negative relationship 
between the parameters and ICERs was observed for the utility associated with health 
state 1 for all cohorts, although only a decrease in utility in the M70 cohort was found to 
push ICERs above £30,000 per QALY. Similar findings were observed for the utility 
associated with health state 2; however, a reduction in this utility caused an accelerated 
increase in ICERs for the M50 and F50 cohorts compared with the 70-year-old cohorts.  
76 
 
Figure 2-2: One-way analysis of utility health states. (a) Utility health state 1, baseline = 
0.8015 QALYs; (b) utility health state 2, baseline = 0.7471 QALYs; (c) utility health state 
3, baseline = 0.7133 QALYs; and (d) utility health state 4, baseline = 0.5350 QALYs. 
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When the utilities of health states 3 and 4 were examined, a positive relationship existed 
between parameters and cohort ICERs. Within utility health state 3, the M70 and M50 
cohorts surpassed the £30,000 per QALY ratio when utilities were increased; however, 
only the M70 cohort tipped this ratio when the utility of health state 4 was examined. 
Treatment costs were varied by increments and decrements of £25, in the range ± £125 
from a baseline of £696.49, £784.28 and £970.40 for first-, second- and third-line 
treatment costs, respectively (Figure 2-3). For first-line treatment costs, a negative 
relationship was observed between this parameter and ICERs of all cohorts, but the M70 
cohort was the only grouping to surpass the £30,000 per QALY mark when treatment 
costs were reduced to £600. For second-line treatment costs, a positive relationship was 
found in the M70 and F70 cohorts, while a marginal negative relationship was observed 
in the M50 and F50 cohorts; however, the £30,000 per QALY mark was not exceeded in 
any cohort. For third-line treatment costs, a slight positive relationship was observed 
within all cohorts; however, the £30,000 per QALY mark was not surpassed for any 
cohort. The nature of these relationships can be attributed to the fact that proposed 
practice and current practice utilises the different treatment lines to varying extents 
across the patient characteristic framework (for example, proposed practice implements 
first line treatment to a lesser degree than current practice as it identifies fast progressors 
sooner. Thus, these patients receive more aggressive treatments lines earlier). 
First-line treatment effects on rate of VF progression were analysed in 0.05 dB/year 
decrements from 0 to –0.5 dB/year from a baseline of 0 dB/year, –0.74 dB/year and –
1.22 dB/year for first-, second- and third-line treatment costs, respectively (Figure 2-4). 
It is worth noting here, again, that an improvement in treatment effects is associated 
with a decrease in the rate of MD progression. The second- and third-line treatment 
effects were varied in increments or decrements of 0.05 dB/year and the impact on the 
ICER was assessed in the range ± 0.25 dB/year. For first-line treatment effects, an 
improvement in effectiveness increased ICERs. The M70 cohort surpassed the £30,000 
per QALY mark at –0.15 dB/year, while the F70 cohort exceeded this ceiling ratio at 
roughly –0.3 dB/year; the F50 and M50 cohorts did not surpass the £30,000 per QALY 
mark. When second-line treatment effects were examined, improving intervention 
effectiveness increased ICERs in the M50 and F50 cohorts and decreased ICERs in the 
M70 and F70 cohorts. However, the £30,000 per QALY mark was only surpassed by the 
M70 cohort when the treatment effect was equal to approximately –0.6 dB/year.  
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Figure 2-3: One-way analysis of treatment costs. (a) First-line treatment costs, baseline 
= £696.49; (b) second-line treatment costs, baseline = £784.28, (c) third-line treatment 
costs, baseline = £970.40. 
 
 
 
 
 
 
 
 
 
79 
 
Figure 2-4: One-way analysis of treatment effects. (a) First-line treatment costs, 
baseline = 0; (b) second-line treatment costs, baseline = -0.74; and (c) third-line 
treatment costs, baseline = -1.22. 
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The costs of implementing proposed practice, the costs of patients progressing into a 
state of visual impairment and the time horizons utilised in the model were also chosen 
for one-way analysis for validation purposes. Implementation costs were varied between 
£0 and £900,000 in £100,000 steps and the impact on the ICER was assessed from a 
baseline of £410,000. Increasing implementation increased ICERs in all cohorts; the 
£30,000 ceiling ratio was exceeded in the M70 cohort only when this cost was equal to 
roughly £800,000. Costs of visual impairment were expanded to £9000 per subject in 
£1000 increments from the initial baseline assumption of £0 as a result of the NHS 
perspective of the model. As visual impairment costs increased, ICERs decreased for all 
cohorts, with the total cost associated with current practice superseding that of proposed 
practice over the 25-year time horizon at approximately £5000 for the M70 cohort, £4000 
for the F70 cohort and £2500 for the M50 and F50 cohorts.  
The impact of the time horizon was examined at 5-year intervals in both directions. For 
all 70-year-old cohorts, ICERs were observed to begin plateauing after 15-year time 
horizons; however, ICERs grew exponentially below 15 years. For the 50-year-old cohorts, 
ICERs were observed to continually shrink as time horizons expanded with reductions 
beginning to plateau after a horizon length of 45 years. All cohorts surpassed the £30,000 
per QALY mark when the time horizon was shortened to approximately 10 years in length. 
 
2.4.3 Deterministic sensitivity analysis: Tornado Diagrams 
Tornado diagrams were constructed to represent model outcomes for the limits 
associated with each parameter, thereby mapping how the maximum and minimum 
values impact on ICERs. In addition, the costs associated with progressing into visual 
impairment were also explored using deterministic sensitivity analysis. For all parameters 
utilised within the model, outcomes were sorted in order of ICER impact, resulting in the 
tornado appearance. Tornado analysis was consequently performed on the full 
simulation results that the model derived (see Figure 2-5). 
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Figure 2-5: Tornado analysis of baseline parameters used in the model. 
 
When analysing the full simulation data, utility health states were found to have the 
greatest impact on the derived ICER. In particular, utility health state 4 had the most 
significant impact, with findings suggesting that the variability around this parameter was 
sufficient to push the ICER beyond the £30,000 ceiling ratio. The projected cost of visual 
impairment was the next most important factor in the tornado analysis, altering the ICER 
by ±£12,326.98, with the lowest estimation of visual impairment costs sufficient to push 
the ICER beyond the £30,000 per QALY mark. Costs associated with the different 
treatment modalities were the next most important parameters with the variability 
around the cost of first-line treatment affecting the ICER most, followed by second- and, 
then, third-line treatments. The percentage of patients with a moderate rate of 
progression in the 70-year-old cohorts featured next in the diagram, followed by discount 
rate. All other parameters had less than a £5000 impact on the ICER from the minimum 
to maximum value. 
When deterministic sensitivity analysis focused specifically on the M70 cohort, a greater 
number of parameters pushed the ICER beyond the £30,000 per QALY limit, including the 
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utility associated with health states 1, 3 and 4, the costs of visual impairment, the costs 
of first- and second-line treatments, the proportion of patients with moderate or slow 
progression in the 70-year-old cohorts and, finally, the effects associated with second-
line treatment. Within the M50 and F50 cohorts, the only parameter observed to drive 
the ICERs beyond the £30,000 cut-off was the cost of visual impairment. For the F70 
cohort, utility health state 4, costs of visual impairment and percentage of patients with 
moderate VF progression forced ICERs beyond NICEs ceiling ratio 
 
2.4.4 Probabilistic Sensitivity Analysis 
 
Figure 2-6: Cost-effectiveness planes by cohorts studied 
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Greater variability was observed in CEP plots for the 70-year-old cohorts than for the 50-
year-old cohorts (Figure 2-6); simulated incremental costs associated with the 70-year-
old cohorts were considerably higher than those associated with the 50-year-old cohorts 
because more older patients were simulated in the model, while incremental utilities 
were also significantly higher in the 70-year-old cohorts than in the 50-year-old cohorts. 
In addition, there were twice as many observations in the north-west (dominated) 
quadrant of the plane in the 50-year-old cohorts (M50 = 540, F50 = 578) than in the 70-
year-old cohorts (M70 = 211, F70 = 219). 
 
Figure 2-7: Cost-effectiveness acceptability curves (CEACs) across all cohorts studied. 
 
 
Subsequently, CEACs were defined from these simulations (Figure 2-7). Willingness to pay 
for each QALY gained was varied from £0 to £50,000 and the proportion of simulations 
deemed acceptable at this level was noted. Similarly shaped CEACs were observed for 
the M50 and F50 cohorts, and for the M70 and F70 cohorts. At a £30,000 cost per QALY 
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ceiling ratio, the proportion of observations deemed acceptable in the M70, F70, M50 
and F50 cohorts was 57.33%, 67.78%, 73.36%, and 74.26% respectively. When the ceiling 
ratio was increased to £50,000 cost per QALY, the proportion of observations deemed 
acceptable was 81.69%, 86.35%, 84.22%, and 84.44% for the M70, F70, M50 and F50 
cohorts respectively. The 50-year-old cohorts’ CEACs were observed to plateau sooner 
than those for the 70-year-old cohorts, with the M70 cohort CEAC consistently lower than 
in other cohorts in terms of probability of acceptance. The F70 cohort’s CEAC was 
consistently lower than those from the 50-year-old cohorts up until the £42,000 per QALY 
mark, at which point its ICER had an increased probability of acceptance compared with 
the 50-year-old cohorts. 
 
2.4.5 Deterministic and probabilistic sensitivity analyses in combination 
The DSA of VF costs, discount rates, risk distributions and costs of visual impairment was 
combined with PSA in order to examine how variation in this specific parameter may 
impact on the probability of acceptance for proposed practice at given willingness to pay. 
In terms of VF costs, analysis was varied from the baseline of £56.54 and varied from a 
maximum of £70.45 to a minimum of £38.76. In the base case analysis at a £30,000 
willingness-to-pay threshold, an increase in the cost of a VF test reduced the probability 
of proposed practice being cost-effective from 57.33% to 45.63%, while the low 
estimation increased probability to 71.11%. Altering this cost in the other cohorts 
produced similar results, but with a smaller percentage change, particularly in the 50-
year-old cohorts. 
In terms of discount rates utilised, analysis was started from the baseline of 3.5% and 
varied from a maximum of 5% to a minimum of 0%. In the base-case cohort with a 
£30,000 willingness-to-pay threshold, the removal of discounting increased the 
probability of cost-effectiveness from 57.33% to 71.91%, while an increase in discounting 
reduced this probability to 49.13%; similar results were identified in the other cohorts. 
The differences in the probability of cost-effectiveness between the low discount and 
high discount were found to reduce as willingness to pay per QALY gained was increased. 
In terms of the risk distributions assumed within the model, analysis started at the 
baseline of 80% low risk and 20% high risk, and this was varied from a ratio of 70% low 
risk and 30% high risk to 90% low risk and 10% high risk. In the base case with a £30,000 
85 
 
willingness-to-pay threshold, a decrease in the proportion of high-risk patients increased 
the probability of cost-effectiveness from 57.33% to 57.34%, while an increase resulted 
in a reduction of probability to 55.06%. These findings were generally reflected in the 
other cohorts. 
Finally, in terms of the costs of visual impairment, analysis was varied from a baseline of 
£0 and varied from a maximum of £1758.50, the maximum degree of visual impairment 
costs before current practice became dominated by proposed practice. The introduction 
of costs of visual impairment to the base case increased the probability of proposed 
practice being cost-effective with visual impairment costs of £250, £500, £750, £1000 
being associated with an increase in probability of 4.04%, 5.87%, 9.68%, 12.76% and 
86.73%, respectively, at the £30,000 willingness-to-pay threshold. 
 
 
2.5 Discussion  
2.5.1 Summary  
The study described in this chapter sought to examine whether or not increased VF 
monitoring at the earliest stages of disease identification (i.e. six VF tests in the first two 
years after diagnosis) would be cost-effective compared with the current practice of one 
VF test per year. The economic evaluation results show that proposed practice is 
associated with higher costs, but more QALYs, than current practice. Under the full 
simulation, the ICER was £21,679 and 834.65 years of visual impairment were avoided 
with proposed practice (10,000 individuals). When the model was run for the male cohort 
who were 70 years old (lowest residual life expectancies relative to the other cohorts), 
the ICER rose to £26,531, with a probability of being cost-effective at 57.3% at £30,000 
threshold value. Since the economic model was constructed from the perspective of the 
UK NHS, when societal gains are accounted for (the costs of visual impairment beyond 
the UK NHS), the cost-effectiveness of proposed practice expands. Comprehensive DSA 
and PSA were performed. DSA identified that the ICERs were most sensitive to the 
uncertainty surrounding the parameters utilised for utility health states, particularly for 
utility health state 4, while the uncertainty associated with the costs of the different 
treatment lines was also found to impact on the derivation of the ICER. 
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2.5.2 Model baselines and patient characteristics 
Key components of the economic evaluation of current practice compared with proposed 
practice were the patients’ demographics and characteristics of their glaucomatous VF 
defects. This study incorporated a comprehensive analysis of VF data from four eye 
hospitals in England, comprising almost half a million VF tests. Just over 2% of the 50-
year-old cohorts progressed at a ‘fast’ rate, while 4.22% of the 70-year-old cohorts 
progressed at this rate. While these percentages were notably small, the relative values 
were also of interest, as they provide evidence that older patients tend to suffer a faster 
rate of progression than younger patients, supporting recent published research (75). An 
attempt was made to ensure that the distribution of patients across different health 
states in the model was reflective of that observed in real clinics. For example, if the 
proportion of those already diagnosed with severe glaucoma or visual impairment in the 
model was overestimated, possible utility gains associated with proposed practice would 
be understated. Examination of the four VF databases revealed that more patients in the 
50-year-old cohorts than in 70-year-old cohorts would be defined as having severe 
glaucoma, while the proportion of patients classified as visually impaired was similar in 
both cohorts. 
 
2.5.3 Costs of treatment 
Under one-way analysis, an inverse relationship was observed between first-line costs 
and cost-effectiveness of proposed practice while the converse was true for second- and 
third-line treatments. This can be explained by the fact that proposed practice is less 
biased towards first-line treatment than current practice; decision nodes indicated that 
first-line treatment is prescribed in 7 out of the 16 (44%) possible patient characteristic 
combinations when patients’ rate of progression is unknown, while only 14 out of the 64 
(22%) possible patient combinations were prescribed this level of treatment once rates 
of progression were identified. Proposed practice accelerates the time taken to identify 
the rate of progression and, therefore, first-line treatment is used to a lesser extent than 
in current practice. This implies that a reduction in costs of first-line treatment would 
reduce the cost of current practice more than proposed practice. Conversely, second- 
and third-line treatments are more prominent in proposed practice for the 70-year-old 
cohorts, causing ICERs to rise when the costs of these modalities rise. However, no major 
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impact was observed with an ICER of £26,907 and £26,629 when second- and third-line 
treatment costs were expanded to £900 and £1100, respectively, in the M70 cohort. 
Tornado analysis suggested that first-line treatment cost is the most sensitive parameter, 
followed by second- and third-line treatment costs; however, 50% variations in these 
parameters were not significant enough to push ICERs beyond £30,000 per QALY. 
 
2.5.4 Health state utilities 
Tornado analysis under full simulation identified utility health state 4 as the most 
important parameter impacting on the ICER and, at its highest estimation, the ICER 
expanded to £38,829. Furthermore, it was the only utility parameter to push the 
estimation of cost-effectiveness beyond the accepted NICE £30,000 per QALY ceiling 
ratio. It should be noted that the minimum value assumed for this parameter was 
adjusted to be equal to utility health state 3, implying that VF progression from severe 
glaucoma to visual impairment does not impact on patients’ quality of life. Thus, investing 
in the implementation of proposed practice depends on reducing the number of patients 
making the transition to severe glaucoma, which is accordingly less cost-effective. Cohort 
analysis of health state utilities indicated that the sensitivity of this parameter varied by 
age group. While utility weight for visual impairment state was identified as the most 
significant parameter for the 70-year-old cohorts, utility weight for severe glaucoma was 
found to be the most significant in the 50-year-old cohorts. This was expected because, 
on average, disease stage is more advanced and progression faster in 70-year-old cohorts 
than in 50-year-old cohorts. 
 
2.5.5 Treatment modality effects 
Deterministic sensitivity analysis was also performed on treatment effects associated 
with each line of treatment to assess their impact on findings. Treatment effects play a 
prominent role in the derivation of cost-effectiveness, as the benefit of early 
identification of fast progressors is to provide them with a level of treatment that 
allocates resources efficiently; thus, if treatments were found to be similar in terms of 
effects, the benefits of proposed practice would not be realised. 
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One-way analysis of first-line treatment effects was found to produce consistent 
outcomes, with an increase in efficacy expanding ICERs at an exponential rate. These 
findings were consistent with expectations because increase in efficacy at the first line of 
treatment reduces the productive efficiency gains associated with moving patients to the 
second and third lines of treatment. The variation in second-line treatment effect 
impacted on the 70-year-old cohorts in a consistent fashion, with an increase in 
treatment effect reducing ICERs, while a reduction in treatment effect expanded them. 
For the 50-year-old cohorts the reverse was the case, with an increase in treatment effect 
expanding ICERs and a decrease contracting them. This can be explained by the decision 
nodes attributed to each cohort, as, when the 50-year-old cohorts were prescribed the 
same lines of treatment as the 70-year-old cohorts, the ICERs produced a similar pattern 
of results in both groups of cohorts. Third-line treatment outcomes were consistent with 
expectations, with expansions in treatment effects reducing ICERs as patients are moved 
to the third line sooner with the proposed practice compared with current practice. 
Tornado analysis of treatment effects found none of these parameters pushed ICERs 
beyond £30,000 per QALY. Thus, the model implies that the costs of increasing VF 
monitoring after VF diagnosis, even in all patients, would not be prohibitive. In addition, 
first-line treatment effect did not impact on the full simulation or individual cohort ICERs 
as the model was specified such that patients receive this line of treatment before 
commencement of these strategies. Under the cohort analysis, treatment effects did not 
have a significant impact on ICERs, with second-line treatment effects observed to have 
the biggest impact, especially in 70-year-old patients as a result of the fact that older 
patients are more likely to be conferred second-line treatment than third-line treatment 
compared with 50-year-old patients. 
 
2.5.6 Modelled time horizons 
One-way analysis of the time horizon utilised was performed in order to assess how cost 
and utility streams impact on the derived ICER. Within the context of this study, proposed 
practice frontloads costs as extra VF monitoring takes place at the early stages of analysis. 
Consequently, as the time horizon was contracted, the ICER for all cohorts became less 
cost-effective, especially as time horizons approached 5-year levels. Conversely, as time 
horizons expanded past 25 years, marginal gains were achieved, but these were limited 
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by the residual life expectancies of the cohorts as a significant proportion of patients were 
absorbed by the death state after this period. 
 
2.5.7 Sensitivity analysis 
Cost-effectiveness acceptability curves were generated by varying willingness to pay; this 
analysis verified the hypothesis that the M70 cohort would provide the least cost-
effective results with probabilities of acceptance lower than all other cohorts at all levels. 
The M50 and F50 cohorts produced similar outputs because of their similar residual life 
expectancies, and were more likely to be cost-effective as a cohort. 
It was also observed that the probability of the F70 group being cost-effective increased 
at a greater rate than other cohorts as willingness to pay expanded. This is explained by 
the fact that an increase in willingness to pay acts as a greater constraint to the 
probability of acceptance for older patients than younger patients given their lower 
residual life expectancies. 
Deterministic sensitivity analysis was then combined with PSA in order to examine 
interactions with the derivation of CEACs. Each parameter was marginally altered and 
CEACs were re-simulated to identify how these alterations impact on the probability of 
the proposed practice being acceptable at a given willingness to pay. Consequently, the 
impact of VF test costs, discount rates, risk distributions and costs of visual impairment 
on the CEACs was examined. The resultant CEACs produced rational results given the 
marginal variations in these parameters; however, it was noted that, in the case of the 
risk distributions, there was relatively little movement in the CEACs when this parameter 
was pushed to its rational limits. Furthermore, when costs of visual impairment were 
pushed to the limit identified as the watershed between which total costs of proposed 
practice became lower than those of current practice, the probability of acceptance of 
the proposed practice rose significantly, with low levels of willingness to pay still 
producing a considerable probability of acceptance. 
The impact of VF test cost was larger in scale within the 70-year-old cohorts than within 
the 50-year-old cohorts, which was expected given that the younger cohorts have a 
longer period of time to recoup utility associated with the initial investment given their 
longer residual life expectancies. 
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2.5.8 Choice of model structure 
The analysis performed in this study differs to that of van Gestel et al.(172) in several 
ways. A different type of model (Markov opposed to discrete event simulation [DES]) was 
used and a very different structural framework underpinning the models. Analysis of the 
cost-effectiveness of increased monitoring at the earliest stages of glaucoma 
identification was also undertaken. Van Gestel et al. chose to increase follow-up across 
the full horizon of analysis, which largely explains the differentials in ICERs associated 
with each study. In contrast to the findings of this study, the van Gestel et al. study 
suggests that reduced monitoring across their model’s full treatment horizon may result 
in productive gains at specific willingness-to-accept thresholds. 
Nevertheless, this study and the van Gestel et al. model is not directly comparable, with 
the latter focusing on lifelong IOP monitoring and management, whereas this study 
centres on VF progression. Furthermore, following NICE recommendations(38), this 
model primarily sourced data from the UK while van Gestel et al. used Dutch population 
data. Finally, this model had a single objective – to investigate the cost-effectiveness of 
increased early stage monitoring in the simplest, most accessible, method possible – 
whereas the DES model by van Gestel et al. aimed to provide a more complex and 
malleable model, therefore hindering comparison. However, it is worth noting that the 
economic model constructed in this study can be considered as a hybrid between Markov 
modelling and DES methods, as one significant benefit of the DES model is its ability to 
simulate patient characteristics within its framework, something that Markov models 
have not generally been able to do with transparency(173). The Markov model 
constructed within this chapter has been constructed such that its patient characteristics 
do inform how patients move across the model over time; patients’ ages, genders and 
risk profiles are all taken into account within the model’s decision nodes and, therefore, 
transition probabilities. 
 
2.5.9 Clinical management 
Intrinsic to any model mapping clinical management is ability to sufficiently replicate true 
practice. Economic models, whether in the form of Markov models or DESs, are relatively 
limited in their ability to reproduce clinical decision-making in the real world. This model 
sought to limit this constraint by seeking the advice of practising ophthalmologists in 
91 
 
order to provide interpretation of what informs clinical decision-making in glaucoma 
management. Clearly, decision-making can vary from clinician to clinician; for example, 
some clinicians may take a more aggressive stance than others when it comes to 
glaucoma treatment. Furthermore, while the clinical review panel was consulted during 
the formulation of the nodes, other glaucoma subspecialists may disagree with the step 
increases in treatment lines used. In particular, some clinicians may not subscribe to the 
view that the information gained from increased VF monitoring forms such a vital 
component in decision-making. Nevertheless, VF testing remains the only direct method 
for measuring patients’ visual function and, therefore, to gauge if a treatment is effective 
in avoiding future impairment. Furthermore, in order to facilitate the transparency of the 
model, the decision nodes defining treatment pathways were simplified. As a 
consequence, it was not possible to include patient preferences in treatment 
prescription. Patient preferences represent a growing concern in health-care provision 
within the UK, with NICE explicitly identifying its incorporation as a key objective within 
its guidelines for treatment of glaucoma(127). 
A key objective of NICE is to inform patients about treatments so that their preferences 
can be considered, maximising patient input. Within the context of the economic model 
here, it is possible that some glaucoma patients would wish to avoid surgical procedures 
despite being identified as fast progressors; this is important to bear in mind when 
interpreting the results from this model. If such a situation was included in the model, 
the cost-effectiveness of proposed practice would be reduced as the increase in power 
of information would not yield the same improvements in VF progression in these 
individuals.  
In addition, it was assumed that patients entering into the model were immediately 
provided with first-line treatment, as this is usually prescribed as soon as an individual is 
identified as having COAG. This might be considered a limitation of the model. However, 
all patients were prescribed this treatment within the model’s decision nodes so as not 
to derive an increase in treatment effect and therefore a reduction in probability of 
transitioning to a worse health state. A small subset of patients may not be not prescribed 
prior treatment, but the likelihood of this event was reduced by only including patients 
with significant VF damage at presentation (patients with an MD or pattern standard 
deviation outside 95% normal limits). 
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2.5.10 Trend of visual field deterioration 
An assumption of the model is that progression of MD is linear. While many previous 
studies have modelled MD in this way(63) the analyses of VF data in this report provides 
evidence that this model may be an oversimplification. After bimodal stratification of 
patients’ age, it was observed that a larger proportion of older subjects than of younger 
subjects progressed at a fast rate; this finding is also supported by recent research (174). 
Further studies are required to better understand the progression of glaucomatous VF 
loss and MD over time. 
Within the Markov model, it was stipulated that stable patients would be provided with 
the same level of treatment as those identified as slow progressors. This stipulation is 
questionable as some clinicians may decide to monitor these patients less frequently if it 
appears that a reduction in quality of life will not occur within their lifetime. However, 
this would result in an increase in cost-effectiveness of early stage monitoring as, by 
removing or reducing treatment for this cohort, cost savings would be made without 
reducing the utility derived from proposed practice since disease is not worsening in this 
cohort. 
This model, and others, also fail to take account of false-positive decisions that might 
arise from increased testing. No attempt has been made to consider the prospect of false 
‘overtreatment’. A discussion of this is given elsewhere(175). A development of the 
model should include some attempt to consider this important aspect of managing 
patient. 
  
2.5.11 Costs within the model 
Given results from a multisite clinical audit(1), it was assumed that existing service 
provision was performing at 100% capacity and that further infrastructure would be 
required in order to undertake proposed practice. However, efficiency gains in the 
management and organisation of VF testing may be possible. It was beyond the scope of 
this study to examine in detail the costs associated with extra resource use, but cost of 
implementation was incorporated into DSA and PSA to gauge its impact on final 
outcomes. A parameter value of £410,000 was varied between a derived minimum limit 
of £287,000 and a maximum limit of £820,000, resulting in ICERs of £20,770 and £24,706 
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(full simulation) and £25,398 and £30,303 (M70 cohort) respectively. These findings are 
very important because they indicate that uncertainty around implementation costs 
should not necessarily limit the final assessment of model outcomes, as the parameter 
was only found to surpass £30,000 per QALY by £303 in the cohort deemed to be the 
least cost-effective. However, it should be noted that alternative methods of calculating 
implementation costs exist. For example, if the additional VF tests required for proposed 
practice (40,000) were to be multiplied by the costs of performing VF tests (£56.54), an 
implementation cost of £2,261,600 would be arrived at. If this implementation cost was 
utilised within the model, a full simulation ICER of £35,352 would be identified, a figure 
higher somewhat higher than the £30,000 per QALY ceiling ratio associated with NICE. A 
scoping exercise about service provision for increasing VF testing is therefore 
recommended. 
Under the current health economic model, a static interpretation of costs across the 25-
year time horizon was adopted, which does not account for the impact of pharmaceutical 
patent expiry and, thereby, the introduction of generic pharmacotherapy. The 
accessibility of generic medications to health-care providers would reduce costs 
associated with all three treatment modalities, since each includes topical medication 
components. Given that both current practice and proposed practice incur medication 
costs, the impact of a reduction in such costs on the ICER is difficult to theorise, as these 
cost parameters interact with each strategy to differing extents. It is worth noting that 
medical costs may also expand as a result of the introduction of generic medications. 
LeLorier et al.(176) examined the impact of the launch of the generic substitution of 
lamotrigine (Lamictal®, GlaxoSmithKline, Brentford, UK), an anti-epileptic drug, in Canada 
between 2002 and 2006; the authors found that generic lamotrigine was associated with 
higher overall medical costs than the branded alternative because of increases in non-
pharmacotherapy cost components of treatments. 
The economic model was specified from the perspective of the UK NHS; consequently, it 
accounts for only direct costs of the disease and not for any indirect costs or social costs. 
This is an important limitation and has consequences on the precision of estimates for 
cost-effectiveness. Still, indirect costs and societal costs can only really add to the utility 
of the preferred practice. Previous studies have sought to quantify these costs in order 
to analyse their importance in glaucoma management and visual impairment. Lafuma et 
al.(136) estimated the non-medical costs associated with visual impairment in France, 
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Italy, Germany and the UK. Local prevalence rates of visual impairment were established 
along with estimates for the rates of non-registered visually impaired persons. Estimates 
of non-medical costs included institutional care, non-medical devices, residential 
adaptations, burden on carer, paid home help, loss of income and social allowances 
related to visual impairment. The main community cost components of visual impairment 
in the UK were loss of income (between 23% and 43%), burden on carer (between 24% 
and 39%) and paid assistance (between 13% and 29%). The authors also estimated that 
the total annual cost of visual impairment in the UK was €15.18bn. If indirect and social 
costs were included in the model, proposed practice would be more cost-effective. 
Proposed practice dominated (i.e. generated more QALYs at a lower average cost) 
current practice for a cost of visual impairment above £1758.50. Existing studies have 
found that the costs to society are possibly three times that amount(135, 177) suggesting 
there to be a stronger case for cost-effectiveness of increased early-stage monitoring 
when impact to society is accounted for. 
 
2.5.12 Treatment effect deterioration 
In the model, the impact of treatment effects on the rate of VF progression did not 
decline across the time horizon. However, the treatment effectiveness is known to fall 
between retreatment sessions, so the impact of treatment may be overstated in this 
model, resulting in a potential overestimation of cost-effectiveness. Nonetheless, this 
limitation was constrained by the inclusion of complex treatment regimens as identified 
with the study by Traverso et al.(134) who found that treatment defined by glaucomatous 
health state incorporated a range of treatment modalities spread over various time 
periods. 
It was beyond the scope of the model to account for the development of side-effects that 
can occur as a result of glaucoma treatment. Modelling these factors is beyond the scope 
of this study, although the model did take into account treatment complications in terms 
of utility health states. Moreover, Burr et al.(161), in their derivation of the Glaucoma 
Utilities Index that was employed here, identified local side-effects as one of the least 
important factors informing quality of life, but this is still open to debate and further 
study. 
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2.5.13 Future research 
Successful clinical management of glaucoma means making correct decisions about 
intensifying treatment, or initiating intervention, when patients are at risk of developing 
visual disability. Yet little is known about what VF defects at different stages of glaucoma 
specifically affect patients’ abilities to perform everyday visual tasks. Various studies have 
looked into differing methodologies of identifying and quantifying the relationship 
between quality of life and deteriorating health states caused by glaucoma(101, 160, 178-
180). In addition, little is known about ways in which patients can adapt to conditions in 
order to limit the impact on self-reported quality of life and the derived QALY 
estimates(181). In such situations, factors such as patient characteristics and the time 
from diagnosis can significantly impact on QALYs associated with differing health states 
of the disease, with their quantification possibly being overestimated. Economic models 
using these quality-of-life metrics may, therefore, overestimate the benefits of strategies 
such as the one proposed in this study; further research is required. 
In addition, further analysis of the cost of implementing a strategy to increase early-stage 
monitoring of glaucoma is required. While this economic model found the strategy to be 
cost-effective, it was identified that an alternative methodology of calculating 
implementation costs would derive different results. To accurately define this cost, the 
existing spare capacity within the UK NHS glaucoma services needs to be quantified in 
order to inform how much extra infrastructure is required to increase monitoring, as the 
investment in this infrastructure could play a significant role in whether strategies, such 
as the proposed practice studied here, are cost-effective. 
The wisdom of relying on a simple measure such as change in MD over time to identify a 
trend towards VF deterioration requires further examination to improve the accuracy of 
economic modelling in glaucoma. It may be advisable to also consider other 
characteristics beyond MD, such as the location of damage when considering VF 
progression. Finally, it seems practical to consider stratifying patients to less or more 
intense VF testing, with an idea of moving away from one diet of testing to fit all. For 
example, it would be useful to investigate whether the reliability of test results varies 
according to the approach taken. Although this study has illuminated the benefit of 
getting more perfect clinical information, it must recognise that perimetry still seems to 
be an imperfect test(182-184). 
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2.6 Conclusion  
In conclusion, this study supports the recommendation by NICE for a randomised 
comparative trial (RCT) to assess the real-world implications of increased monitoring at 
the earliest stage of glaucoma identification. In particular, the health economic model 
described in this chapter has demonstrated that this proposed practice is likely to be cost-
effective and the analyses revealed little evidence to suggest that the strategy would not 
be cost-effective. Further studies of the impact of the glaucoma on the quality of life of 
those with the condition are required to further the understanding of the cost-
effectiveness of proposed practice, as sensitivity analysis suggested that health state 
utilities have a considerable influence on ICER results. In addition, the impact of diagnosis 
of glaucoma and subsequent ‘adjustment’ to the condition(184, 185) needs to be 
considered, as this may negatively bias patients’ perceptions of quality of life with 
glaucoma and, therefore, quantification of utility. 
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Chapter 3:  Disease severity in newly 
diagnosed glaucoma patients with visual field 
loss: trends from more than a decade of data 
 
The work reported in this chapter formed a paper in Ophthalmic and Physiological 
Optics(2); see List of Supporting Publications. The results of this chapter have also been 
presented as a read paper at the Association for Research in Vision and Ophthalmology 
(ARVO) meeting, Florida, USA, May 2014, the International Perimetry Society (IPS) 
meeting, New York, September 2014, and the UK and Eire Glaucoma Society (UKEGS) 
meeting, Bristol, November 2014. Trishal Boodhna performed the statistical analysis of 
the data and led the write up of the manuscript, Professor David P. Crabb conceived the 
study and oversaw the drafting of the manuscript. 
 
 
3.1 Introduction 
The health economic model described in the previous chapter is reliant on accurate 
quantification of the parameters. One aim of the work described in this chapter is to 
consider the accuracy of the distribution of existing health states in which glaucoma 
patients are entering into the model. This parameter is particularly important as it 
represents the “proportion of vision” that can be “saved”. For example, if the vast 
majority of patients were identified as having already progressed to a state of visual 
impairment at detection, then there is little benefit that increased monitoring can yield. 
Whilst sensitivity analysis indicated variation in individual proportions of existing health 
states did not vary the ICER beyond NICEs £30,000 hypothetical ceiling ratio, it should be 
noted that these health state distributions are interdependent, so an increase in one 
health state distribution will necessarily lead to a reduction in another. Given its 
univariate nature, deterministic sensitivity analysis can only examine one parameter at a 
time and may therefore not accurately indicate the degree of impact on the ICER, making 
it important that proportions are ascertained as precisely as possible. The analysis 
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undertaken in this chapter therefore seeks to refine the method of data extraction from 
the Medisoft database in order to increase the confidence around the inputs utilised in 
the Markov model. The methods identified in this study were then re-employed (with 
reconfiguration to focus on the patients worst eye) in the Markov model that was 
constructed in Chapter 5 of this thesis, resulting in more robust model outcomes. This 
same process was also undertaken for the methods identified in Chapter 4 of this thesis, 
with the model in Chapter 5 again being updated to reflect the more robust data. 
Beyond health economic modelling, late presentation with advanced disease in itself is a 
risk for an adverse long term outcome and worthy of study. There has been, for example, 
calls to increase the speed of service delivery to patients and to better identify those in 
most need(150, 151). A population screening programme for glaucoma would not be 
cost-effective and there is no existing national glaucoma detection strategy(63). In the 
UK, the vast majority of glaucoma cases are opportunistically identified by community 
optometrists during the course of a routine eye examination(63).  Glaucoma suspects are 
then typically referred to secondary care for further examination and definitive diagnosis. 
An evidenced based debate about alternative referral pathways for glaucoma in the UK, 
in order to constrain the growing burden on hospital eye services, is ongoing(138, 139, 
186-190). Adding to this debate is not the subject of the work described in this chapter, 
but developing methods for auditing and monitoring aspects of detection and diagnosis 
is useful as service delivery comes under scrutiny. 
The utility of large-scale electronic records from routine clinical practice is beginning to 
be realised in clinical research, generating important and exciting findings(191). There 
are some good recent examples of this type of research methodology used in 
ophthalmology where examination of large data sets from several clinical centres can be 
used to complement information gleaned from traditional audits(192, 193). Automated 
perimetry has been widely used in glaucoma clinics for more than 20 years and large 
historical archives of digital VF records can be used to answer questions about health 
service delivery of glaucoma(153). Beyond the investigation of distributions of existing 
health states to improve the health economic model, a key aim of this study was to 
investigate trends associated with glaucoma detection in England. This study therefore 
also sought to examine whether patients are more likely to be diagnosed with less severe 
VF damage in recent years compared to the past. Specifically, the hypothesis that the 
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average severity of vision loss at glaucoma detection, in those diagnosed with a 
glaucomatous VF defect, improved over a 13-year period in England is tested. 
 
3.2 Methods 
Medisoft visual field databases (Medisoft Ltd., www.medisoft.co.uk) from different 
clinical centres in England were made available for this retrospective study. These 
archives contained 473,252 VFs from 88,954 patients from four centres: Moorfields Eye 
Hospital glaucoma clinic in London (320,334 VFs recorded between 1989 and 2012), 
Cheltenham General Hospital Gloucestershire Eye Unit (50,144 VFs; 2000–2011), Queen 
Alexandra Hospital in Portsmouth (31,879 VFs; 1999–2011) and the Calderdale and 
Huddersfield NHS Foundation Trust (70,955 VFs; 2000–2011). The study adhered to the 
Declaration of Helsinki and was approved by a research governance committee of City 
University, London. All the data were anonymised and transferred to a secure database. 
No other clinical data were made available apart from patient’s age and the dates of the 
VF tests. Only VFs recorded on the HFA with the 24-2 test pattern, a Goldmann size III 
stimulus using the Swedish Interactive Testing Algorithm (SITA Standard or SITA Fast) 
were included for further analyses. This reduced the data to 423,194 VFs (83,573 
patients) because a number of VFs recorded at one of the sites (Moorfields) in the earlier 
time periods were acquired using the older full-threshold algorithm. 
The study population was defined as patients with measurable VF loss in at least one eye 
at diagnosis (at presentation to the clinic). Patients were only included if they had a VF 
with a MD flagged as outside the 95% normative limits by the HFA VF analysis software 
(MD < 2.07 dB)(113). This criterion had to be satisfied for at least two visits to the clinic 
to improve the precision of the estimate of an individual having glaucomatous VF loss, in 
the absence of any other clinical record. The MD in the worse eye (the one with the more 
negative value) at the first clinic visit was then taken as the surrogate measure of 
detectable VF severity at diagnosis. The date of the first visit and the age of the patient 
at that visit were recorded. The decision to examine the 13-year time period between 1st 
January 1999 and 31st December 2011 was made to maximise the equivalence of the 
contribution of data from the four centres. These inclusion criteria reduced the sample 
to 25,521 patient records. This reduced number of patient records, given the initial size 
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of the archive, simply reflects many of the recorded VFs are from sequences of follow-
ups or are on suspicious referrals or glaucoma suspects. 
Within the context of this thesis it is important to note that, whilst the health economic 
model focused on MD of the better eye, this study focussed upon the MD of the worse 
eye. As previously noted, worse eye MD is a good surrogate for ‘level of disease’ at case 
detection and trends in glaucoma detection are the focus of this study. Conversely, 
functional impairment for a patient is better related to the health of the better eye and 
functional vision and quality of life was the focus of the health economic model. The same 
methodology can be used to estimate better eye MD, and it is these results that are used 
to updated the HE model in the final chapter.  
A linear model of VF severity, as estimated by MD in the worse eye, against date of 
diagnosis was constructed to examine trends over time, with a null hypothesis of average 
VF severity at the point of diagnosis not changing over the study period. Patients with 
MDs better than 6 dB in their worse eye were categorised as having early VF loss, whilst 
those with MDs worse than 12 dB in their worse eye were considered to have advanced 
VF loss. All other patients were considered to have moderate disease severity. These 
values were taken from a widely used criterion for glaucoma disease staging(162, 194). 
Temporal change in the proportion of patients in these categories was examined using a 
conditional density plot; this shows how a categorical variable, in this case severity of VF 
loss (early, moderate, advanced), changes over values of a continuous variables (time). 
All statistical analyses were carried out in the open source programming language, R. 
 
3.3 Results 
 
A scatterplot of VF severity, as measured by the MD in the worse eye, for each patient 
against date of diagnosis is shown in Figure 3-1 along with the trend line from the linear 
model. The slope of this line was positive, indicating average VF loss at diagnosis 
improved over the 13-year period by 0.11 dB per year (95% confidence interval 0.08–0.13 
dB per year) and this was significantly different from zero (p < 0.0001). Median age of the 
sample of patients, at the date of diagnosis, was 67 (interquartile range 55–76) years. 
Linear regression revealed a statistically significant, albeit modest, relationship between 
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VF severity and age at diagnosis, with MD in the worse eye at diagnosis worsening by an 
average of 0.01 dB per year increase in age (p < 0.0001; R2 < 1%). There was no 
relationship between age and time over the 13-year period, indicating that average age 
of the patient sample was not increasing with time (p = 0.32). 
 
Figure 3-1: Scatterplot of MD in the worse eye for each patient against date of diagnosis 
(bottom). A histogram showing the number of patients by year (top); in most years 
there were approximately 2000 patient records. 
 
 
The change in the proportion of patients categorised as having early, moderate or 
advanced VF loss in their worse eye at diagnosis over time is shown in Figure 3-2. The 
whole value percentage figures represent relevant proportions summed over the first 
(1999–2001) and last (2009–2011) 3 years of the study period: the average proportion of 
patients presenting with early VF loss increased from 41% to 50% (p < 0.0001; Chi-Square 
Test) whilst the average proportion of patients presenting with advanced VF loss 
decreased from 30% to 21% (p < 0.0001; Chi-Square Test). 
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Figure 3-2: Conditional Density Plot indicating the temporal change in the relative 
proportion of severity of VF loss (early, moderate, advanced) in the worse eye at 
diagnosis. The whole percentage figures are derived from the average of the first and 
last 3 years of data respectively. 
 
 
3.4 Discussion 
Average VF loss at the point of glaucoma diagnosis became less severe over the 13-year 
study period in England by approximately 1 dB per decade on the HFA MD scale. A recent 
modelling exercise, using data from some of the centres considered in this study, 
indicated that only a minority of patient eyes in secondary care (7–8%) progress at a rate 
worse than 1 dB per year(153). Therefore, one of these patients, diagnosed 10 years ago, 
would have, on average, progressed to a level of visual disability a year sooner than an 
equivalent patient diagnosed today because the VF loss would be more severe at the 
outset. This attempt to contextualise the improvement of detection of VF loss is 
hampered by several assumptions but illustrates the real clinical gains from these 
improvements in case finding glaucomatous VF loss are only modest. Similar conclusions 
were drawn from a long term trend study undertaken in Olmsted County with the authors 
observing that despite improvements in 20 year blindness probabilities being evident 
within their data set taking place over a 45 year time period between 1965 and 2009 a 
significant proportion of patients were still progressing to visual disability(195). On the 
other hand, by the end of the study period, one half of all patients newly diagnosed with 
103 
 
glaucomatous VF loss were detected with early VF damage in their worse eye; a 
significant improvement from a figure of 41% at the time of the beginning of the new 
millennium, a finding supported by O’Colmain and colleagues(196).  This trend ought to 
reduce visual impairment because more patients benefit from earlier treatment to slow 
progression(78). 
The results of this study only relate to the population of patients diagnosed with 
glaucoma with some VF loss in the first place and not those diagnosed on other clinical 
features of glaucoma, or those detected to be at risk because they have, for example, 
ocular hypertension. The measure of VF severity at diagnosis, HFA MD in the worse eye, 
is merely a surrogate and absence of a full clinical record means that it cannot be certified 
that all the patients have a diagnosis of glaucoma, or the date of a first VF record is the 
actual point of diagnosis. Nevertheless, the size of the data analysed, with more than 25 
000 patients from four geographically different areas, ensures the estimates of level of 
VF loss at diagnosis in glaucoma are reasonable and informative. 
Different factors might explain the observations drawn from these data. Detection may 
have improved because optometrists in the UK are increasingly well equipped(197, 198) 
and better trained(199) to detect glaucoma. Response to the NICE guidelines for the 
diagnosis and management of glaucoma published during the study period may also have 
contributed to the findings(127). Interpretation of the guidelines on case finding in 
glaucoma has, however, been controversial and these results do not specifically add to 
this debate; recent audits of full clinical records suggest more glaucoma referrals but the 
accuracy of these, as measured by the positive predictive value of diagnosis, has not 
improved(11, 200-202). One of these studies, considering data a year either side of the 
publication of the NICE guidelines, reported a significant improvement in the level of VF 
loss at presentation, and this supports the findings of this study(200). 
Glaucoma is an age-related condition and there is an association between glaucoma 
severity and age(203, 204); an older patient, when compared to a younger one, is more 
likely to present with more advanced VF loss. This notion is only just supported by the 
very modest relationship seen between age and VF severity at diagnosis within this data. 
Since the population is getting older a negative temporal trend in later disease 
presentation might be expected and, therefore, these results showing a positive trend 
suggest the improvement in ‘earlier detection of glaucomatous VF loss’ is perhaps better 
than it seems. However, it is interesting to note that in this sample the average age of a 
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patient at diagnosis did not change over the study period. So testing the null hypothesis 
of no-change in VF severity at diagnosis was reasonable and supports the interpretation 
of the results that the improvement in ‘earlier detection of glaucomatous VF loss’ is 
modest at best. 
These findings reiterate the well reported dilemma of many patients with glaucoma 
presenting themselves to eye specialists when the disease is already at an advanced 
stage: data at the end of the study period indicates that one-fifth of newly diagnosed 
patients with VF loss have damage that automated perimetry would classify as advanced 
in at least one eye. Research suggests these patients are, for example, likely to come from 
lower socio-economic groups, have no family history of glaucoma, do not have high 
intraocular pressure (IOP) and do not attend an optometrist regularly(150, 151, 204, 205). 
Population screening for glaucoma would reduce the incidence of late presentation of 
disease but has been shown to not be cost effective(63). Better case finding with 
development of community-based enhanced optometric services that may include a 
repeat measures scheme, coupled with sufficient financial incentive, is likely the best way 
to improve the accuracy of glaucoma detection and reduce late disease 
presentation(138, 139, 186, 190, 198). 
Examination of the VF should be an important component of routine assessment for 
glaucoma and it is particularly important for detecting patients with normal IOP. 
Automated perimetry however is not considered an easy option for the suspect or the 
practitioner(206), and case finding results based on perimetry are subject to 
variability(207). Moreover, the mandatory contract for the General Ophthalmic Service 
for the testing of sight does not allow for repeat VF assessment. Obsession with 
‘preperimetric’ glaucoma and newer technologies are not required to reliably detect 
early to moderate VF loss. Rather it is a case of incentivising the use of available 
technology, and using it appropriately in primary care that is more important – as 
articulated a decade ago(208) and, given these results, remaining true today. 
Due to the retrospective nature of the study, there are certain limitations worth noting 
such as the absence of clinical knowledge about the individual patients examined. This is 
mitigated however by the fact that the study was based on a massive number of patient 
records drawn from repeat attendees of glaucoma clinics. Furthermore, whilst the study 
was multi-centred, the sampling of these was not done systematically. In addition, one 
of the centres, Moorfields, has an atypical profile of referred patients when compared to 
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other centres with a recent audit indicated that 39% of new referrals to the glaucoma 
service at Moorfields were initiated by optometrists and this rate is much higher 
elsewhere(201). Also, results are not applicable to other countries with different health 
care systems as data collected for this study was sourced from clinics based in England 
only. Moreover, the surrogate measure for glaucomatous VF loss (MD) could be affected 
by other visual comorbidities, especially vision loss from cataract. As there is no 
information on the history of patients studied, it is therefore not possible to ascertain 
whether improvements in MD over time have resulted from an increasing rate of cataract 
surgery in the population. No exclusion criteria based upon HFA reliability criteria were 
used because many were missing from the original databases. This is considered a 
limitation because VFs flagged as unreliable by these indices are typically excluded in 
clinical practice, although evidence of their usefulness is questionable(98, 99). It is 
assumed however that a similar proportion of VFs across all severities would have been 
excluded using these indices which would leave the main estimates unaffected. Capacity 
of the clinics sampled may also have changed over time but this would not affect 
estimates of the population of patients that have some form of VF loss at diagnosis. It 
may prevent consideration of all VFs being an estimation of glaucoma referrals, making 
it impossible to differentiate between suspects, patients or false positives. Finally, the 
data is not particularly ‘current’ because the database extractions were performed in 
2012. 
 
3.5 Conclusion 
In conclusion this study provides some evidence that one aspect of glaucoma detection 
in England is modestly improving over time. It is more important to emphasise the data 
strongly suggests too many glaucoma patients continue to present to secondary care, 
and begin treatment, when disease is quite advanced in at least one eye. Whilst this study 
had no agreement to report differences in results between the four centres, this study 
still serves to highlight a novel idea of using large VF data archives to audit service delivery 
of glaucoma detection and monitoring across different centres and regions. Digital 
records from automated perimetry lend themselves to the task of electronic audits and 
this report ought to stimulate initiatives for glaucoma similar to those applied to other 
eye disease, like the UK National Ophthalmology Database programme(192, 209, 210). 
Aligning such data with health economic analyses, such as that undertaken in Chapter 2 
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of this thesis, can help identify methods to improve the efficiency with which glaucoma 
is managed in primary and secondary care, and help to reduce visual impairment. 
Following the methods identified in this study, the health economic model reported in 
Chapter 2 was updated to reflect the more accurate definition of the various health state 
distributions that patients could have in the better eye. The updated model is reported 
on in Chapter 5 of the thesis. 
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Chapter 4: Are rates of vision loss in patients in 
English glaucoma clinics slowing down over 
time? Trends from a decade of data 
 
The work reported in this chapter has formed a paper in Eye(3); see List of Supporting 
Publications. The results in this chapter have also been presented in part as a paper 
presentation at the British Congress of Optometry and Visual Science (BCOVS), London, 
2015. Trishal Boodhna performed the statistical analysis of the data and led the write up 
of the manuscript, Luke J. Saunders assisted with the statistical analysis of the data, 
Professor David P. Crabb conceived the study and oversaw the drafting of the manuscript. 
 
 
4.1 Introduction 
In continuation from Chapter 3, this chapter seeks to investigate further the parameters 
that form the foundation of the health economic model undertaken in Chapter 2. Whilst 
Chapter 3 identified methods to better examine the distributions of glaucoma severities 
at initial presentation, this chapter seeks to identify methods to better examine the 
distribution of rates of glaucomatous VF loss more accurately. As previously noted, rates 
of VF loss determined from a series of examinations in time can be clinically useful in 
managing a patient with glaucoma. They do however vary enormously among patients 
and can only be determined by observation of individuals. Recent studies, using data 
from treated patients in routine care, have yielded estimates for median rate of MD loss 
that vary considerably from −0.05 to −0.62 dB/year(211-214). Beyond helping to identify 
methods to improve the accuracy of the health economic model, adding to this literature 
by considering another large cohort of real-world data would be worthwhile. 
Furthermore, there does not appear to be existing studies considering how average rates 
of VF loss may have changed in the same sample of clinics over a significant period of 
time and this is the main idea explored in this paper.  
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Routinely collected clinical data can be used to assess real-world outcomes from 
implementing evidence-based findings from trials. These assessments can be carried out 
by taking advantage of large data sets collected from electronic patient records, and 
there are some good recent examples of this type of approach being used in 
ophthalmology(192, 193, 210, 215). Automated perimetry has been routinely used in 
glaucoma clinics for more than 20 years and VF data recorded electronically in many 
centres can be used to monitor trends in health service delivery of glaucoma(2, 153). This 
approach, using large-scale VF data, is adopted in the methodology of this study.  
The first decade of the new millennium saw a shift to new topical treatment for glaucoma 
and ocular hypertension. For example, Owen and colleagues, using data from nearly a 
half of one million patients registered at 131 general practices across the UK, identified 
2003 to be the year that number of prescriptions for prostaglandins overtook beta 
blocker-only medication. It remains unclear whether the introduction of these 
treatments impacted on disease progression in patients with glaucoma(152). This 
question is immune to a research study, no matter the experimental design. However, an 
objective of this study is to gather some insight by considering large-scale VF data 
recorded over a 13-year period in order to test the hypothesis that rates of VF loss 
differed in patients diagnosed before and after 2003. In addition, beyond developing 
methods to better identify the prevailing distributions of progression rates in the UK, this 
study also aims to describe the distribution of rates of VF loss stratified by age and 
severity of VF loss at baseline, along with a consideration of how these strata of patients 
may be followed more or less frequently during follow-up. 
 
4.2 Methods 
Medisoft VF databases (Medisoft Ltd., Leeds, UK) containing 473,252 VFs from 88,954 
patients were downloaded in 2012 from glaucoma clinics at Moorfields Eye Hospital in 
London, Cheltenham General Hospital Gloucestershire Eye Unit, Queen Alexandra 
Hospital in Portsmouth and the Calderdale and Huddersfield NHS Foundation Trust. Data 
access was granted by the Caldicott guardians at each centre. All patient data were 
anonymised and transferred to a single secure database. No other clinical data were 
made available apart from patient’s age and the dates of the VF examinations. 
109 
 
Subsequent analyses of the data were approved by a research ethics committee of City 
University London and this study adhered to the Declaration of Helsinki. 
Only VFs recorded on the Humphrey Visual Field Analyzer (HFA, Carl Zeiss Meditec, 
Dublin, CA, USA) using a Goldmann size III stimulus with a 24-2 test pattern acquired with 
the Swedish Interactive Testing Algorithm (SITA Standard or SITA Fast) were included, 
reducing the data set to 423,194 VFs. Series of data from patients >40 years recorded 
between 01 January 1999 and 31 December 2011 were then extracted with only those 
patients measured consistently with SITA Fast or SITA standard included. 
 
Figure 4-1: A schematic illustrating the VF series inclusion criteria and method for 
calculating rates of MD loss (dB/year) for three example eyes detected in 2001 (a), 2003 
(b), and 2006 (c). Eyes were excluded if <5 VF examinations or <4 years of follow-up. 
The first VF in each series was omitted to account for perimetric learning effects. Rate 
was calculated from linear regression of the baseline VF and the series of exams that fell 
within a 4-year period after it (white window). So, for example, for series (a) the sixth 
and seventh recorded VFs fall outside this window and are not used in the calculation. 
This ensures that all rates are estimated with equivalent precision allowing for 
comparisons over time. A minimum of three VFs were required to be in this 4-year 
window. This rate was then assigned to the date of the baseline exam. 
 
Eyes with short follow-up (less than 4 years or less than five examinations) were excluded. 
The first VF examination in each series were then removed from further analysis to 
account for perimetric learning effects(91, 216, 217). Precision of estimating the rate of 
MD loss (dB/year) using simple linear regression varies enormously by the length of 
follow-up(218). An attempt was made to control for this by only calculating the rate 
within a fixed 4-year period (window) from the baseline test (see Figure 4-1). Each series 
110 
 
had to have at least three examinations within this period. Of course, this does not mean 
eyes with longer follow-ups were excluded. Yet, this fixed window was important for 
comparison of rates across the study period because those diagnosed at the start of the 
study period would have had much longer follow-ups than those towards the end of the 
study period. 
A total of 18,926 eyes met the inclusion and exclusion criteria. These data represent 
patients in glaucoma clinics who are receiving routine care. Rates of MD loss (dB/year) 
were recorded and ranked by date of the baseline test. The data were then simply divided 
into two parts by chronological order. Thus, distribution of the rates of MD loss from 
baseline examinations in the first (15.01.99 to 16.09.03; n=9463 eyes) and second 
(17.09.03 to 05.09.08; n=9463 eyes) half of the study period could be compared. An eye, 
or a patient could only appear in one time period. 
Furthermore, eyes with rates of MD loss better than 0 dB/year were defined as stable; 
those with rates between 0 and −0.5 dB/year were defined as slow rate progressors; 
those with rates between −0.5 and −1.5 dB/year were defined as medium rate 
progressors, whereas those with rates worse than −1.5 dB/year were defined as fast rate 
progressors. Temporal change in the proportion of patients in these categories was 
analysed with a conditional density plot; this shows how a categorical variable, in this 
case stable, slow, medium, and fast progressors, changes over values of a continuous 
variable (time or estimated date of diagnosis). 
Eyes were stratified to determine the relationship between age and severity of MD loss 
at baseline with rates of VF loss. Eyes were stratified into simple age categories: younger 
patients (<60 years, n=6311) and older patients (>70 years, n=6385). All others were 
considered to be average age patients (n=6230). Eyes with MDs better than −6 dB, 
between −6 dB and −12 dB or worse than −12 dB were categorised as having early 
(n=10 920), moderate (n=3122), or advanced/severe (n=2063) VF loss, respectively. 
These values were taken from a widely used criterion for summarising disease stages in 
glaucoma and are represented within the colour schemes of Figure 1 (mild represented 
by green, moderate represented by orange, and severe represented by red)(162). 
A simple metric for the frequency of examination during the 4-year follow-up period was 
also calculated. Eyes with three, four, or five examinations in this period were defined as 
receiving approximately ‘annual testing’. All others were considered to be having more 
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frequent VF surveillance. The percentage of eyes that had annual testing was then 
compared across the disease severity and age strata. This metric was also calculated for 
eyes with progression rates between 0 and 0.5 dB/year, 0.5 and 1.5 dB/year, and worse 
than 1.5 dB/year being categorised as slow (n=5849), medium (n=3774), and fast 
progressors (n=1123), respectively. All statistical analyses were carried out using the 
open-source programming language, R(219). 
 
4.3 Results 
 
Figure 4-2: Distribution of MD rate in eyes diagnosed in two periods of the decade. 
Median, 25th (lower quartile), and 10th percentile are indicated. Curved lines represent 
a spline fit to the histogram. Note the histogram is censored at +1db/year. 
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In total, VF series from 18,926 eyes from 13,984 patients were analysed. Median 
(interquartile range) age, MD at baseline, and number of examinations in the 4-year 
follow-up were 65.5 (56.7–72.6) years, −2.8 (−6.6 to −0.7) dB, and five (four to five), 
respectively. The distribution of rates of MD loss (dB/year) in eyes diagnosed in the period 
1999–2003 and 2003–2008 are shown in Figure 4-2. Although the median progression 
rate of theses distributions are different, indicating that average rates of VF loss slowed 
in the second period, the lower percentiles (25th and 10th) remained the same 
suggesting that there was no change in the proportion of patients who are more rapidly 
progressing. Median (interquartile range) age and MD at baseline in eyes diagnosed in 
the period 1999–2003 were 65.2 (56.4–72.2) years and −2.9 (−6.7 to −0.8) dB, 
respectively. Median (interquartile range) age and MD at baseline in eyes diagnosed in 
eyes diagnosed in the period 2003–2008 were 65.8 (57.1–73.0) years and −2.6 (−6.3 to 
−0.7) dB, respectively. 
The change in the proportion of eyes categorised as having stable, slow, medium, or fast 
VF loss is illustrated in Figure 4-3. The percentage figures indicate the change in relative 
proportions of progressors across the two halves of the study period. It is noteworthy 
that the proportion of eyes defined to be medium or fast progressors remains largely the 
same over the entire study period. 
 
Figure 4-3: Conditional Density Plot showing the temporal change in the relative 
proportion of eyes with different rates of VF loss (stable, slow, medium, fast), across the 
midpoint of the study period. A 3% increase in the proportion of stable progressors was 
identified in this study with a 2% and 1% reduction identified for the slow and medium 
progressors, respectively. No change was observed in the fast progressors. 
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Distributions of progression rates by age and disease severity is illustrated in Figure 4-4. 
Older eyes (>70 years) were found to progress considerably faster than younger eyes (<60 
years). Median rate of MD loss was similar across disease severity as measured by MD at 
baseline. However, inspection of the curves fitted to the histogram and the 10th 
percentile values suggest fewer patients with early VF loss (green) are likely to have rapid 
progression. At the 10th percentile eyes with mild, moderate, and severe damage 
progress at rates of −1.1, −1.5, and −1.3 dB/year, respectively. 
 
Figure 4-4: Distribution (spline fit of histogram) of MD rate in eyes grouped by baseline 
age (top) and baseline severity of VF loss (bottom). Median and 10th percentile values 
are indicated over the study period. 
 
 
The percentage of eyes receiving annual VF testing as stratified by age, severity of 
glaucoma, and rate of MD loss is shown in Figure 4-5. These data suggest that surveillance 
of patients with VF testing does not vary at all by age or stage of disease. More surprising, 
eyes losing vision quickly still mainly only receive annual VF testing. 
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Figure 4-5: Pie charts estimating the proportion of eyes receiving annual VF testing by 
(a) patient age (years), (b) glaucoma severity, and (c) glaucoma progression rate. 
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4.4 Discussion 
Rate of VF loss (dB/year) is a straightforward concept. For example, an eye diagnosed 
with an MD of −8 dB will take 12 years to reach a level of assumed significant VF 
impairment (MD of −20 dB) if they progress at a rate of −1 dB/year. This is an 
oversimplification because impactful localised central and binocular VF loss is sometimes 
not best measured by a single perimetric index like MD. Still, these calculations are 
clinically useful when managing a patient over time, especially when decisions need to 
be made about intensifying treatment. Recently, Chauhan and colleagues (4) reported 
median (interquartile range) MD rate to be −0.05 (0.13, −0.30) dB/year in 2324 
unselected manifest and suspect glaucoma cases. This study had an almost identical 
methodology and returned almost identical values albeit in a multicentre sample that 
was approximately six fold larger. Confirmation that patients under routine glaucoma 
care demonstrate slow rates of VF progression is important to report because other 
studies have not been equivocal about this(214). 
The wide-ranging longitudinal data provides new knowledge about how MD rate might 
be changing over time. Interestingly, the median rate of MD loss was faster in patients 
diagnosed in the first half of the decade as compared with the second. This might be 
attributed to significant changes in the topical treatment of glaucoma patients and 
suspects which took place in the first part of that decade. The first randomised placebo-
controlled trial to show effectiveness of prostaglandin treatment to preserve the VF has 
only recently been published, despite widespread use for many years(220). Owen and 
colleagues(221), using extensive GP prescription data, indicated prostaglandins became 
the dominant first-line glaucoma therapy in the UK in 2003, which conveniently coincides 
with the time point used to split the longitudinal data. On the other hand, in the absence 
of other information, the improvement in average MD rates might be attributed to 
changes in clinical management of cataract or other clinical management guideline 
changes during the 13-year period. Moreover, as is often the case, average values do not 
describe the entire distribution of the data. For example, the number of patients who 
were progressing rapidly did not change (Figure 4-3) and the 10th percentile of this 
distribution remained fixed throughout the period of follow-up (Figure 4-4). It would be 
fair to conclude that for the progression rates that matter most, there was no change 
over the time period observed. This historical trend reflects there not being a dramatic 
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change in treatment options for glaucoma, as there has been for other chronic eye 
diseases(222, 223). 
Stratification of the sample by age revealed a clear relationship between the rate of MD 
loss worsening with older age. Patients over 70 years had considerably worse median 
rate of loss compared with younger patients. In this case, this large effect was applicable 
to the entire distribution of data (Figure 4-4) and this is noteworthy. This finding supports 
the results from other studies that have reported the same effect(224-226) and refutes 
the finding in at least one other study (albeit in patients with untreated normal tension 
glaucoma only) that there is no association between age and rate of VF progression(227). 
The distribution of rate of MD loss also varied by baseline MD as indicated in the 
difference of the tails of the distribution rather than in the measures of central tendency 
in Figure 4-4. The 10th percentile for the distribution in the rates of loss from those 
patients with early VF loss indicated that rapid progressors are less likely to come from 
this group of patients when compared with those with moderate or advanced VF loss at 
diagnosis. This is revealing because it underlines the reduced risk of visual disability in 
those patients who are diagnosed in the earlier stages of the disease, not only because 
they have greater preserved vision to start with but they are, according to the data, less 
likely to progress rapidly than those patients who are diagnosed at a later stage(78, 228, 
229). It is worth noting that the magnitude of this effect is, however, quite small. 
Moreover, precision of estimates of MD rates in individual eyes varies with VF damage 
and this has been established elsewhere(230). In other words, there is more variability in 
more damaged VFs, but this will likely not affect comparisons between such large groups 
of eyes. 
A cross-sectional audit study conducted in several centres in England indicated that the 
large majority of patients have one VF examination per year(231) and this seems true for 
the patients observed over the period of time in this study. Recent research evidence, 
reflected in clinical guidelines, has suggested that more frequent VF testing would help 
to identify rapidly progressing patients and this would have both clinical and potential 
health economic benefits(1, 128). At the same time, this would require a shift in 
resources, clinician opinion, and patient views about automated perimetry(206, 232). 
This study clearly shows a worse rate of VF loss was associated with older age and, albeit 
to a lesser extent, level of VF damage at diagnosis. Yet most patients simply receive the 
same diet of testing over time (Figure 4-5). In other words, there was no evidence that 
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patients were stratified to receive more or less frequent examinations given their age, 
progression rate, or severity of glaucoma. In fact, it looks like there is a trend for patients 
with more rapid progression to less likely receive more frequent VF testing. There are 
certainly some interesting research studies that have recommended alternative types of 
VF follow-up schemes, in particular studies that have examined the clinical and cost-
effectiveness of increased monitoring to detect fast progressors(1, 15, 175, 233), but 
these have yet to translate to clinical practice. It would be interesting to consider 
stratification of VF resources to patients who might benefit more or less from them and 
this ought to be a question for future prospective studies. 
The main problem with the design of this study is the absence of any clinical indicators 
on the eyes other than the VF results. So, for example, there was no information about 
exact diagnosis, intraocular pressure, optic nerve head characteristics, individual patient 
history, or other risk factors. Likewise, there was no information about types of treatment 
and concomitant eye disease. At the same time, these data represent unselected people 
in glaucoma clinics who are receiving routine care. Moreover, the sheer size of the data 
provides interesting insights that might not be uncovered by controlled prospective 
studies on smaller numbers of people. This study has other notable limitations: it was 
multicentre but the sampling was not carried out systematically and the data are not 
particularly current because the extractions were carried out in 2012. Furthermore, HFA 
reliability indices are used to exclude poorly carried out examinations in clinical practice, 
but these were not used in this study because many were missing from the original 
database. A secondary argument that the strict inclusion criteria required for this study 
could have impacted results could also be made. In this study, VF data was excluded on 
the basis of undertaking multiple different testing algorithms, patients were therefore 
required to have undertaken only one form of testing algorithm in order to achieve data 
equivalence. It was rare however for patients to change testing algorithm across their 
historical VF testing history, exclusion by this criteria therefore would not impact results 
significantly. Data was also excluded on being outside the equivalence dates, therefore 
data from the 1980s were excluded as our time period focussed on VFs dated between 
1999 and 2011. These VFs were few in number however so it was not expected to have 
introduced any exclusion bias to the study. It is also important to note that the exclusion 
methodology implemented within this study necessitates contraction of the data set. 
Eyes were required to have at least 5 VFs in order to ascertain an accurate estimate of VF 
progression and these had to be sourced over at least 4 years, and such criteria was 
118 
 
necessary to ensure robust and consistent estimations of rate could be achieved with 
equal degrees of precision. 
 
4.5 Conclusion 
In conclusion, the results from this study suggest that patients in clinics in England, on 
average, experience a relatively slow rate of VF deterioration. It is important to recognise, 
however, that a proportion of eyes progress at a rate sufficiently fast that is likely to result 
in a visual impairment classification within their lifetimes. Furthermore, although this 
study found that median rates of MD loss appear to be declining, it is of note that this 
trend was not evident in patients who matter the most; that is, individuals with medium 
to fast rates of VF loss. Of course, results refer to a patient population and have little 
bearing on the management of individuals. Yet, this study illustrates the use of large VF 
databases to monitor and audit service delivery of glaucoma treatment. Digital records 
from automated perimetry are amenable to electronic audits and this report seeks to 
motivate initiatives for glaucoma similar to those put into place for other eye diseases. 
These data can then be used in combination with health economic techniques, as 
performed in Chapter 2 of this thesis, in order to investigate potential efficiency gains 
within the treatment of glaucoma and potentially reduce the burden of visual impairment 
in the UK. As such, following the methods identified in this study, the health economic 
model constructed in Chapter 2 was updated to reflect the more accurate definition of 
progression rate distributions that were simulated, this time focusing upon the better 
eye only. The findings of this re-simulation are reported in Chapter 5 of this thesis. 
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Chapter 5: Update of the Health economic 
model and the evaluation of different 
monitoring intervals in glaucoma patients 
 
The work reported in this chapter has formed a paper in BioMed Central: Health Services 
Research; see List of Supporting Publications. Trishal Boodhna undertook the health 
economic modelling, performed the statistical analysis of the data and led the write up of 
the manuscript and Professor David P. Crabb conceived the study and oversaw the 
drafting of the manuscript. 
 
 
5.1 Introduction 
This chapter seeks to investigate further the parameters that form the foundation of the 
health economic model undertaken in Chapter 2. Within Chapter 2, the cost-
effectiveness of using different monitoring intervals to detect VF progression rates in all 
newly-diagnosed COAG patients using a health economic model developed for the 
purpose was examined. Two different VF monitoring schemes defined as current practice 
(annual VF testing) and proposed practice (three VF tests per year in the first two years 
after diagnosis) were examined within the model. Within Chapter 5, the constructed 
model is summarised and updated to examine the hypothesis that cost effectiveness 
improves by implementing proposed practice on groups of patients stratified by age and 
severity of glaucoma at diagnosis.  
Furthermore, a new component of the model, estimating costs of visual impairment, is 
added. It is hypothesised that proposed practice applied to some groups of patients will 
yield improved clinical information and therefore increase the cost-effectiveness of 
clinical care. The outcome of this economic evaluation could potentially provide 
information to assist decision-makers in the allocation of the available resources so that 
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benefits can be maximised; it could also be used to help design an appropriate 
prospective study on frequency of monitoring in glaucoma. 
 
5.1 Methods 
5.1.1 Health economic model 
The Markov model (see Figure 5-1) was constructed to compare proposed practice 
against current practice for patients with newly diagnosed COAG during a 25-year 
horizon. Markov models are commonly used for quantifying the costs and health 
consequences of patients moving through different disease stages over time(26, 234, 
235). In the model, patients can start in any one of four states of severity of disease at 
diagnosis. It was assumed that one cycle through the Markov model is one-year long. In 
each cycle through the model, the costs and utilities are calculated for each cohort of 
patients. In a particular model cycle, patients can remain within their existing health 
state, or progress towards a worse health state. Progression towards a worse disease 
severity is the only possible transition because vision loss in COAG is irreversible. It is also 
assumed that patients move sequentially and cannot skip states due to the slow 
evolution of the disease. Patients may also leave the model and move into an absorbing 
state (‘Death’).  
 
Figure 5-1: The structure of the Markov Model for glaucoma. Patients can only 
transition to the next state in sequential order, remain in the same state or be classified 
as deceased at each Markov cycle 
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The disease process in glaucoma is a complex multivariable one and long-term outcomes 
for individuals are often unpredictable. This model only conceptualises disease 
progression and its treatment as they manifest in clinical practice. First, the model is only 
applicable to patients that have a diagnosis of COAG as defined by NICE and is not 
relevant to patients with a diagnosis of ocular-hypertension or others that are at risk of 
glaucoma. Next, VF damage alone is used as a proxy for glaucoma disease severity. 
Disease progression is modelled by means of the speed (rate) at which the MD worsens. 
Then, a simplifying assumption was made that the effect of treatment lowers IOP, which 
in turn affects the VF progression rate and reduces the movement between the disease 
states. The model then assesses the impact of being able to institute treatment decisions 
earlier because of the better clinical information afforded by the proposed practice 
compared to current practice. 
In order to reduce model complexity and allow simple decisions about treatment 
pathways it was assumed that a patient can be characterised according to four 
categorical variables at the point of diagnosis of COAG: 
 Age (younger patient; older patient) 
 Severity of disease (mild; moderate; severe; visually impaired) 
 Rate of progression (stable; slow; medium; fast) 
 Risk of progression (high risk; typical risk) 
 
Age of patient is reduced to a dichotomous variable – the modelled younger and older 
patient has an age of 50 and 70 years at diagnosis respectively, making up 28.2 and 71.8% 
of the cohort respectively.  The rationale for these values and distribution is detailed in 
the description of the model in Chapter 2.  Severity of Disease (health states) was defined 
according to a commonly used classification of MD (194). Conveniently this scheme has 
been used in previous health economic models of glaucoma health service delivery and 
allows for use of utilities reported elsewhere(63, 236, 237). Mild disease is defined as VF 
loss with an MD better than -6dB. Moderate disease is defined as VF loss with an MD 
between -6dB and -12dB. Severe disease is defined as VF loss with an MD between -12dB 
and -20dB; very few of these patients would satisfy the visual field component for legal 
fitness to drive for example(113). Of course, people function visually with both eyes and 
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the better seeing eye is the best estimate of visual function(106). Therefore, these levels 
of disease severity were required to exist in the patient’s better eye (defined as the eye 
with the better MD) since this best reflects the patients visual morbidity(104). Patients 
with MDs worse than -20dB were classified as visually impaired (132). 
 
Table 5-1: Parameters for the updated model were estimated from a retrospective 
analysis of an electronic patient record containing 473,252 VFs downloaded in 2012 
from Moorfields Eye Hospital in London; Cheltenham General Hospital Gloucestershire 
Eye Unit; Queen Alexandra Hospital in Portsmouth and the Calderdale and Huddersfield 
NHS Foundation Trust. Baseline progression rate and existing damage in the better eye 
were revised following the methods used in Chapter 3 and 4 examining levels of rates of 
loss and existing disease severity distributions at diagnosis) 
Parameter Stratification 50 y/o 70 y/o 
Progression Rate 
Distribution 
Stable (0 dB/year) 46.7% 37.9% 
Slow (-0.25 dB/year) 37.8% 36.6% 
Medium (-1 dB/year) 12.5% 19.1% 
Fast (-1.5 dB/year) 3.0% 6.4% 
Health State Distributions Mild (> -6dB) 83.0% 79.8% 
Moderate (-6dB to -12dB) 10.8% 15.0% 
Severe (-12dB to -20dB) 5.6% 4.1% 
Visually Impaired (<-20dB) 0.6% 1.1% 
Initial Damage Mild -3.1 dB -3.1 dB 
Moderate -8.3 dB -8.4 dB 
Severe -15.5 dB -15.4 dB 
Visually Impaired -24.0 dB -23.6 dB 
 
Rate (Speed) of progression in an individual patient can be estimated from MD loss per 
year for patients using linear regression of MD against time(3). The more negative the 
rate the faster the progression speed. These rates are categorised as stable (≥0 dB/year), 
slow (between 0 to -0.5 dB/year), medium (between -0.5 and -1.5 dB/year) or fast (worse 
than -1.5 dB/year). It is important to note that observed rate of progression is only 
available to the clinician in the model when sufficient VFs have been done to precisely 
detect it - this is termed ‘perfect information’. It is therefore this variable that varies 
between proposed and current practice. Risk of progression in COAG is nebulous and 
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multifactorial. Apart from level of IOP, risk of progression is composed among other 
factors of baseline diagnosis of exfoliation syndrome, decreased corneal thickness, 
structural changes to the optic nerve head and the retinal nerve fibre layer and co-
morbidity of other eye diseases(64).  For this model, the simplifying step of denoting 
patients to have high progression risk or typical progression risk was taken and the input 
parameters were taken from the model described in Chapter 2. Consequently, at 
diagnosis of COAG, there are 64 types of ‘patients’ based on the permutations of the 
initial model parameters. The relative proportions belonging to each group were 
estimated from data observed in glaucoma clinics in England. For this chapter, figures for 
severity of disease and rate of progression were updated following the findings of 
Chapter 3 and Chapter 4 and these are summarised in Table 5-1. Whilst these chapters 
focussed upon the patient’s better eye, Chapter 5 utilises the patient’s worse eye as worst 
performing eyes are the driver behind decision making regarding treatment modalities. 
Therefore, whilst the methodology to derive data is the same, the final outputs differ due 
to the change in eye studied. Furthermore, the distribution of patients stratified by initial 
health state described in this Chapter varies from that observed in the distribution 
specified in Chapter 2 (Table 2.6). This is explained by the more refined inclusion criteria 
used with the Medisoft data set to identify initial health state distributions. Whilst the 
distribution for Chapter 2 was established by simply stratifying the dataset by age and 
disease severity, stricter inclusion criteria was used for this Chapter following the 
methods identified in Chapter 3 to better specify this distribution. 
The health economic model simulates glaucoma progression in 10,000 hypothetical 
COAG patients stratified by age (50 and 70 years) and severity of glaucoma at diagnosis. 
The probability of transition to the next state in the model followed published 
methodology of Hernández et al.(236) and Briggs et al.(26); these are driven by the 
treatment pathways that are used to ameliorate the rate of progression. Again, these are 
detailed in greater depth in Chapter 2 but what follows is a short description of the 
principles underpinning them. 
People newly diagnosed with COAG are offered ‘pharmacological treatment’ and this is 
denoted treatment pathway 1. Patients with COAG who are at risk of progressing to visual 
impairment despite this first line treatment are offered intensified treatment which 
might be surgery with pharmacological augmentation. Typically, this would only be done 
after an observing evidence of disease progression. It is this information that might be 
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yielded earlier by proposed practice. In the model in Chapter 2, this intensified treatment 
pathway is denoted as 2 or 3. The former would typically be combinations of alternative 
pharmacological treatments or ‘laser treatment’ whereas the latter would be 
trabeculectomy with pharmacological augmentation. To model the decision making 
process behind treatment allocation and its impact upon the probability of transition to 
worse states of disease, two ophthalmologists with a specialist interest in glaucoma, were 
consulted to construct simplified treatment pathways that patients would face in a NHS 
hospital setting. 
For the model in Chapter 2, the treatment pathways are used in a time period denoted 
as ’imperfect information‘, where the managing clinician is ‘unaware’ of the patient’s true 
rate of VF progression, simply because they have not been monitored closely enough. 
After a defined number of VF tests, the patient’s progression rate is identified, and then 
enter into a time period defined as ‘perfect information’. The clinician now has the 
opportunity to continue to provide the patient with the existing degree of treatment, or 
to intensify it. These pathways are linked by a series of decision nodes detailed in Chapter 
2 (Table 2-3). As an example, a younger patient entering into glaucoma care at health 
state 1 (mild damage) and defined as being at low risk of progression would receive 
treatment pathway 1. If the patient was subsequently defined as having a fast rate of 
progression, then they would be moved to 3rd line treatment but only when the clinician 
has ‘perfect information’. This functionality was built into the model in order to reflect 
the resource reallocation that occurs once the clinician identifies those patients who are 
potentially undertreated. This temporal improvement in patient management is what 
underpins this study, as the more expedient allocation of efficient treatment modalities 
differentiates the proposed practice from current practice. However, this reallocation 
comes at a cost and this is described briefly below. 
A key component of the cost-effectiveness of proposed practice is the cost of additional 
resources for more VF testing. After all, this is seen as the main barrier for implementing 
increased surveillance and more examinations(232). Costs were sourced from the 
reference costs (170) and along with the costs of treatment, (derived from a study 
reported by Traverso et al.(134)) are taken directly from the model in Chapter 2. A further 
driver of the cost-effectiveness of the proposed practice is the quality-of-life 
improvement gained from reducing the chances of VF loss and visual impairment. In this 
study, utility weights associated with each health state were derived from those 
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developed and implemented by Burr and colleagues(63, 161). Consequently, those 
defined with mild, moderate, severe disease and visual impairment were attributed a 
utility of 0.8015, 0.7471, 0.7133 and 0.5350 per year respectively. 
 
5.2 Model Analysis 
The main outcome measure was the ICER derived by proposed practice as an alternative 
to current practice as applied to all newly diagnosed patients (full model). A further 
outcome measure was the years of healthy vision saved with proposed practice 
compared to current practice. Patients were then stratified into four groups with each of 
the four groups modelled separately to receive proposed practice while all other patients 
would receive current practice. The model results, with the ICER being the primary 
outcome, were then used to test the hypothesis that applying proposed practice to a 
specific group of patients would be more cost-effective than making it available to all 
newly diagnosed patients. 
In the original model in Chapter 2, indirect costs of severe visual impairment from COAG 
were not included. These are governmental and societal costs for supporting a visually 
impaired person, such as visual rehabilitation, social services, or local authority care 
rather than costs of blindness to the individual.  Estimating these costs is problematic, 
country dependent and tricky to establish(238). Still, some useful estimates are available 
(135); these costs were inflated to 2015 levels using the retail price index and were 
identified as ranging between £1,375 and £17,100 for the first year of blindness and 
£1,325 and £16,800 for each subsequent year thereafter. The most conservative estimate 
from the range identified was incorporated because of the uncertainty of the estimates 
as applied to glaucoma blindness. As such, a modest cost of £1,777 was used in the 
updated model to represent the economic burden of progression to visual impairment. 
Sensitivity analyses were performed in order to examine how parameter uncertainty 
interacted with model outcomes(239, 240). Preliminary sensitivity analysis was 
performed at the earliest stages of model development in order to facilitate the 
understanding of how inputs interact with model outcomes. One-way deterministic 
sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) were performed on 
the outputs generated by the Markov model once rationality in these outputs was 
assumed. From the derived ICERs, incremental cost-effectiveness planes were 
126 
 
constructed and from these cost-effectiveness acceptability curves (CEACs) were drawn 
indicating the probability of proposed practice being accepted at given levels of 
willingness to pay(26, 57).  
Ethics approval for this modelling exercise was not required. Access to the non-
identifiable patient data summarized in Table 1 was granted by the Caldicott Guardian at 
each participating centre. Subsequent analyses of the data, including that done in this 
work, were approved by a research ethics committee of City University London. 
 
5.2 Results 
5.2.1 Model Outputs 
In total, 10,000 patients were simulated to enter into the health economic model with a 
positive cost differential of £298 per patient identified between proposed practice and 
current practice (Table 5-2). This implies higher costs with proposed practice but this 
corresponds with a positive utility differential (0.014 QALYS per patient). Consequently, 
an ICER of £21,392 per QALY was derived for proposed practice, a figure within the 
hypothetical NICE ceiling ratio of £30,000. Furthermore, a total of 785 visual impairment 
years were saved as a result of increased early monitoring associated with the proposed 
practice across the 25-year time horizon. These results are relevant to applying proposed 
practice to all newly diagnosed patients. Table 5-2 summarises the results for the 
scenarios when proposed practice is allocated to four specific subgroups of patients. 
 
Table 5-2: ICERs produced once the proposed practice was provided to specific 
subgroups stratified by age and glaucoma severity. 
Age Subgroup Severity 
Subgroup 
Incremental 
Costs 
Incremental 
Utility 
ICER 
All All £298 0.014 £21,392 
Younger Patient Early £306 0.021 £14,797 
Late £3,251 0.049 £66,219 
Older Patient Early £287 0.014 £21,024 
Late £4,170 0.030 £138,891 
 
127 
 
The best ICER associated with proposed practice was yielded from the younger cohort 
diagnosed with early (to moderate) stage VF loss in their better eye. Worse ICERs, 
incompatible with hypothetical willingness to pay thresholds, are returned for those 
patients that are already at an advanced disease state on diagnosis in their better eye. 
After annual costs of visual impairment (£1,777 per year) were incorporated into the 
model, an incremental cost of £159 per patient (incremental utility of 0.14) was identified 
between proposed practice and current practice. There is no change in terms of 
incremental QALYs given that societal costs of visual impairment do not impact upon the 
patient themselves, so this yielded an ICER of £11,382 per QALY being derived for 
proposed practice. This represents a significant reduction in the ICER compared to results 
without visual impairment costs added. The latter were then varied to identify the 
threshold for cost neutrality between the current practice and proposed practice across 
both the full simulation. Under the full simulation, a value of £3,798 was identified as the 
required costs of visual impairment to equate proposed practice to current practice. 
 
5.2.2 Sensitivity Analysis 
DSA results are presented in a Tornado diagram for the full simulation (Figure 5-2). The 
horizontal axis is the outcome (the ICER for allocating current practice to all newly 
diagnosed patients); along the vertical axis, parameters are ordered and horizontal bars 
represent the outcome range associated with the specified parameter’s range (maximum 
and minimum value limits impact upon ICERs). For all parameters, outcomes were sorted 
in order of ICER impact. Uncertainty surrounding the implementation cost parameter and 
the visual impairment cost parameter resulted in the highest ICER variations but neither 
were sufficient to push the ICER beyond the £30,000 per QALY ceiling ratio. The next most 
important parameters were treatment costs and utility health states. Progression rates 
had little impact despite being varied by 10% in either direction.  
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Figure 5-2: Tornado Diagrams measuring the impact in variation in parameters for the 
health economic model with included visual impairment costs (ICER = £11,382). 
Maximum and minimum limits for parameters were identified. ICERs were derived and 
ordered in terms of impact (greatest to lowest ICER variation). 
 
Unsurprisingly, in the PSA (see figure 5-3), greater cost-effectiveness was observed when 
costs of visual impairment were included (b) compared to when it was not (a). The 
observations in (b) are lower on the plane (indicating lower costs) with little change in 
the width of the observations (indicating similar effectiveness). Proposed practice in 
younger patients with early glaucoma (c), placed observations significantly lower on the 
plane than in the simple model (a), indicating a significant improvement on cost-
effectiveness. Patients (both young and old) with advanced glaucoma yielded a 
compressed cluster of observations. Simply, the model is inferring that those with late 
glaucoma have less vision to save; therefore, less incremental utility can be derived. For 
older patients with early glaucoma (e), observations were more spread across the cost-
effectiveness plane suggesting greater likelihood of utility gain given their greater 
preserved vision. 
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Figure 5-3: Cost-Effectiveness Planes for the different subgroups analysed. 
 
Unsurprisingly, in the PSA (see figure 5-3), greater cost-effectiveness was observed when 
costs of visual impairment were included (b) compared to when it was not (a). The 
observations in (b) are lower on the plane (indicating lower costs) with little change in 
the width of the observations (indicating similar effectiveness). Proposed practice in 
younger patients with early glaucoma (c), placed observations significantly lower on the 
plane than in the simple model (a), indicating a significant improvement on cost-
effectiveness. Patients (both young and old) with advanced glaucoma yielded a 
compressed cluster of observations. Simply, the model is inferring that those with late 
glaucoma have less vision to save; therefore, less incremental utility can be derived. For 
older patients with early glaucoma (e), observations were more spread across the cost-
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effectiveness plane suggesting greater likelihood of utility gain given their greater 
preserved vision. 
 
Figure 5-4: Cost Effectiveness Acceptability Curves across the subgroups analysed. 
 
 
CEACS were derived from these simulations (see Figure 5-4). Willingness to pay for each 
QALY gained was varied from £0 to £50,000 and the proportion of simulations deemed 
acceptable at this level were recorded.  Similar shaped CEACs were observed for the 
model with and without the visual impairment costs added. However, the shift of the 
CEAC to the left for the model with visual impairment costs included indicates an 
increased probability of acceptance of this scenario. At the £30,000 per QALY ceiling ratio, 
the proposed practice was acceptable 82% of the time when these indirect costs were 
modelled whilst only 65% of the time when they were not. When proposed practice was 
provided to patients with early glaucoma, there was less deviation from the simple model 
with 70% (old) and 74% (young) being observed to be acceptable at the £30,000 per QALY 
ratio. CEACs trail close to zero for the patients diagnosed with late disease indicating a 
significant lack of cost-effectiveness likelihood for these subgroups. 
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5.3 Discussion 
This modelling exercise primarily sought to examine whether increased VF monitoring at 
the earliest stages of disease identification in COAG (i.e. six VFs in the first two years after 
diagnosis) would be cost-effective compared with the assumed current practice of one 
VF per year. An ICER of £21,392 indicates that the proposed practice is a cost-effective 
strategy for all patients given a hypothetical £30,000 per QALY NICE acceptability ceiling 
ratio.  So these health economic findings support the EGS guideline recommendation of 
undertaking 6 VFs in the first two years after glaucoma diagnosis.  
Introduction of costs of visual impairment further increased the cost-effectiveness of the 
proposed practice to £11,382. A cost of visual impairment threshold of £3,798 per year 
was identified as the minimum value required ensuring that the proposed practice would 
equate to current practice in terms of costs across the full 25-year time horizon of the 
model. Put another way, if cost of visual impairment per year is assumed to be greater 
than £3,798 per year then, proposed practice is preferable to current practice. This figure 
sits at the lower end of the distribution of the costs estimated in the Meads et al. study 
(£1,325 to £16,800 per year throughout the duration of patients residual lifetime)(135). 
Moreover, other studies have estimated costs of visual impairment to be significantly 
greater. For example, Lafuma and colleagues reported a value of €13,674/year in the UK 
in 2006 (equating to about £11,000/year when inflated to 2015 values and converted to 
pound sterling) and Burr et al. suggested the figure could be as high as £40,000/year(136, 
237). Therefore, if the values found in these alternative studies were used, the proposed 
practice would be the cheaper long-term patient pathway compared to current practice 
due to the costs saved by reducing the amount of patients progressing to visual 
impairment over the 25 years. Moreover, this report should stimulate more research into 
the hidden costs of burden of sight loss and encourage other researchers to include them 
in their health economic models when studying conditions that lead to sight loss and to 
investigate further. For instance, ‘hidden’ costs arise because people with visual 
impairment tend to have longer hospital stays for co-existing morbidities (241, 242) 
whilst risk of falling is higher for the visually impaired, inevitably leading to more ‘hidden’ 
costs(243).  
Within this modelling exercise, patients were loosely defined to be in a severe disease 
state if the MD is worse than -12dB in the better eye. This threshold is not entirely 
arbitrary because it approximately equates to a patient failing the VF component of legal 
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fitness to drive in the UK(113) and has been used in staging disease severity in COAG 
before.  In those patients with VF loss better than this threshold, proposed practice seems 
particularly cost-effective. Patients with sight loss worse than this threshold would likely 
be on maximum therapies anyway and the model suggests it would be less cost-effective 
to monitor them closely at the outset. This might appear controversial but it simply 
reflects the limited treatment options in late stage glaucoma. Interestingly the idea that 
surgery ought to always be the primary treatment option for people diagnosed with 
advanced glaucoma is being tested in an on-going large randomised trial in the UK 
(https://www.tagsstudy.co.uk/).  
This study found that the proposed practice is more cost-effective in younger patients 
(see Table 5-2). This is unsurprising because the costs of proposed practice are more likely 
to be recovered for a person with longer residual life expectancy, with the economic 
argument of early investment in preserving future vision. More intensive monitoring of 
these patients is obviously worthwhile in order to establish speed of loss and improve 
their clinical management. Yet findings within this thesis indicate that frequency of 
monitoring in clinics in England does not vary by the age of the patient (or rate of loss or 
disease severity for that matter) - younger and older patients simply get the same diet of 
VF testing (see Chapter 4, Figure 4-5). Therefore, and at the very least, the model provides 
evidence for the potential cost-effectiveness of stratifying patients to more or less 
monitoring and this is an important conclusion from this work. A prospective research 
study examining this issue is recommended. At the moment, there is a tendency to have 
a ‘one size fits all’ approach to monitoring the diagnosed patients and this is likely a 
suboptimal method for monitoring large cohorts of patients.   
Sensitivity analysis identified implementation costs as the most important parameter 
impacting upon the ICER, resulting in ICERs ranging from £8,400 per QALY at its minimum 
value to £24,700 per QALY at its maximum value. A full costing study examining the range 
of values is clearly required to truly ascertain whether this maximum value is accurate or 
if there is already sufficient excess capacity to allow for the proposed practice (the 
minimum modelled assumption). The second most important parameter within the 
sensitivity analysis was the costs of visual impairment. The minimum assumption of costs 
to society equalling £0 resulted in a maximum ICER of £21,400. However, this perceived 
minimum limit is unlikely to be representative in the real world especially given the 
negative externalities associated with glaucoma. The message about the need for further 
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studies to estimate these costs more precisely is therefore reiterated(237); without them 
the predictions from health economic models of age-related eye disease will always lack 
precision. Costs associated with the 1st line of treatment modelled within this study were 
identified as the third most important factor within the Tornado analysis with the lowest 
assumed value (£389) resulting in an ICER of £17,800. As proposed practice accelerates 
the time it takes to get an ‘upgrade’ in treatment modality provision, patients are 
therefore moved away from the 1st line of treatment at an increased rate. If costs for the 
1st line of treatment are relatively low, it becomes less economically efficient to move to 
the 2nd and 3rd line of treatment, therefore making the proposed practice less cost-
effective. This result points to the need for better data on true costs of treatment for 
glaucoma and this is worthy of further research. 
 
5.3.1 Limitations of the study 
It is difficult to accurately model real world clinical decision making.  Here clinical decision 
pathways were developed in consultation with two practicing glaucoma specialists. 
Decision making varies from clinician to clinician however and it is possible that a clinical 
review panel made up of different ophthalmologists could have resulted in alternative 
decision nodes being constructed. In addition, three possible treatment lines only were 
implemented for simplicity but in reality there are significantly more possible variations 
in treatment lines that the patients could undergo.  
Critically this model does not consider the effect of false positive decisions on VF 
progression. After all, it has been shown that increasing VF testing will inevitably affect 
specificity(175). Therefore, with proposed practice patients may receive intensified 
treatment when it is not required and the model is not adjusted for this cost.  The model 
also assumed the VF changes in a linear fashion only. This is reasonable given work done 
in this area(244) but deterioration to noticeable binocular vision loss may be more 
suddenly noticed in patients(245).  
An economic evaluation using discrete event simulation might also model the process 
more accurately and this has been used elsewhere(164). Still, such models are complex 
and difficult to interpret and a Markov model structure offers simplicity and 
transparency. The model structure is likely also limited by the way in which disease 
severity was categorised - more work is needed to establish meaningful stratification of 
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functional loss in glaucoma. These results only considered a summary measure from the 
VF. Research has shown that an index like MD does not capture location and spatial 
extent of VF loss in patients(245). For example, two patients with the same MD might 
have different visual function. Moreover, there is debate about using a measure of 
binocular VF loss and aligning this with utilities(104, 106). Finally, the model does not 
capture the co-morbidities of patients; this could be concomitant eye disease or other 
chronic conditions.  
 
5.3.2 Future Research 
Measuring impact of visual function loss on quality of life requires further study in order 
to test the clinical- and cost-effectiveness of health service delivery of COAG(111). 
Further research to quantify the costs of sight impairment is also a priority. Also, little is 
known about how patients adapt to gradual sight loss in glaucoma and this subject is 
worthy of further study; This could have a significant bearing on estimating utilities in 
health economic models for COAG(181). Indeed it could be suggested there are clear 
uncertainties surrounding the utilities in these models despite exemplar studies 
attempting to derive meaningful values(161). New research should look at the precision 
and accuracy of these values. Furthermore, whilst a range of ‘theoretical’ implementation 
costs were examined in the sensitivity analysis of model results, it was beyond scope to 
examine in detail the costs associated with implementing proposed practice; this clearly 
ought to be the subject of further research along with consideration of the thoughts on 
increased testing of patients and clinicians(206, 232). Consideration of innovative and 
affordable health service delivery redesign is likely to be a wider debate that needs to be 
addressed too, as has been recently suggested for people with ocular hypertension(246). 
 
5.4 Conclusion 
Results from this modelling exercise indicate the health economic benefits of intensifying 
monitoring of patients after they have been newly diagnosed with COAG.  Increasing the 
number of VF examinations to better determine those patients’ that are rapidly losing 
vision appears to be cost-effective; this might be particularly true for younger patients. A 
study on the resource implications for glaucoma follow-up and costs of sight impairment 
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from COAG would be worthwhile. A prospective study of different follow-up patterns, 
especially stratified among different patient groups is recommended.  
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Chapter 6: Conclusions 
 
Whilst a considerable amount of research has taken place examining how best to identify, 
treat and monitor glaucoma patients, there is little existing literature examining 
guidelines for glaucoma service provision from a health economic perspective. Whilst 
maximisation of patient outcomes represents a key objective with the UK NHS, there has 
to be a consideration of the costs derived in order to achieve them. This is especially the 
case given the finite nature of the financial resources that are used to produce the 
outcomes. Given the zero-sum game associated with taxation only based funding 
structures, the provision of resources for one strategy requires that resources are less 
readily available to finance other strategies. It is therefore imperative that budget holders 
are provided with sufficient information so as to choose the treatment and management 
strategies that represent the best value for money. This thesis and the studies contained 
within it seeks to use real world clinical data in combination with health economic 
principles to examine suggested monitoring guidelines for glaucoma whilst also 
attempting to establish the trends associated with service provision to establish whether 
improvements are being made. Below, I summarise the findings of the five thesis 
chapters and the conclusions drawn from them before summarising the novel 
contributions of the thesis and describing further questions and study arising from this 
research. 
 
6.1 Summary 
The study described in Chapter 2 investigated the cost-effectiveness of undertaking 6 VFs 
in the first two years in order to expedite the identification of those patients most likely 
to progress to a state of visual impairment within their lifetimes. A health economic 
model was constructed to compare this proposed practice against the current practice of 
annual VF testing. The health economic model found that it would be cost effective to 
undertake this increased monitoring strategy under NICEs hypothetical cost-
effectiveness ceiling ratio although further research was required to assess the costs of 
the extra infrastructure that would be required to implement such a strategy. 
Furthermore, greater understanding of how health state utility is quantified in glaucoma 
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is required as the parameters used in the study were found to potentially impact upon 
the assessment of cost-effectiveness. 
The study in Chapter 3 examined the distributions of existing health states in greater 
detail by retrospectively analysing VF data sourced from around England. The study also 
examined the trends associated with the degree of severity at presentation over time in 
order to assess whether detection is improving over time. It was observed that there was 
moderate evidence that glaucoma patients were being detected earlier over time 
however a key finding of the study was that too many glaucoma patients begin treatment 
once the irreversible disease has already progressed to an advanced stage in at least one 
eye. 
The study described in Chapter 4 retrospectively investigated rates of VF progression in 
England in order to identify whether rates of disease worsening is getting better over 
time given the improvements in treatment techniques that have occurred periodically. 
The study in this chapter also investigated the distribution of rates and the frequency of 
patient follow up stratified by age and severity of loss at baseline to expound on how 
rates and monitoring can vary by patient characteristics. It was observed that rates were 
improving over time, however the average rate of improvement was small and there was 
no reduction in the proportion of rapidly progressing eyes over the decade examined. 
The study also confirmed the wide belief that that older eyes and those eyes with greater 
disease severity progressed at a more rapid rate whilst the study also found that the 
frequency of monitoring of the VF did not vary by likelihood of progression to visual 
impairment. 
The study in Chapter 5 represented and update of the model constructed in Chapter 2 to 
incorporate the more detailed findings of Chapter 3 and Chapter 4 in terms of existing 
health state distributions and stratified progression rates respectively. The model was 
also updated to account for the societal costs associated with glaucoma in order to count 
the true total costs associated with the condition. The cost-effectiveness of increased 
monitoring at the earliest stages of identification was found to increase as the indirect 
costs of visual impairment were incorporated into the model even when updates to the 
distributions of existing damage and progression rates were implemented. 
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6.2 Further work 
6.2.1 Illness Perception in Glaucoma Study (IPIG) 
As previously discussed, cost-effectiveness evaluation has sought to further the 
understanding of efficiency in visual health by synthesising data on utility and costs 
through the processes of cost effectiveness analysis(63, 164). In order to quantify 
incremental benefit, subjective assessments of improvements in quality of life are 
required. These assessments are often represented by non-patients valuing the utility of 
these improvements. Non-patients therefore often determine which drugs and 
interventions are funded and provided by the NHS in the UK.  
Existing methods of utility quantification are being increasingly questioned however. 
There is evidence to suggest a disparity exists between how non-patients predict life 
would be like with a condition compared against patients’ actual experiences. In a study 
of 80 patients against 80 non-patients, Walsh et al. found non-patients to predict that life 
would be worse with a health state than patients actually report(185). These disparities 
in judgment were reasoned due to non-patients failing to take into account that patients 
adapt to living with a health state, a supposition supported by other academic 
literature(247-249). This could potentially result in non-patients failing to accurately 
anticipate the preferences of patients when valuing the utility of quality of life 
improvements. 
Furthermore, in another study examining the relationship of the quality of life associated 
with visual disability from glaucoma, Odberg et al. studied the patient perception of 
glaucoma identified through questionnaire responses(184). Of the 589 questionnaires 
studied, 80% of subjects reported negative emotions at diagnosis, 31% were found to be 
afraid of going blind whilst 46% reported that they had not detected any issues with their 
visual function prior to their glaucoma diagnosis. It was consequently argued that the 
diagnosis of glaucoma itself reduces quality of life of the patient despite only half of those 
studied experiencing any problems with their visual function. This discontinuity between 
patient perceptions and self-reported quality of life implies that negative emotional 
perceptions of the condition glaucoma can potentially outweigh the impact on visual 
function itself. This suggests non-patients are perhaps not sufficiently qualified to provide 
insight into how glaucoma should be prioritised. 
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There are therefore two main issues with how quality of life is investigated in glaucoma. 
Firstly, that non-patients lack the knowledge that patients are able to adapt to their 
conditions over time. Secondly, that both patients and non-patients are potentially 
negatively affected by a diagnosis of glaucoma itself given the negative emotional 
representations associated with the condition. To investigate these issues in greater 
depth, two studies are currently planned: the Illness Perception in Glaucoma: case–
control study (IPIGa) and the Illness Perception in Glaucoma: non-patient study (IPIGb). 
 
6.2.2 IPIGa: Methods and Materials 
The IPIG case-control study looks at real patients diagnosed with COAG or OHT and 
compares the emotional representations of those with a new diagnosis compared to 
those that have had their diagnosis for at least two years. The primary aim of this study 
is to assess the negative impact of the actual ‘diagnosis’ of COAG or OHT upon perceived 
quality of life. This is important because prognosis in most patients with these chronic 
conditions is actually quite positive, with the majority of patients not reaching a 
significant level of visual disability within their lifetime(153). This has implications about 
how ‘diagnosis’ of glaucoma is communicated in a clinical setting. Furthermore, the 
health economic values placed on chronic conditions are inherently linked to its illness 
perception. This study intends to show that this illness perception is ‘dynamic’ in 
glaucoma; different outcomes could be obtained depending on the time that has passed 
since diagnosis. Health economic measures such as QALYs are derived from assessment 
of health states using a complicated calculation which weighs the cost of a treatment 
against its benefit, this study therefore aims to examine the accuracy of such metrics. 
 
6.2.3 IPIGb: Methods and Materials 
Following on from the IPIG: case-control study, The IPIG: non-patient study will examine 
the impact comprehension of glaucoma has on the perception of glaucoma by 
respondents with self-reported healthy visual function. As previously discussed, non-
patients are often used in the assessment of quality of life to establish priority of access 
to resources. In addition, they are also being used to compare intervention effectiveness 
for health economic cost effectiveness analyses such as those undertaken in Chapter 2 
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and 5 of this thesis. It has however already been shown that non-patients overestimate 
the impact a glaucoma diagnosis would have upon quality of life. The aim of this study 
therefore is to illustrate the role knowledge of the characteristics of the disease plays 
when quantifying potential impacts. 
 
6.3 Thesis contributions 
Overall, there are various contributions to the field that have resulted from this thesis: 
- The thesis has tested the health economic implications of undertaking the EGS 
guidelines of performing 6 visual fields in the first two years to better identify 
those patients most of risk of visual impairment in their residual lifetimes 
(Chapter 2) 
- The thesis has established estimates using real world clinical data for the severity 
of vision loss at diagnosis in glaucoma patients in England (Chapter 3). 
- The thesis has examined and identified the rates of which improvements in 
glaucoma identification in England has been taking place over time (Chapter 3). 
- The thesis found that a significant proportion of patients are presenting to 
glaucoma care services in the UK in the first instance with significantly progressed 
VF damage (Chapter 3). 
- The thesis has investigated to see whether rates of visual field progression in 
England has been improving over time and whether improvements in disease 
progression are being observed in those patients at most risk of suffering from 
visual impairment in their lifetime (Chapter 4). 
- The thesis has provided confirmation that older patients and those with the most 
advanced stages of disease are most likely to progress at faster rates of 
deterioration (Chapter 4). 
- The thesis has established that frequency of follow up does not vary by age, 
disease severity or by rate of progression, suggesting that little focus is being 
placed on those most at risk patients (Chapter 4). 
- This thesis found that the implementation of the EGS guidelines would be most 
cost-effective if targeted specifically at younger patients and those at earlier 
stages of disease severity (Chapter 5). 
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